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ABSTRACT OF DISSERTATION 
AZITHROMYCIN THERAPY REDUCES CARDIAC INFLAMMATION AND 
MITIGATES ADVERSE CARDIAC REMODELING AFTER MYOCARDIAL 
INFARCTION 
Introduction: Myocardial infarction (MI) remains the leading cause of morbidity and 
mortality worldwide. Induced by cardiomyocyte death, MI initiates a prolonged and 
uncontrolled inflammatory response which impairs the healing process. Immune 
cells, such as macrophages, play a central role in organizing the early post-MI 
inflammatory response and the subsequent repair phase. Two activation states of 
macrophages have been identified with distinct and complementary functions 
(inflammatory vs. reparatory). This bimodal pattern of macrophage activation is an 
attractive therapeutic target to favorably resolve post-MI inflammation and 
enhance recovery. It has been demonstrated that azithromycin (AZM), a commonly 
used antibiotic with immunomodulatory effects, polarizes macrophages towards 
the reparatory phenotype. AZM has an excellent safety profile and has been 
approved for human use. We hypothesize that AZM reduces inflammation and 
improves heart function in MI.  
Methods and results: In our initial studies, we demonstrated that oral free AZM 
(160 mg/kg daily for 7 days), initiated 3 days prior to MI, enhances post-MI cardiac 
recovery as a result of shifting macrophages to the reparatory state. We observed 
a significant reduction in mortality with AZM therapy. AZM-treated mice showed a 
significant decrease in pro-inflammatory and an increase in reparative 
macrophages, decreasing the pro-inflammatory/reparative macrophage ratio. 
Macrophage changes were associated with a significant decline in pro- and an 
increase in anti-inflammatory cytokines. Additionally, AZM treatment was 
correlated with a distinct decrease in neutrophil count due to apoptosis, a known 
signal for shifting macrophages towards the reparative phenotype. Finally, AZM 
treatment improved cardiac recovery, scar size, and angiogenesis. We designed 
this proof of concept study using pre-MI AZM therapy to achieve steady state levels 
prior to injury. Therefore, in our follow-up studies we targeted inflammatory 
macrophages using a non-Pegylated liposomal formulation of AZM (Lazm) which 
has been shown in multiple studies to promote drug efficacy and minimize off-
target effects. To test the hypothesis that Lazm is more effective and safer than 
free AZM, low doses of free/liposomal AZM (10 or 40 mg/kg, administered 
intravenously) were initiated immediately after MI. We observed that Lazm induces 
early resolution of the post-MI inflammatory response as evidenced by switching 
 
of the activation state of monocytes/macrophages towards the reparatory 
phenotype. Neutrophils were substantially decreased, particularly pro-
inflammatory neutrophils.  Cytokine profiles were also shifted to the anti-
inflammatory status with Lazm therapy. Taken together, AZM treatment resulted 
in a significant shift in macrophage activation towards the reparatory state. The 
shift in inflammatory state was accompanied by a decrease in apoptosis and infarct 
size in the injured heart, as well as enhanced angiogenesis and LV functional 
recovery in our long-term studies. In addition, Lazm was protective against off-
target effects of AZM on the heart. 
Conclusion: This is the first evidence of a novel and clinically-relevant therapeutic 
strategy to modulate post-MI inflammation. We found that AZM reduces cardiac 
inflammation and improves adverse cardiac remodeling after infarction via 
promoting a shift of macrophage activation state. The overarching significance of 
this work is the modulation of sterile inflammation, which can be a viable 
therapeutic target in many conditions including stroke and heart attack. 
Additionally, this is the first study to demonstrate the immune modulation 
properties of liposomal AZM, which has wide potential therapeutic applications 
beyond the cardiovascular field. Importantly, liposomal formulation of AZM is 
protective from its cardiac off-target effects. Our findings strongly support clinical 
trials using AZM as a novel and clinically relevant therapeutic target to improve 
cardiac recovery and reduce heart failure post-MI in humans. 
Keywords: Myocardial infarction, Post-myocardial infarction inflammation, 
Macrophage, Macrophage polarization, Azithromycin, liposomal azithromycin.  
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Chapter I. Introduction 
1.1 Background  
1.1.1 Myocardial infarction 
Myocardial infarction (MI) and its common complication, heart failure, are 
leading causes of morbidity and mortality worldwide (Spatz, Beckman et al. 2016).  
Although the hospitalization rate for MI has significantly decreased in the last 15 
years (~1238 vs ~ 750/ 100000 individual per year) (Spatz, Beckman et al. 2016), 
the five-year post-MI mortality rate remains high (~50%) (Lindsey, Saucerman et 
al. 2016). Cardiac death is mainly related to heart failure, induced by adverse post-
infarction cardiac remodeling (Lindsey, Saucerman et al. 2016). Moreover, heart 
failure in the USA contributed to more than $20 billion in medical expenses in 2012 
(Writing Group, Mozaffarian et al. 2016). This cost is expected to increase to more 
than $53 billion by 2030 due to increasing prevalence (Heidenreich, Albert et al. 
2013).             
MI refers to a clinical condition characterized by full or partial epicardial 
coronary artery occlusion due to rupture or erosion of vulnerable plaques (White 
and Chew 2008), which leads to myocardial injury and/or death from inadequate 
oxygen supply (Spatz, Beckman et al. 2016). Insufficient blood and nutrient supply 
may lead to coronary artery constriction and thrombus micro-embolisation, 
producing a more severe form of MI attack. When the occlusion persists for more 
than 30 minutes, irreversible injury occurs to the myocardium. Beyond 6 hours of 
arterial occlusion, the entire jeopardized myocardial region becomes necrotic and 
the infarct size massively increases. Necrotic areas expand from the central zone 
of the blocked artery, through the severely damaged endocardial layers, towards 
the borders, the less ischemic subepicardium, and eventually lead to transmural 
cardiac injury. Factors such as size and location of the injured zone supplied by 
the occluded artery, severity of the ischemia, temperature, and systemic 
hemodynamic status determine the ultimate infarct size (Skyschally, Schulz et al. 
2008). Variability in resistance to ischemic injury and collateral circulation also 
2 
contribute to the progression of MI and, ultimately, its expansion (Heusch and 
Gersh 2017).  
MI animal models show that the infarct size influences long-term survival 
and ventricular function (Pfeffer, Pfeffer et al. 1979, Pfeffer, Pfeffer et al. 1985). 
From a clinical standpoint, the likelihood of getting congestive heart failure, cardiac 
aneurysm formation, and/or  myocardial rupture significantly increases if the 
patient experiences infarct expansion (Jugdutt and Michorowski 1987). During the 
resorption of dead tissue, the tensile strength of the injured area temporarily 
declines and the non-contractile wall becomes highly susceptible to structural 
deformation (Pfeffer 1995). Necrotic cardiomyocytes are replaced by fibrous 
connective tissue, leading to histological changes in the myocardium (Fishbein, 
Maclean et al. 1978). Fibroblast proliferation and collagen deposition progress 
simultaneously, leading to scar formation, leaving the living cardiomyocytes in the 
infarct zone to align to form a compressed collagen matrix. Heart dimensions begin 
to change and the damaged zone becomes thin and elongated (Pfeffer and 
Braunwald 1990). As a result, the ischemic insult induces serious and tangled 
modifications to the cellular and extracellular components of the heart muscle, 
producing alteration in cardiac capacity, architecture and function in a process 
called left ventricular (LV) remodeling. These changes begin immediately post-MI 
and progress for weeks to months at the site of injury, as well as in the surviving 
uninjured zones (Anversa, Olivetti et al. 1991, Beltrami, Finato et al. 1994).  
Of note, peri-infarct border of the injured myocardium is also affected by the 
ischemic insult but contains viable myocardium contiguous with evolving infarction. 
At this zone, viable cardiomyocytes experience remarkable changes in cell-cell 
and cell-extracellular matrix interactions due to the death of neighboring 
cardiomyocytes and formation of scar tissue (Matsushita, Oyamada et al. 1999). 
In the past, peri-infarct zone was denoted exclusively by location as a part of 
myocardium adjacent to the infarcted zone. However, recent research suggests 
that this region is distinguished by its location and function. An increment in wall 
stress is observed in the peri-infarct border, causing a decrease in cardiac muscle 
contractility (Bogen, Rabinowitz et al. 1980). Studies also show that the activity of 
3 
Gqα, a protein contributing to myocardial hypertrophy, and phospholipase C 
elevate in this zone compared to more remote areas (LaMorte, Thorburn et al. 
1994). In addition, cardiomyocytes in the peri-infarct zone play an essential role in 
initiating post-MI inflammation through production of pro-inflammatory mediators 
such as IL-6 and TNF-α (Frangogiannis 2014). 
Immediately after cardiomyocyte death, an over-exaggerated inflammatory 
response is activated in the infarct/peri-infarct zones (Frangogiannis, Smith et al. 
2002). Post-MI inflammation is initiated by necrotic cardiomyocytes to facilitate 
cellular debris removal (Frangogiannis, Smith et al. 2002). However, this response, 
characterized by leukocyte penetration into the infarcted myocardium, leads to 
exacerbated cardiac damage and infarct expansion (Frangogiannis, Smith et al. 
2002). In addition to central necrosis, the myocardial injury is further exacerbated 
by the recruitment of inflammatory cells and their products such as extracellular 
matrix metalloproteinases (MMPs). Multiple lines of evidence in animal and human 
studies suggest that a more controlled inflammatory response, and thus, a 
significantly reduced cardiac injury, can be achieved by limiting polymorphonuclear 
leukocyte (PMN) recruitment and activation at the site of injured tissue (Hill and 
Ward 1971, Crawford, Grover et al. 1988). Furthermore, post-MI inflammation is 
important for proper cardiac healing and scar formation (Entman and Smith 1994, 
Frangogiannis, Youker et al. 1998, Mehta and Li 1999) . 
Reperfusion of the ischemic myocardium precipitates ischemia-reperfusion 
(I/R) injury, leading to further damage of the infarcted myocardium (Frangogiannis, 
Smith et al. 2002). I/R injury has a complicated multifaceted myocardial pathology 
and is mainly influenced by the magnitude/duration of the blockage and the 
following reperfusion injury. In ischemia, Intracellular pH and ATP concentrations 
plummet due to anaerobic metabolism and lactate accumulation. As a result, 
ATPase-dependent ion transport pathways become inactive, leading to increased 
intracellular and mitochondrial calcium concentrations (calcium overload), cell 
swelling and rupture, and cell death by necrosis, apoptosis, necroptosis, and 
autophagy (Kalogeris, Baines et al. 2012). In the reperfusion state, oxygen supply 
returns to normal levels, however; there is a massive production of Reactive 
4 
Oxygen Species (ROS) and intense recruitment of pro-inflammatory neutrophils to 
the site of injury, exacerbating ischemic damage. The most likely mechanisms 
driving I/R cell dysfunction, injury, and/or death include: a) resupply of molecular 
oxygen during the reperfusion phase induces large amounts of ROS, b) intense 
neutrophil infiltration induces a potent inflammatory response, c) calcium overload, 
d) deterioration of endothelial function, e) mitochondrial permeability transition
(MPT) pore opening, and f) thrombosis (Yellon and Hausenloy 2007, Kalogeris,
Baines et al. 2012).
Cardiomyocyte death and extracellular matrix (ECM) deterioration in the 
injured myocardium produce alarming molecules, known as danger-associated 
molecular patterns (DAMPs), which initiate and exaggerate the inflammatory 
response (Timmers, Pasterkamp et al. 2012). Additional initiation of inflammation 
occurs via the nuclear chromatin-binding protein, High-mobility group box-1 
(HMGB1), through activated Toll-Like Receptor (TLR) and Receptor for Advanced 
Glycation End products (RAGE) (Andrassy, Volz et al. 2008). Molecules, 
generated from ECM fragments, such as low molecular weight hyaluronan and 
fibronectin fragments, ATP, and Heat Shock Proteins (HSPs) induce inflammation 
post-MI as well (Huebener, Abou-Khamis et al. 2008, Dobaczewski, Gonzalez-
Quesada et al. 2010, Arslan, de Kleijn et al. 2011, Timmers, Pasterkamp et al. 
2012). DAMPs stimulate the complement cascade system, leading to the 
recruitment and local infiltration of immune cells (Hill and Ward 1971). DAMPs, 
through TLRs, activate the immune response to remove dead tissues but they also 
start the healing process (Frangogiannis, Smith et al. 2002). The post-MI 
inflammatory response is a complicated process controlled by various 
inflammatory mediators. The most important players in this response are: 
1.1.1.1 Complement activation 
Necrotic cardiomyocytes release subcellular membrane components 
enriched in mitochondria, which activate the classical complement cascade 
components (C1, C2, C3, and C4) (Pinckard, Olson et al. 1975). These 
components trigger the inflammatory response in the injured myocardium through 
5 
a complement-mediated inflammatory response. Protein and mRNA levels of 
members of the classical complement pathway are elevated at the site of 
myocardial injury (Vakeva, Agah et al. 1998, Yasojima, Kilgore et al. 1998) . 
Complement pathway activation contributes to the recruitment of neutrophils and 
monocytes (Dreyer, Michael et al. 1992). Some studies show that monocyte 
chemotactic activity in the heart lymphatic drainage in the early phase of the I/R 
injury is mainly attributed to C5a, a product of complement cascade activation 
(Birdsall, Green et al. 1997). Research  also shows that some agents like cobra 
venom factor, antibody-induced inhibition of individual complement components, 
and soluble form of complement receptor type 1, could have some benefits in 
reducing infarct size and myocardial necrosis through inhibition of the classical 
complement cascade activity (Weisman, Bartow et al. 1990, Kilgore, Friedrichs et 
al. 1994, Lucchesi and Kilgore 1997, Czermak, Lentsch et al. 1998, Griselli, 
Herbert et al. 1999). 
1.1.1.2 Reactive oxygen species 
Reactive oxygen species (ROS) damage myocardial and vascular tissues 
through stimulation of cytokine production in the injured myocardium (Dhalla, 
Elmoselhi et al. 2000, Lefer and Granger 2000). Studies show that ROS are key 
players in the chemotaxis of leukocytes (Granger 1988) through induction of 
complementary cascades, upregulation of P-selectin expression, pro-inflammatory 
chemokine levels increase and potentiation of the capacity of neutrophil interaction 
with the endothelial Intercellular Adhesion Molecule 1 (ICAM-1) (Patel, 
Zimmerman et al. 1991, Sellak, Franzini et al. 1994, Lakshminarayanan, Beno et 
al. 1997, Lakshminarayanan, Drab-Weiss et al. 1998, Akgur, Brown et al. 2000). 
ROS destroy ECM molecules, degrade phospholipids in the membrane, and thus, 
induce cell damage and death (Fridovich 1978, Del Maestro, Thaw et al. 1980). 
Free radical scavengers such as enzymes, superoxide dismutase and catalase, 
have proven beneficial in reducing scar size in an experimental canine MI model, 
through inhibition of ROS signaling (Jolly, Kane et al. 1984). Mice that overexpress 
copper, zinc superoxide dismutase (SOD1) show a significant protection against 
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ischemic cardiac injury (Wang, Chen et al. 1998). SOD1 is a cytosolic enzyme that 
efficiently limits intracellular O2 levels during oxidative stress situations such as 
I/R, in which multiple cellular oxidases become active (Zweier 1988). Superoxide 
and the protonated form, ⋅OOH, denature cellular enzymes like aconitase and 
fumarase, causing a marked change in O2 levels (Gardner and Fridovich 1992). O2 
interacts with the metal-catalyzed Haber Weiss reaction to produce ROS (Hess 
and Kukreja 1995). Moreover, O2 interaction with nitric oxide produces oxidant 
peroxynitrite, which causes cellular damage via protein nitration (Xia, Dawson et 
al. 1996). However, some studies including human trials do not show significant 
recovery in LV function with antioxidants (Gallagher, Buda et al. 1986, Uraizee, 
Reimer et al. 1987, Richard, Murry et al. 1988, Maxwell and Lip 1997). 
 
1.1.1.3 Extracellular matrix (ECM) 
Besides their structural support of the injured myocardium, ECM proteins 
are important regulators of post-MI inflammation (Frangogiannis 2012). Dynamic 
changes in ECM components contribute to the inflammatory response through 
modulation of adjacent fibroblast, endothelial cell, and inflammatory cell activity  
(Frangogiannis 2012). ECM fragments induce cytokine and chemokine synthesis, 
plasma-derived matrix accumulation, immune cell extravasation, and initiate the 
pro-inflammatory response in the early phases post-MI (Frangogiannis 2012, 
Timmers, Pasterkamp et al. 2012). Indeed, clearance of ECM fragments from the 
ischemic area is important in resolving inflammation and initiating anti-
inflammatory pathways. Moreover, hyaluronan fragments, which are generated via 
ECM network disruption, may also resolve inflammation via CD44 pathway 
signaling (Frangogiannis 2012). Additional ECM-related mechanisms controlling 
post-MI inflammation include a matricellular protein which is significantly increased 
in the damaged zone, Thrombospondin (TSP)-1, TSP-1 can regulate inflammation 
through stimulation of TGF-β and activation of anti-inflammatory pathways 
(Frangogiannis and Entman 2005, Frangogiannis 2012). 
 
 
7 
1.1.1.4 Pro-inflammatory Chemokines and cytokines 
Expression of cytokines and adhesion molecules is simultaneously 
upregulated after MI injury, and is primarily induced by nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor (IKKβ) (Lenardo and Baltimore 
1989). Multiple mediators such as cytokines and ROS stimulate NF-κB. NF-kB 
induces expression of genes that contribute to inflammation, cell adhesion, and 
growth (Stancovski and Baltimore 1997). Additionally, activation of NF-kB by TLRs, 
which are stimulated by complement cascade and ROS, induces production of 
adhesion molecules in the endothelial cells and pro-inflammatory cytokines and 
chemokines in fibroblasts, white blood cells, and vascular cells (Nian, Lee et al. 
2004, Gordon, Shaw et al. 2011). Suppression of post-MI inflammation and 
reduction of infarct size are observed with in vivo transfer of NF-κB decoy 
oligodeoxynucleotides via interference with the action of this transcriptional factor 
(Morishita, Sugimoto et al. 1997). 
Various chemokines are quickly upregulated after infarction, leading to 
accumulation of inflammatory cells in the ischemic myocardium (Frangogiannis 
2007). Neutrophils are attracted to the injured area through CC chemokines, while 
glutamic acid-leucine-arginine motif (ELR)-negative CXC chemokines attract 
lymphocytes and may play anti-fibrotic and angiostatic (stopping angiogenesis) 
roles (Frangogiannis 2014). Leukocytes bind with chemokines on the surface of 
activated endothelial cells and the matrix through adhesive film interaction 
(Frangogiannis 2014). Leukocytes express different chemokine receptors, so that 
certain chemokine/chemokine receptor pairs stimulate and interact to control 
infiltration of a specific leukocyte subpopulation (Proudfoot, Handel et al. 2003, 
Nahrendorf, Swirski et al. 2007, Dobaczewski, Xia et al. 2010).  
Pro-inflammatory cytokines, such as interleukin 1-beta (IL-1β), are 
upregulated and activated in the injured myocardium immediately after insult 
(Bujak and Frangogiannis 2009). IL-1β production depends on the creation of 
multiprotein oligomers, known as inflammasomes (Schroder and Tschopp 2010). 
Activation of inflammasomes occurs in leukocytes and resident fibroblasts in the 
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infarcted area and in cardiomyocytes in the border zone (Kawaguchi, Takahashi 
et al. 2011, Mezzaroma, Toldo et al. 2011). IL-1β promotes the expression of 
multiple inflammatory genes; including inflammatory cytokines, chemokines, 
adhesion molecules, inducible nitric oxide synthase (iNOS), type 2 
cyclooxygenase, and type 2 phospholipase A2 (Bujak and Frangogiannis 2009). 
As a result, IL-1β may induce more damage to myocardium via recruitment of 
additional immune cells to the heart (Bujak and Frangogiannis 2009). IL-1β levels 
are elevated in MI patients in the first few hours after attack (Guillen, Blanes et al. 
1995). Indeed, recent evidence in patients with chronic atherosclerotic disease 
suggests that targeting IL-1β with the specific monoclonal antibody, canakinumab, 
significantly decreases recurrent cardiovascular events (Ridker, Everett et al. 
2017).  
Data from our lab and others documented the early expression of tumor 
necrosis factor-alpha (TNF-α) in the myocardium after ischemic injury (Gordon and 
Galli 1990). TNF-α acts upstream of IL-6, since neutralizing antibodies for TNF-α 
can block the production of IL-6 (Frangogiannis, Smith et al. 2002). TNF-α acts 
through multiple receptors with divergent actions (TNF-R1 and TNF-R2). TNFR1 
activation mediates NF-κB activation, cardiomyocyte apoptosis and inflammation 
in the infarct and peri-infarct zones (Hamid, Gu et al. 2009). On the contrary, TNF-
R2 is crucial for the healing process via reduction of inflammation and NF-kB 
activation and enhancement of cell survival (Hamid, Gu et al. 2009). TNF-α, mainly 
produced by macrophages, is a cornerstone to the initiation and maintenance of 
the inflammatory response after MI.  Indeed, elevated levels of TNF-α in humans 
suffering MI are correlated with more rapid deterioration in heart function and 
higher risk of mortality (Dunlay, Weston et al. 2008). IL-6 family members play an 
important role in both cardiac inflammation and healing after infarction (Fischer 
and Hilfiker-Kleiner 2008). Studies employing an anti-IL-6 receptor antibody show 
significant reduction in cardiac inflammation, infarct size, and adverse cardiac 
remodeling (Kobara, Noda et al. 2010). However, the role of IL-6 in post-MI is 
multifaceted and studies utilizing genetic deletion of IL-6 do not yield improvement 
in  infarct size, LV function, or chronic adverse cardiac remodeling, suggesting a 
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role for IL-6 in proper cardiac healing (Fuchs, Hilfiker et al. 2003). More information 
about targeting certain cytokine/chemokine and other signaling pathways is 
located in Table 1.1. 
 
1.1.1.5 Cellular players in inflammation after ischemic cardiac injury: 
Multiple populations of bone-marrow (BM) derived and cardiac cells are 
involved in the inflammatory response after MI. The most important players in post-
MI inflammation include: 
 
1.1.1.5.1 Cardiomyocytes 
Cardiomyocyte death stimulates the inflammatory response post-MI 
through release of several alarming/danger signals. Additionally, cardiomyocytes 
in the border zone express the inflammasome, leading to the production of IL-1β, 
which subsequently upregulates the inflammatory response (Frangogiannis 2014). 
 
1.1.1.5.2 Platelets 
Platelets actively participate in the regulation of inflammatory and 
reparatory phases following cardiac injury (von Hundelshausen and Weber 2007). 
They contribute to the production of chemokines, cytokines, and growth factors in 
the injured myocardium (Frangogiannis 2014). Activated platelets, through 
formation of a fibrin-based provisional matrix, enhance hematopoietic cell influx 
into the infarct /peri-infarct zones (Dobaczewski, Xia et al. 2010).  
 
1.1.1.5.3 Mast cells 
Unlike small animals, the heart of large animals is occupied by a large 
number of mast cells (Gersch, Dewald et al. 2002). A canine model of experimental 
MI observed that resident mast cells in the injured zones exhibit a quick and 
massive degranulation after infarction, leading to the release of high quantities of 
pre-synthesized pro-inflammatory mediators like TNF-α and histamine 
(Frangogiannis, Lindsey et al. 1998). Degranulation of mast cells was found 
exclusively in the ischemic and reperfused zones of the injury. TNF-α induces IL-
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6 production, leading to additional recruitment of mononuclear cells to the injured 
myocardium. In addition, histamine is an important autacoid in I/R injury via 
promotion of IL-6 production and leukocyte movement. However, recent work 
investigating the role of mast cells after infarction in mice shows that mast cells 
protect cardiomyocytes from damage post-MI and promote contractility (Ngkelo, 
Richart et al. 2016). 
  
1.1.1.5.4 Dendritic cells 
Although myocardial damage activates dendritic cells, their exact role 
remains unclear. Findings are contradictory; some studies show beneficial effects 
via modulation of post-MI inflammation and production of IL-10 (anti-inflammatory 
cytokine). Other studies show that these cells activate and prime CD+4 T cells in 
the setting of MI (cardiac-specific autoreactive cells), leading to cardiac 
autoimmune attack and damage (Anzai, Anzai et al. 2012, Van der Borght, Scott 
et al. 2017). 
 
1.1.1.5.5 Fibroblasts 
The second most abundant population of cells in the heart is fibroblasts 
(Souders, Bowers et al. 2009). After MI they are activated, stimulating the 
inflammasome platform (Kawaguchi, Takahashi et al. 2011), which leads to an 
increase in IL-1β production. Cardiac fibroblasts are also capable of producing 
chemokines and cytokines and, therefore; they are directly involved in modulation 
of the inflammatory response after MI (Frangogiannis 2014). 
 
1.1.1.5.6 Endothelial cells 
Endothelial cells are key players in inflammation after MI via production of 
pro-inflammatory chemokines, such as monocyte chemoattractant protein-1 
(MCP-1) and interferon gamma-induced protein 10 (IP-10), in the affected territory. 
Additionally, production of cytokines in the infarcted area stimulates the expression 
of adhesion molecules on the surface of endothelial cells, which causes a profound 
adhesion of circulating inflammatory cells and initiates their migration into the 
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injured myocardium (Frangogiannis, Mendoza et al. 2001, Bujak, Dobaczewski et 
al. 2009). Hence, production of pro-inflammatory chemokines and adhesion 
molecules by endothelial cells at local sites of myocardial injury is crucial to the 
initiation and maintenance of the inflammatory response post-MI. 
 
1.1.1.5.7 Vascular cells and pericytes 
Angiogenesis is an essential element of the healing process (Frangogiannis 
2014). Wound healing of the injured myocardium is highly correlated with the 
intensity of angiogenesis since more nutrients and oxygen will be available through 
a plentiful vascular network. Enhanced production of angiogenic growth factors 
facilitates the formation of a hyperpermeable microvascular network 
(Frangogiannis 2014). Vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), and other angiogenic growth factors are generated and 
released in the first hours after cardiac insult (Li, Brown et al. 1996, Lee, Wolf et 
al. 2000, Frangogiannis 2014). Inhibiting the formation of granulation tissue, 
enhancing the resolution of inflammation, and stabilization of scar tissue are 
processes regulated by the maturation of new blood vessels at the infarct/peri-
infarct zones (Zymek, Bujak et al. 2006, Frangogiannis 2014). Platelet-derived 
growth factor (PDGF) is important in myocardial healing post-MI. PDGF, through 
activation of the PDGF receptor, stimulates mural cell recruitment through the 
vasculature into the infarcted myocardium, leading to accelerated acquisition of a 
mural coat by these newly formed blood vessels (Zymek, Bujak et al. 2006).  
 
1.1.1.5.8 Lymphocytes 
Multiple lymphocyte subpopulations (CD4+ and CD8+ T-cells, 
Foxp3+regulatory cells (Tregs), invariant natural killer (iNK) T-cells, and γδT-cells) 
infiltrate the injured heart. Regulatory T-cells (Tregs) play a key role in the 
immunomodulatory changes after MI (Frangogiannis, Mendoza et al. 2000, 
Hofmann and Frantz 2015). Recent evidence suggests that Tregs are involved in 
the suppression of post-MI inflammation through modulation of the macrophage 
and fibroblast response (Dobaczewski, Xia et al. 2010, Saxena, Dobaczewski et 
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al. 2014, Weirather, Hofmann et al. 2014). Upregulation of INF-gamma by Tregs 
induces anti-fibrotic changes in the heart through overexpression of IP-10 (anti-
fibrotic chemokine CXCL10/IFN-γ) (Bujak, Dobaczewski et al. 2009, Ramjee, Li et 
al. 2017). In addition, it has been observed that CD4+ T-cell-deficient mice have 
higher levels of leukocytes and pro-inflammatory monocytes with more 
deteriorated cardiac remodeling during follow-up (Liu, Wang et al. 2016).  
Apart from Tregs, circulating cytotoxic T (CD8) lymphocytes are elevated in 
the first week post-MI, suggesting a potential role in post-MI inflammation. In a rat 
model of experimental MI, harvesting these cells from the heart after infarction and 
culturing them with healthy neonatal cardiomyocytes induces a cytotoxic effect on 
cardiomyocytes (Varda-Bloom, Leor et al. 2000). However, whether their 
recruitment to the injured myocardium exacerbates injury has not been established 
yet (Ong, Hernandez-Resendiz et al. 2018). Finally, B lymphocytes are also crucial 
players in the pathology of MI and adverse cardiac remodeling. Mature B 
lymphocytes secrete large amounts of CCL7 and stimulate Ly6Chi monocyte 
migration and infiltration to the injured myocardium, leading to progression of 
cardiac injury and poor recovery (Zouggari, Ait-Oufella et al. 2013). 
 
1.1.1.5.9 Neutrophils 
The first population of inflammatory cells that infiltrates the injured 
myocardium is neutrophils (Figure 1.1) (Reimer, Murry et al. 1989). This influx is 
dependent on the complement cascade, ROS synthesis, and ELR/CXC 
chemokines (Frangogiannis 2014). Neutrophils are attracted to the MI zone 
through complement C5a, which is an important mediator in the stimulation and 
chemoattraction of neutrophils (Reimer, Murry et al. 1989). Research shows that 
depletion of complement system using cobra venom factor blocks 
polymorphonuclear neutrophil (PMN) recruitment and activation and reduces 
myocardial damage after I/R injury (Hill and Ward 1971, Crawford, Grover et al. 
1988). These outcomes are likely related to the effects of C3a, C4a, and C5a on 
vessels, to the increased vascular permeability, to the altered vessels tone, and to 
the production of cytolytic membrane attack complex (C5b-9). C5b-9 induces 
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formation of transmembrane channels, promotes calcium influx to the cell, and 
interferes with cardiomyocyte function.  
Conversely, other studies show that endothelial cells may be a primary 
source for certain neutrophil chemotactic factors (Strieter, Kunkel et al. 1988). For 
instance, TNF-α and/or IL-1β treatment activates endothelial cells to produce a 
neutrophil chemotactic factor, with a similar structure to the human monocyte-
derived neutrophil activating factor (NAF) (Thelen, Peveri et al. 1988). 
Hypoxia/reperfusion challenge to endothelial cells stimulates neutrophil 
attachment to the surface of endothelial cells (Reimer, Murry et al. 1989), via an 
interaction between neutrophil CD18 and endothelial intracellular adhesion 
molecule-1 (ICAM-1)(Smith, Rothlein et al. 1988). In addition, endothelial 
leukocyte adhesion molecule-1 (ELAM-1) can also facilitate adhesion between 
neutrophils and endothelial cells (Bevilacqua, Pober et al. 1987, Smith, Marlin et 
al. 1989). Chemoattraction of neutrophils to the injured myocardium is further 
enhanced in the first 48 hours by the upregulated activity of myocardial 
myeloperoxidase (Mullane, Kraemer et al. 1985). 
In acute inflammation, neutrophils are essential in removing dead cells and 
debris, as well as in resolving inflammation and maintaining homeostasis (Ortega-
Gomez, Perretti et al. 2013). Recruited neutrophils secrete products to facilitate 
inflammatory cell infiltration to the infarcted zone (Frangogiannis 2012, Ma, 
Yabluchanskiy et al. 2013). However, these products are toxic and may lead to 
more damage to the local cardiomyocytes and endothelium  (Reimer, Murry et al. 
1989). Neutrophils release a wide range of products such as proteolytic enzymes 
(producing liquefaction of cells), platelet-activating factor, arachidonic acid 
metabolites, and ROS(Reimer, Murry et al. 1989). ROS such as superoxide anion 
(O2⨪), hydrogen peroxide (H2O2), hydroxyl radical (• OH), and hypochlorous anion 
(OCL-) (Reimer, Murry et al. 1989), are mainly produced by neutrophils after 
infarction. ROS destroy extracellular matrix molecules, degrade phospholipids in 
the membrane, and thus, induce cell damage and death (Fridovich 1978, Del 
Maestro, Thaw et al. 1980). Activated neutrophils produce a positive feedback 
mechanism by converting phospholipids in the cell membrane into arachidonic 
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acid, which then transforms into a strong chemotactic molecule, hydroxy-
eicosatetraenoic acid (HETE), by the effect of certain lipoxygenases. HETEs are 
important chemoattractants responsible for further neutrophil infiltration into the 
injured myocardium (Snyderman and Goetzl 1981). In addition, neutrophils 
generate an array of pro-inflammatory cytokines which further recruit mononuclear 
cells (Frangogiannis 2014).  
Prolonged neutrophil accumulation in the heart post-MI is deleterious (Chia, 
Nagurney et al. 2009, Guasti, Dentali et al. 2011). Some studies show that there 
is a beneficial “time window” for neutrophil infiltration into the infarcted 
myocardium, beyond which persistent neutrophil accumulation leads to infarct 
expansion and exacerbated heart failure (Simpson, Fantone et al. 1988). Studies 
show that inhibiting neutrophil stimulation and infiltration into the injured 
myocardium is effective in preventing infarct expansion and irreversible myocardial 
damage (Reimer, Murry et al. 1989). Systemically, high neutrophil counts after MI 
are associated with progression of atherosclerosis and comorbid complications in 
murine models (Doring, Drechsler et al. 2015). Clinical data suggests that any 
further delay in neutrophil apoptosis after MI contributes to this exaggerated 
inflammatory response (Garlichs, Eskafi et al. 2004). 
While controversial, research shows neutrophil products released post-MI 
can influence the recruitment of different subsets of monocytes (Ly6Chi and Ly6Clo) 
in the first week after MI in mice (Nahrendorf, Swirski et al. 2007). Neutrophils may 
play a role in the migration and local activation of the predominant cardiac 
monocytes, Ly6Chi (classical, pro-inflammatory), 4 days after injury (Soehnlein, 
Zernecke et al. 2008, Frodermann and Nahrendorf 2017). Additionally, animal data 
suggests that neutrophils negatively affect myocardial healing by selectively 
recruiting pro- rather than anti-inflammatory monocytes (Nahrendorf, Swirski et al. 
2007, Soehnlein, Zernecke et al. 2008). Indeed, treatment with monoclonal 
antibodies against either α or β subunits of surface membrane adhesion 
glycoprotein (Mo1), which facilitates neutrophil aggregation and 
monocyte/neutrophil interaction, is protective against myocardial damage and 
reduces myocardial risk area (Simpson, Todd et al. 1990).  
15 
Although there is wide acceptance that neutrophils are important mediators 
of cardiac injury after ischemia, aggressive neutrophil depletion studies following 
MI have shown contradictory results (Horckmans, Ring et al. 2017). Some studies 
show reduced scar size with neutrophil depletion, while others fail to demonstrate 
any beneficial effects (Romson, Hook et al. 1983, Chatelain, Latour et al. 1987). 
The migrated and accumulated neutrophils in the cardiac tissue may cause more 
tissue damage due to dysregulated repair processes. A recent study shows that 
depletion of neutrophils using anti-Ly6G antibody in a murine experimental MI 
model reduces Ly6Chi monocyte (pro-inflammatory) release from the spleen and 
accumulation in the injured myocardium. Moreover, there was an increase in the 
proliferation of macrophages in the anti-inflammatory activation state in the injured 
myocardium, and impaired heart healing (Horckmans, Ring et al. 2017). These 
changes improve with resupply of the neutrophil product, neutrophil-derived 
lipocalin (NGAL), which acts via myeloid-epithelial-reproductive tyrosine-protein 
kinase (mertk) to enhance cardiomyocyte efferocytosis, suggesting an essential 
role for neutrophils in the healing process after infarction. (Horckmans, Ring et al. 
2017). Aggressive depletion of neutrophils, the first immune cells infiltrating the 
injured myocardium responsible for inflammation regulation, may not be the most 
practical method examining the role of these cells in healing since this strategy 
may disturb the entire inflammatory response. To our knowledge, this is the first 
study showing that M2 macrophages may have detrimental effects on cardiac 
recovery. They identified M2 macrophages using 3 markers (arginase, YM1, and 
IL-4).  Further research shows that this is not sufficient analysis to determine 
specific macrophage phenotype. Their view of the macrophage-neutrophil 
interaction as merely dependent on activation of mertk by NGAL to resolve post-
MI inflammation does not take into consideration that cardiomyocytes can directly 
activate mertk in macrophages through efferocytosis (Wan, Yeap et al. 2013). 
Using more specific strategies, like NGAL-/- specific knock out in neutrophils or 
inhibition of neutrophil adhesion, are probably better in identifying the effects of 
neutrophils in the healing process. 
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These contradictory results targeting neutrophils may be due to a dual role 
of neutrophils in cardiac inflammation and healing. While the initial wave of 
inflammatory/primed neutrophils can lead to exaggerated cardiac damage if not 
cleared in a timely fashion, the activity of neutrophil clearing can reduce 
inflammation and initiate the healing process. Clinical data suggests that delayed 
neutrophil apoptosis after MI contributes to an exaggerated inflammatory response 
(Garlichs, Eskafi et al. 2004). Additionally, a recent report shows that the 
neutrophil/lymphocyte ratio positively correlates to myocardial necrosis and C-
reactive protein (CRP) elevation (Tahto, Jadric et al. 2017). Apoptotic neutrophils 
have anti-inflammatory and angiogenic effects through production of apoptotic 
factors (annexin A1 and lactoferrin) and polarization of macrophage activation 
states to the anti-inflammatory phenotype which results in production of 
inflammatory resolving mediators, such as IL-10 and TGF-β (Soehnlein and 
Lindbom 2010).  
Resolution of cardiac inflammation after MI occurs 3-7 days after the acute 
event (Dewald, Ren et al. 2004). It is likely that apoptotic cell removal from the 
injured myocardium is the most influential cellular mechanism in resolution of 
inflammation due to production of inhibitory mediators by phagocytes (Huynh, 
Fadok et al. 2002). The life-span of neutrophils is somehow increased in the 
presence of TNF-α and IL-1β, in the early pro-inflammatory microenvironment 
(Colotta, Re et al. 1992). Monocytes and differentiated macrophages sterilize the 
site of injury through phagocytosis of dead cardiomyocytes and apoptotic 
neutrophils (Frodermann and Nahrendorf 2017). The mechanisms of inflammation 
resolution attributed to engulfment of apoptotic granulocytes include: a) neutrophil 
death generates resolving mediators which inhibit inflammatory cell recruitment to 
the heart (Bournazou, Pound et al. 2009), b) macrophage engulfment of apoptotic 
neutrophils stimulates the anti-inflammatory machinery to produce inflammation 
resolving cytokines (IL-10 and TGF-β) and lipid mediators and reduce pro-
inflammatory cytokine production (Soehnlein and Lindbom 2010).  
The disparate contributions of neutrophils to MI pathology may relate to 
multiple activation states of a single cell type. Recent work investigating the 
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temporal activation of neutrophils reports that they have two distinct activation 
states in ischemic heart: pro-inflammatory (N1) (CD11b+/Ly6G+/CD206-) and anti-
inflammatory (N2) (CD11b+/Ly6G+/CD206+) (Ma, Yabluchanskiy et al. 2016). The 
N1 phenotype is associated with LV thinning and dominates the heart after infarct. 
The N2 phenotype increases in abundance over time and correlates with proper 
healing (Ma, Yabluchanskiy et al. 2016). Interestingly, post-MI migrating 
neutrophils are CD206- in the bloodstream, then become CD206+ in the heart, 
which could suggest that the activation state is changed by microenvironment (Ma, 
Yabluchanskiy et al. 2016). Accordingly, this may explain the disparate outcomes 
of strategies targeting neutrophils, and at the same time, could represent an 
attractive therapeutic avenue in MI treatment via reprogramming of neutrophils to 
the anti-inflammatory phenotype.  
 
1.1.1.5.10 Monocytes 
Monocytes and macrophages, as members of the innate immunity system, 
play crucial roles in the heart at steady state, as well as after injury (Hulsmans, 
Sam et al. 2016). They are the second most prevalent immune cells in the injured 
myocardium, after the early neutrophil accumulation (Zlatanova, Pinto et al. 2016). 
In mice, there are two subsets of monocytes: a) Ly6Chi chemokine (C-C motif) 
receptor-2 (CCR2) hi chemokine (C-X3-C motif) receptor-1 (CX3CR1) lo 
(classical/pro-inflammatory), which infiltrate the heart early, immediately after 
neutrophils (day1), and disappear during the resolution phase of inflammation, b) 
Ly-6CloCCR2loCX3CR1hi monocytes (nonclassical/anti-inflammatory), which are 
recruited to the heart beginning on the third day after injury (Nahrendorf, Swirski 
et al. 2007, Nahrendorf and Swirski 2013, Hulsmans, Sam et al. 2016). Monocytes 
migrate to the heart from the bone marrow (BM) and spleen in two sequential 
periods of monocyte movement (Nahrendorf, Swirski et al. 2007, Nahrendorf and 
Swirski 2013). In humans, research has identified three subsets of monocytes 
based on the expression of CD14 and CD16: a) classical/pro-inflammatory 
(CD14++CD16−), b) intermediate (CD14++CD16+), and c) nonclassical/anti-
inflammatory (CD14+CD16++) monocytes (Hulsmans, Sam et al. 2016). It is likely 
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there are very few monocytes in the heart during steady state (Hulsmans, Sam et 
al. 2016). Information about the classification and surface markers of immune cells 
in the heart after MI is found in Table 1.2. 
In BM, hematopoietic stem cells (HSCs) give rise to common myeloid 
progenitors. These progenitors differentiate into granulocyte myeloid progenitors 
that give rise to Ly6Chi monocytes (Hettinger, Richards et al. 2013). Ly6Chi 
monocytes migrate from the BM to the peripheral blood, a process controlled by 
the monocyte chemoattractant protein-1 (MCP1)/CCR2 signaling axis (Serbina 
and Pamer 2006, Hulsmans, Sam et al. 2016). Studies show that the Ly6Clo 
monocytes derive from Ly6Chi under the control of a nuclear receptor subfamily-4-
dependent transcriptional process (Hanna, Carlin et al. 2011). Although it is rare 
for this to happen in the steady state condition, HSCs may also migrate to 
extramedullary hematopoietic sites such as the spleen and initiate 
monocytopoeiesis after tissue injury (Leuschner, Rauch et al. 2012, Robbins, 
Chudnovskiy et al. 2012). The spleen may also host monocytes, providing an 
important source of rapid response to tissue injury and inflammation, as seen in 
the first 24 hours after MI (Swirski, Nahrendorf et al. 2009). Under the control of 
adrenergic stimuli, bone marrow HSCs move towards the spleen and reside there. 
In the first 24 hours after MI, Ly6Chi monocyte recruitment to the heart occurs, 
mainly from the spleen (40%) (Leuschner, Rauch et al. 2012, Honold and 
Nahrendorf 2018). 
Ly6Chi monocytes differentiate into pro-inflammatory macrophages under 
the effect of M-CSF. These two populations are involved in the removal of dead 
cells and tissue debris via phagocytosis, resulting in production of proteolytic 
enzymes, which may lead to increased tissue damage. On the other hand, Ly6Clo 
monocytes participate in tissue healing via induction of angiogenesis, fibroblast 
proliferation, and collagen accumulation (Dutta and Nahrendorf 2015). Ly6Clo 
monocytes are the primary sources of fibronectin, which is essential in stabilizing 
the infarct region and preventing cardiac rupture (Frangogiannis, Smith et al. 
2002). Similar to neutrophilia, profound monocytosis disturbs healing post-MI, 
while inhibition of pro-inflammatory monocyte recruitment improves cardiac 
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recovery (Dutta and Nahrendorf 2015). Studies show that MCP-1 deletion, an 
important regulator of monocyte recruitment to the injured myocardium, results in 
a substantial decrease in monocyte infiltration into the heart. Although MCP-1 
deficient mice did not differ in scar size from wild type mice, they had significant 
improvement in LV function, implying the importance of monocyte repair processes 
in the infarcted myocardium (Dewald, Zymek et al. 2005). In human studies, an 
increased number of pro-inflammatory monocytes after MI correlates with higher 
incidence of future clinical events (Han, Jing et al. 2014). Moreover, clinical studies 
reveal that elevated levels of inflammatory blood monocytes CD14+CD16− in MI 
patients increase the risk of poor myocardial salvage and heart failure during long 
term follow-up (Maekawa, Anzai et al. 2002, Tsujioka, Imanishi et al. 2009). 
 
1.1.1.5.11 Macrophages  
At steady state, macrophages are the primary immune cells in organs such 
as the liver, brain, and heart (Hulsmans, Sam et al. 2016). In the murine heart, ̴ 
10% of non-cardiomyocyte cells are macrophages with a comparable percentage 
in the human heart (Pinto, Paolicelli et al. 2012, Heidt, Courties et al. 2014). 
Macrophages have a spindle-like shape and typically exist in the interstitial space 
or near endothelial cells (Nahrendorf, Swirski et al. 2007, Pinto, Paolicelli et al. 
2012, Heidt, Courties et al. 2014). Macrophage numbers significantly increase 
post-MI due to infiltration of monocytes and the enhanced self-renewal capacity of 
resident macrophages (Heidt, Courties et al. 2014). As illustrated in lineage tracing 
studies, there are two major macrophage populations in the adult heart, classified 
according to their origin. The first population is embryonically-derived cardiac 
resident macrophages; these cells are present at birth and are maintained largely 
by local proliferation. The second subset is Ly6Chi-differentiated bone BM-derived 
macrophages (Ginhoux, Greter et al. 2010, Schulz, Gomez Perdiguero et al. 
2012). Of note, intestinal and dermal macrophages derive mostly from Ly6Chi cells 
in peripheral blood, originated from the BM, due to the fast-turnover rate (Zigmond, 
Varol et al. 2012, Tamoutounour, Guilliams et al. 2013). A recent study shows that 
the self-renewal capacity of embryonically derived macrophages substantially 
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decreases with age and BM-derived monocytes become the major source of 
macrophages, even under physiological conditions (Molawi, Wolf et al. 2014). 
Under normal physiological status, most cardiac macrophages are 
embryonically derived. These cells classify into multiple subsets based on the 
expression of histocompatibility-2 (MHC-II) and CCR2 (Epelman, Lavine et al. 
2014). Embryonically derived macrophages primarily originate from embryonic 
yolk-sac progenitors and from local proliferation of cardiac macrophages, without 
major contribution from BM-derived monocytes. Most cardiac resident 
macrophages are MHC-IIlo CCR2− (Epelman, Lavine et al. 2014, Leid, Carrelha et 
al. 2016). The second largest population of macrophages is MHC-IIhi CCR2−, 
arising from MHC-IIlo CCR2− macrophages (Epelman, Lavine et al. 2014). The third 
and most rare population is CCR2+ cells, which generate from hematopoiesis in 
the fetal liver and migrate during embryonic development to the heart (Epelman, 
Lavine et al. 2014, Leid, Carrelha et al. 2016, Honold and Nahrendorf 2018).  
Embryonically-derived CCR2- macrophages are primarily located in the 
myocardial wall and play crucial developmental roles in the formation of blood 
vessels and development of the heart conduction system (adult atrioventricular 
and sinus nodes) (Honold and Nahrendorf 2018). Research shows that 
macrophages communicate with cardiomyocytes through Cx43 (connexin 43) gap 
junctions and depolarize simultaneously with attached cardiomyocytes (Pinto, 
Paolicelli et al. 2012, Honold and Nahrendorf 2018). Conversely, CCR2+ 
macrophages reside in the trabecular projections of the endocardium and have a 
limited role in heart development (Honold and Nahrendorf 2018). Cardiac resident 
macrophages can also contribute to early neutrophil extravasation after infarction 
by production of CXCL (C-X-C motif chemokine ligand) 2 and CXCL5, facilitating 
transendothelial leukocyte migration into ischemic myocardium (Hulsmans, Clauss 
et al. 2017, Honold and Nahrendorf 2018). 
Although it remains highly controversial, the belief is that Ly6Chi monocytes 
differentiate into Ly6Clo macrophages shortly after migration to the heart. Research 
shows that Ly6Clo macrophages infiltrate the injured myocardium directly from the 
blood in the reparative phase. They reside in the heart for many weeks in low 
 
 
 
21 
 
numbers with unclear function and limited capacity to renew locally (Leuschner, 
Rauch et al. 2012, Courties, Heidt et al. 2014, Hilgendorf, Gerhardt et al. 2014). 
Another controversial finding is that cardiac macrophages with embryonic origin 
die locally soon after infarction, therefore; they are not involved in post-MI 
inflammatory events (Leuschner, Rauch et al. 2012).  
Macrophage function is primarily dependent on the surrounding 
environment. Adoptive studies show that lung transplantation of peritoneal 
macrophages leads to significant changes in the gene expression profiles and 
function of macrophages, which were compatible in new environments (Lavin, 
Winter et al. 2014). Steady state macrophage function is not fully understood in 
the heart, however; gene-profiling studies suggest they are vital for angiogenesis 
(Pinto, Paolicelli et al. 2012, Honold and Nahrendorf 2018). In addition, 
macrophages perform immunological cardiac functions such as regulation of 
infection defense and removal of dead cells (Ma, Mouton et al. 2018).  
Following MI, Infiltrated monocytes/macrophages phagocytize dead 
cardiomyocytes and neutrophils, thereby removing cellular and tissue debris from 
the injured myocardium (Figure 1.1). These cells produce inflammatory cytokines, 
proteases, and ROS (Frodermann and Nahrendorf 2017). It has been observed 
that macrophage depletion strategies in an experimental MI model cause 
progressive impairments in post-MI inflammation and, ultimately, cardiac recovery 
(van Amerongen, Harmsen et al. 2007, Leblond, Klinkert et al. 2015). Besides that, 
a more severe form of cardiac remodeling occurs with increased macrophage 
numbers, as reported in ApoE−/− (apolipoprotein E)( exhibiting a prolonged post-
MI inflammation)-deficient or chemokine Decoy Receptor D6 (resolving CC 
chemokine–driven inflammatory responses )-deficient mice (Panizzi, Swirski et al. 
2010, Cochain, Auvynet et al. 2012). While these observations may appear 
contradictory at face value, careful teasing apart of the used strategies in these 
studies can elucidate. Macrophages are very heterogenous and plastic 
populations of cells with various and rather complimentary functions. Interventions 
that specifically target a certain category or function of macrophages could be 
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more useful for better understanding the immunopathology of MI, unlike general 
suppression or enhancement of post-MI inflammation. 
In addition to their primary function (phagocytosis and efferocytosis), 
macrophages produce large amounts of chemokines/cytokines/lipid signaling 
molecules after injury (Swirski and Nahrendorf 2013, Ma, Mouton et al. 2018), 
which enable them to communicate with other cells in the heart and other tissues 
(Honold and Nahrendorf 2018). Macrophages secret MMPs and proteolytic 
enzymes, which degrade ECM and accelerate tissue remodeling and scar 
formation (Honold and Nahrendorf 2018). Additionally, macrophages produce 
copious amounts of anti-inflammatory cytokines, such as TGF-β, an essential 
player in cardiac healing and scar stabilization (Frangogiannis, Smith et al. 2002, 
Honold and Nahrendorf 2018). Macrophages induce angiogenesis through 
secretion of Vascular Endothelial Growth Factor (VEGF) (Nahrendorf, Swirski et 
al. 2007). The multiple polarization and activation states of macrophages govern 
their diversity in function (Ma, Mouton et al. 2018). Macrophage activation states 
are reflected by different gene expression profiles and functions, and are 
influenced by different microenvironments, time after injury, macrophage origin, 
and age (Nahrendorf and Swirski 2016, Ma, Mouton et al. 2018). Post-MI, 
macrophages are generally classified into pro-inflammatory/classically 
activated/M1-like or anti-inflammatory/alternatively activated/reparative/M2-like 
based on genetic and cytokine profiles and functions (Nahrendorf and Swirski 
2016, Ma, Mouton et al. 2018). 
Of note, macrophage classification into pro- and anti-inflammatory 
phenotypes is oversimplified and is mainly derived from in vitro systems and 
artificial stimulation strategies (Nahrendorf and Swirski 2016). In vivo, the 
activation state of macrophages more realistically represents a spectrum between 
pro- and anti-inflammatory phenotypes, which is highly influenced by surrounding 
microenvironment. Removing macrophages from these highly complex conditions 
may affect their activation state, as seen in microglia after 7 days in culture 
(Gosselin, Link et al. 2014, Nahrendorf and Swirski 2016). Secondly, M1 and M2 
may represent two extremes of activation state, leading one to ignore important 
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transitionally activated macrophages (Gosselin, Link et al. 2014). Activation of 
human monocytes with M-CSF or G-CSF followed by various stimuli generates 
macrophages with distinctly different profiles from the traditional M1/M2 
classifications, which may be relevant to cardiovascular disease (Xue, Schmidt et 
al. 2014, Nahrendorf and Swirski 2016). Despite the limitations in the M1/M2 
paradigm, it remains a helpful tool in examining changes in macrophage 
phenotype and respective function in response to various stimuli, environmental 
changes, therapeutic interventions, etc. Below, we summarize the main 
characteristics of pro- and anti-inflammatory macrophages.  
1.1.1.5.11.1 Classically activated macrophages (M1; pro-inflammatory) 
 Activated T-helper 1 lymphocytes (Th-1), which secrete large amounts of 
IFN-γ and other pro-inflammatory mediators like lipopolysaccharide (LPS) and 
cytokines (TNF-α, GM-CSF) interact with and classically activate macrophages 
(Mantovani, Sica et al. 2004, Gombozhapova, Rogovskaya et al. 2017). Further 
classification of M1 macrophages subdivides them into M1a if they are activated 
through TLRs or M1b if they are activated through high mobility box group protein 
1 (HMBG1), with lower phagocytic capability than M1a macrophages (Ben-
Mordechai, Palevski et al. 2015, Ma, Mouton et al. 2018). M1 macrophages are 
the dominant myocardial macrophages  in the first 3 days after MI (Ma, Mouton et 
al. 2018). Activated M1 macrophages phagocytize cellular debris, inducing 
changes in MHCII configuration and other cell surface markers (Bauersachs, 
Galuppo et al. 2001, Murray, Allen et al. 2014). This process also stimulates 
production of pro-inflammatory cytokines (IL12, IL-23, IL-27, TNF) and 
chemokines (CXCL9, CXCL10, CXCL11) and expression of cell surface markers 
(CD40, CD80, CD86) (Bauersachs, Galuppo et al. 2001). In addition, classically 
activated macrophages release high quantities of nitric oxide, ROS, and proteolytic 
enzymes (MMP-1, MMP-2, MMP-7, MMP-9, MMP-12), which break down 
fibronectin, collagen, elastin and other extracellular components (Mantovani, 
Biswas et al. 2013, Mulder, Banete et al. 2014, Ma, Mouton et al. 2018). While 
these mechanisms are essential for clearing damaged cardiac tissue after MI, if 
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left unchecked they can exacerbate the ischemic damage, expand the infarct 
region, and delay inflammation resolution (Ma, Mouton et al. 2018). More 
information about pro-inflammatory macrophages is found in Table 1.3. More 
information about markers of different subsets of immune cells is present in Table 
1.4. 
1.1.1.5.11.2 Alternatively activated macrophages (M2; reparative) 
Macrophages alternatively activate in response to anti-inflammatory 
mediators such as IL-4 and IL-13, produced by T-helper lymphocytes (Th-2) 
(Gombozhapova, Rogovskaya et al. 2017). Additional mediators, such as IL-12, 
IL-33, and IL-34, also cause M2 activation (Martinez, Gordon et al. 2006, Pesce, 
Kaviratne et al. 2006, Hazlett, McClellan et al. 2010). Moreover, M1 macrophages 
may be repolarized into M2 through treatment with pro-M2 factors, as detailed here 
(Pelegrin and Surprenant 2009). 
M2 macrophages are further subdivided into M2a, M2b, and M2c subsets 
(Nahrendorf and Swirski 2013) based on mechanism of activation, function, and 
gene profile. For example, M2a and M2c macrophages are important players in 
the adaptive immune response, while M2b macrophages are crucial for regulation 
and suppression of inflammation (Lindsey, Saucerman et al. 2016, 
Gombozhapova, Rogovskaya et al. 2017). Phenotypes can shift from one state to 
another as shown in both in vivo and in vitro experiments (Gombozhapova, 
Rogovskaya et al. 2017, Ma, Mouton et al. 2018). Recent evidence indicates a 
new M2 macrophage subset, M4, identified in response to monocyte activation 
with CXCL4 (Gleissner, Shaked et al. 2010). This phenotype expresses both M1 
(CD86 and major histocompatibity complex II) and M2 ( mannose receptor and 
fibrinogen-like protein 2) genes and their corresponding cytokines, while 
phagocytic function is almost entirely lost (Gleissner, Shaked et al. 2010). 
 M2 is the most dominant macrophage phenotype in the myocardium 5-7 
days after injury (Yan, Anzai et al. 2013, Ma, Mouton et al. 2018). These cells 
phagocytize necrotic cells to accelerate inflammation resolution, forming scar 
tissue (Ma, Mouton et al. 2018). These macrophages characteristically produce 
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large amounts of IL-10, IL-1ra, and decoy type II receptors. Receptors such as 
mannose (e.g. CD206), scavenger, galactose-type, and CD163 are also highly 
expressed by this phenotype (Bauersachs, Galuppo et al. 2001, Dinarello 2005, 
Gombozhapova, Rogovskaya et al. 2017). Furthermore, M2 macrophages secrete 
CCL17, CCL22, CCL24 and TGF-β, which mediate inflammation resolution and 
demonstrate anti-inflammatory effects (Kzhyshkowska, Gratchev et al. 2006, 
Mantovani 2008, Medzhitov and Horng 2009). TGF-β stimulates fibroblast 
generate of extracellular matrix components, as well as induction of myofibroblast 
differentiation (Gombozhapova, Rogovskaya et al. 2017). M2 macrophages 
secrete TGF-β, insulin like growth factor, and platelet-derived growth factor, which 
and promote angiogenesis and cell proliferation (Gombozhapova, Rogovskaya et 
al. 2017).  
After infarct, the macrophage life-span is approximately 20 hours. They are 
continuously replenished by infiltrating monocytes and the phenotypic changes of 
infiltrated macrophages (Lindsey, Saucerman et al. 2016). In humans, 
macrophages are recruited to the heart in a similar pattern but with a delayed 
kinetic due to age-related changes in the immune system (Ma, Mouton et al. 2018). 
Reperfusion strategies inhibit cardiac immune cell infiltration, resulting in an 
accelerated timeline of innate immune activation and reduced adaptive immune 
response (Yan, Anzai et al. 2013, Ma, Mouton et al. 2018). More information about 
anti-inflammatory macrophages is found in Table 1.3. More information about 
markers of different subsets of immune cells is present in Table 1.4. 
1.1.1.6 Inflammation resolution after cardiac ischemia 
Timely resolution of post-MI inflammation is important to prevent adverse 
cardiac remodeling and subsequent heart failure (Ma, Mouton et al. 2018). This 
response peaks in the first five days and decreases gradually (Ma, Mouton et al. 
2018). This process is related to neutrophil recruitment inhibition, apoptotic cell 
(neutrophils, myocytes) and matrix debris removal, and stimulation of fibroblast 
formation and collagen deposition (Frangogiannis 2012). Resolution of post-MI 
inflammation is primarily dependent on engulfment of apoptotic cardiomyocytes 
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and neutrophils which release high quantities of inhibitory mediators (Huynh, 
Fadok et al. 2002). Interruptions to this process negatively affect the following 
healing process (Wan, Yeap et al. 2013). More information about interfering with 
the immune response post-MI is found in Table 1.5. 
Macrophages are key players in the post-MI healing phase (Ma, Mouton et 
al. 2018), as evidenced by a decrease in recovery and exaggeration of adverse 
cardiac remodeling with total macrophage depletion and by the significant 
improvement in cardiac functional recovery with adoptive transfer of activated 
macrophage strategies (Leor, Rozen et al. 2006, van Amerongen, Harmsen et al. 
2007). Macrophages phagocytize apoptotic cells, inducing potent anti-
inflammatory and immune resolution activities. This process induces production of 
anti-inflammatory cytokines such as TGF-β and IL-10, actively participating in 
resolution of post-MI inflammation (will discuss later in Cytokines responsible for 
resolution of inflammation post-MI). Moreover, macrophages primarily contribute 
to fibrotic and angiogenic events post-MI. 
In addition, certain pathways may resolve post-MI inflammation. Expression 
of Interleukin Receptor Associated Kinase (IRAK)-M, an endogenous suppressor 
of innate immune response, has been shown to upregulate in macrophages and 
fibroblasts in the injured myocardium. Accordingly, this results in suppression of 
macrophage-derived cytokine expression and enhancement of a matrix-preserving 
myofibroblast phenotype in the heart (Chen, Saxena et al. 2012). Activation of 
mertk in macrophages is crucial for efficient removal of dead cardiomyocytes and 
initiation of the anti-inflammatory phase. Mertk deficiency is associated with more 
accumulation of apoptotic cardiomyocytes and unresolved inflammation, leading 
to decreased myocardial salvage (Wan, Yeap et al. 2013). Lipid pro-resolving 
mediators (resolvins, lipoxins, protectins, and maresins), potent anti-inflammatory 
compounds activated during phagocytosis, may have an essential role in resolving 
post-MI inflammation (Prabhu and Frangogiannis 2016). Studies show that 
exogenous administration of resolvin E1 or resolvin D1 enhances inflammation 
resolution and prevents adverse cardiac remodeling after infarction (Keyes, Ye et 
al. 2010, Kain, Ingle et al. 2015). There may be other pathways (TLR signaling, 
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Janus activated kinases (JAKs), and Pentraxin-3) that are potential mediators in 
resolution of post-MI inflammation, however their contribution remains unclear and 
needs further investigation (Frangogiannis 2012). 
 
1.1.1.6.1 Cytokines involve in inflammation resolution post-MI 
1.1.1.6.1.1 IL-10  
IL-10 is a potent anti-inflammatory cytokine, mainly expressed by stimulated 
Th2 lymphocytes and alternatively activated macrophages (Mosmann 1994, 
Frangogiannis 2012). IL-10 modifies monocyte/macrophage function, morphology, 
and phenotype. Secretion of IL-1α, IL-1β, TNF-α, IL-6, and IL-8 is inhibited by IL-
10 in macrophages (Frangogiannis 2012). Furthermore, IL-10 may participate in 
matrix remodeling via enhancement of TIMP-1 synthesis, leading to stabilization 
of ECM and scar, and thus, reduction of cardiac rupture risk (Lacraz, Nicod et al. 
1995, Frangogiannis 2012). IL-10 mRNA and protein levels are both increased in 
experimental I/R injury models (Frangogiannis 2012). On one hand, some studies 
show that depletion of IL-10 in mice is associated with exaggerated inflammation, 
excessive neutrophil recruitment, more advanced cardiac remodeling, and 
increased mortality (Yang, Zingarelli et al. 2000). Conversely, other studies reveal 
that IL-10-/- mice have comparable mortality rate and resolution of inflammation to 
wild type mice, but higher levels of TNF-α and MCP-1 in the damaged myocardium 
(Zymek, Nah et al. 2007). In addition, these studies show that deposition of fibrous 
tissue and scar formation are not affected by IL-10 deletion (Aoki and Kao 1999). 
These contradictory results may be explained by redundant and overlapping 
pathways responsible for inflammation resolution that are simultaneously activated 
and rescued in IL-10-/- mice after MI.   
  
1.1.1.6.1.2 TGF-β  
TGF-β is an essential element in the transition from inflammation to healing 
and fibrosis induced by its pleiotropic properties (Bujak and Frangogiannis 2007). 
Via activation of endothelial mononuclear cells, TGF-β inhibits the production of 
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pro-inflammatory cytokines and chemokines (Frangogiannis 2012). TGF-β 
stimulates fibroblast production of ECM proteins (collagen, fibronectin, tenascin, 
and proteoglycans) (Bassols and Massague 1988). Moreover, TGF-β reduces the 
expression of proteinases (plasminogen activator and collagenase) and enhances 
the production of proteinase inhibitors (plasminogen activator inhibitor and TIMP-
1), leading to an inhibition in matrix breakdown (Laiho, Saksela et al. 1986, 
Frangogiannis 2012). As a result, TGF-β plays a dual role post-MI; 1) reducing 
production of pro-inflammatory cytokines and chemokines, and 2) increase of the 
deposition of ECM (Frangogiannis 2012). Research shows that post-MI TGF-β 
administration decreases myocardial injury, an effect that is associated with TNF-
α inhibition (Lefer, Tsao et al. 1990). Other studies suggest that inhibiting the TGF-
β signaling pathway using a TGF-β type II receptor antagonist modulates fibrotic 
tissue accumulation at the injured myocardium and attenuates adverse cardiac 
remodeling (Ikeuchi, Tsutsui et al. 2004, Okada, Takemura et al. 2005). However, 
research also shows that earlier suppression of TGF-β decreases survival rate and 
accentuates LV dilatation and heart failure, suggesting a potential role for TGF-β 
signaling in the inhibition of post-MI inflammatory pathways (Ikeuchi, Tsutsui et al. 
2004, Frangogiannis 2012). These different observations most likely relate to the 
pleiotropic effects of TGF-β on the inflammatory and healing phase post-MI. TGF-
β  can activate both Smad-dependent and-independent pathways. In the 
inflammatory phase, Smad3 actively participates in post-MI inflammation 
resolution and fibrosis. While this signaling cascade does not seem to play a role 
in inflammation resolution in the healing phase, it facilitates interstitial fibrosis in 
the injured myocardium (Frangogiannis 2012). 
 
1.1.1.7 Targeting macrophage phenotypes 
The presence of pro-inflammatory monocytes/macrophages over a 
prolonged period in the myocardium induces infarct expansion (Courties, Heidt et 
al. 2014). Animal studies reveal that shifting macrophages to the reparative 
phenotype induces timely resolution of inflammation and enhances cardiac 
recovery (Weirather, Hofmann et al. 2014). Here, it is important to mention that 
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macrophage polarization is a multifactorial process dependent on interaction with 
other inflammatory cells, age, microenvironment, and time after injury. The balance 
between macrophage phenotypes is reversible (Ben-Mordechai, Palevski et al. 
2015) and can be therapeutically harnessed to enhance cardiac healing after 
ischemic injury. Research shows that early intervention aimed at altering 
macrophage activation state or shifting the balance towards the reparative state 
substantially reduces the risk of developing heart failure (de Couto, Liu et al. 2015, 
Kain, Liu et al. 2017). However, studies in alternative macrophage activation in MI 
have had limited safety in humans. In the next sections, we will critically evaluate 
the different anti-inflammatory approaches previously tested following MI.   
 
1.1.2 Anti-inflammatory treatments in MI 
A balanced inflammatory response fundamentally regulate healing and 
remodeling after MI. However, therapeutic interventions targeting the systemic 
inflammatory pathways have yielded limited success in pre-clinical and clinical 
studies. Modulating the post-MI inflammatory response is an elusive target as 
studies have shown that the complete inhibition of inflammation is rather harmful 
(Frangogiannis 2014). Animal studies using non-steroidal anti-inflammatory drugs 
(NSAIDs) yielded contradictory results regarding protection against myocardial 
injury (Jugdutt, Hutchins et al. 1980, Romson, Hook et al. 1982, Flynn, Becker et 
al. 1984, Mullane, Read et al. 1984). Some studies revealed that NSAIDs were 
able to protect the heart from ischemic injury, albeit with limited success. These 
studies suggest that these protective effects are not related to the inhibition of the 
cyclo-oxygenase pathway in the myocardial tissue (Jugdutt, Hutchins et al. 1980, 
Romson, Hook et al. 1982). It was also observed that ibuprofen, a member of the 
non-steroidal family, inhibits PMN activation by the complement cascade and 
generation of ROS species (Flynn, Becker et al. 1984). Other parts of research 
show no effect of NSAIDs on neutrophil infiltration and no beneficial effect on 
cardiovascular inflammation, remodeling, or development of heart failure (Mullane, 
Read et al. 1984). In clinical trials, NSAID use in coronary artery disease patients 
correlated with higher mortality and recurrent MI (Schjerning Olsen, Fosbol et al. 
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2011). Another anti-inflammatory class of therapeutic agents, glucocorticosteroids, 
were found to delay wound healing and are associated with higher incidence of  
ventricular aneurysm development in MI patients and therefore their use should be 
avoided (Bulkley and Roberts 1974). With modern anti-inflammatory therapies, 
observations from animal experimental studies suggest that suppression of IL-1, 
IL-6, MCP-1, CC chemokines, CXC chemokines, or TNF-α improves the cardiac 
recovery and function post-MI. Research demonstrates that targeting integrin 
signaling (CD11/CD18) reduces neutrophil recruitment after MI and is effective in 
minimizing scar size (Arai, Lefer et al. 1996). Unfortunately, data from clinical trials 
after acute ischemic injury were disappointing (Faxon, Gibbons et al. 2002). 
Deletion of IL-1 and MCP-1 significantly decreased adverse cardiac remodeling 
without noticeable reduction in scar size, which suggests that the inflammatory 
response contributes to reduced cardiac function post-MI without necessarily 
altering cardiomyocyte death (Bujak and Frangogiannis 2009, Frangogiannis 
2014).  On the other hand, selective targeting of potential inflammatory mediators 
in MI such as IL-1β using selective monoclonal antibodies demonstrate some 
success in clinical studies, albeit with high cost and modest benefit (Seropian, 
Toldo et al. 2014). Based on the above data, strategies aimed at modulating the 
inflammatory response rather than profoundly suppressing this response may 
represent promising therapeutic avenues to improve post-MI outcomes.  
 
1.1.3 Macrolides as immunomodulatory drugs 
Macrolides are antibiotic agents with a common structure that contain a 
macrolide ring (Zarogoulidis, Papanas et al. 2012). Macrolides include multiple 
FDA-approved members such as azithromycin, clarithromycin, erythromycin, 
roxithromycin, telithromycin, and dirithromycin, as well as non-FDA-approved 
agents such as carbomycin and josamycin (Zarogoulidis, Papanas et al. 2012). Of 
note, azithromycin (AZM) is an azalide derivative of macrolides, is not an inhibitor 
of CYP3A4, and has a lower potential to interact with food or other drugs, unlike 
other members. Macrolides have wider spectrum of coverage in comparison with 
penicillins and have lower risk of allergic reaction (Zarogoulidis, Papanas et al. 
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2012). The mechanism of action of macrolides as antibiotics is through inhibition 
of protein synthesis in microorganisms, caused by suppression of ribosomal 
translocation and inhibition of peptidyl-transferase action (Ungureanu 2010, 
Zarogoulidis, Papanas et al. 2012). They reversibly bind to the P site on the 50s 
subunit of the bacterial ribosome (Zarogoulidis, Papanas et al. 2012). Macrolides 
are bacteriostatic antibiotics, however; they become bactericidal at higher doses. 
Importantly, macrolides are highly concentrated in leukocytes, and thus, achieve 
high levels at sites of infection (Zarogoulidis, Papanas et al. 2012). 
In addition to antimicrobial activity, macrolides also have 
immunomodulatory and anti-inflammatory properties, as recently demonstrated in 
a large number of studies (Rubin and Henke 2004, Feola, Garvy et al. 2010, 
Zarogoulidis, Papanas et al. 2012). These non-antimicrobial activities are dose-
time-dependent, and the underlying molecular mechanisms remain poorly defined 
(Kanoh and Rubin 2010, Zarogoulidis, Papanas et al. 2012). Macrolides are able 
to reduce the time of inflammation and modulate immune system activation 
(Zarogoulidis, Papanas et al. 2012). Moreover, macrolides display 
immunomodulatory actions through polarization of immune cells to the anti-
inflammatory activation state (Feola, Garvy et al. 2010), modifying the production 
of cytokines (Shinkai, Foster et al. 2006), reducing the generation of ROS, 
preventing neutrophil activation and migration, inducing neutrophil apoptosis, and 
inhibiting nuclear transcription factors (Kanoh and Rubin 2010, Zarogoulidis, 
Papanas et al. 2012). Hence, macrolides are immunomodulatory rather than 
immunosuppressive drugs as they exhibit a non-linear time-dependent inhibition 
of pro-inflammatory mediators (Kanoh and Rubin 2010).  
 
1.1.3.1 Molecular mechanisms of immunomodulatory effects of macrolides 
The mode of action of macrolides as immunomodulatory agents seems  
multifaceted (Kanoh and Rubin 2010). These mechanisms may include: a) 
normalization of the Ca+2 response and maintenance of normal intracellular Ca+2 
concentration (Kanoh and Rubin 2010), b) inhibition of the mitogen-activated 
protein kinase (MAPK) pathway, specifically ERK1/2 (Kaneko, Yanagihara et al. 
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2003, Imamura, Yanagihara et al. 2004, Tsai, Rodriguez et al. 2004, Kanoh and 
Rubin 2010), and c) inhibition of NF-kB and activator protein 1 (AP-1) signaling 
through inhibition of nuclear translocation and signaling (Aoki and Kao 1999, 
Desaki, Takizawa et al. 2000, Kanoh and Rubin 2010). The proposed modes of 
action of immunomodulatory effects of macrolides are summarized in Figure 1.2. 
The following will focus on the immunomodulatory and anti-inflammatory 
properties of AZM as it is the agent of choice in this project. 
1.1.4 Azithromycin 
AZM is highly concentrated in leukocytes, macrophages and neutrophils, 
where it reaches 5 to 100-fold higher concentrations than in serum (Foulds, 
Shepard et al. 1990, Zimmermann, Ziesenitz et al. 2018). The AZM modulation of 
macrophage activation state towards the anti-inflammatory phenotype and the 
cytokine profile to the anti-inflammatory state is well documented (Zarogoulidis, 
Papanas et al. 2012). AZM therapy also reduces glutathione S-transferases 
(GSTs), specifically GST theta 1 (GSTT1) and GST Mu 1 (GSTM1) levels in cystic 
fibrosis cell lines (Jiang, Finkbeiner et al. 1999, McGrath-Morrow and Stahl 2000, 
Leme, Raposo et al. 2010), implying that AZM may have novel antioxidant activity 
(Zarogoulidis, Papanas et al. 2012). Interestingly, IL-10 levels also decline with 
GST, suggesting a relationship between immunomodulatory effects and 
suppression of GST. AZM suppresses H292 cell line stimulation by N-3-
oxododecanoyl homoserine lactone (3-oxo-C12-HSL), a sensory signaling 
molecule produced by P. aeruginosa, due to inhibition of ERK1/2 phosphorylation 
(Imamura, Yanagihara et al. 2004, Kanoh and Rubin 2010).  
Studies reveal that AZM reduces the expression of mRNA and protein levels 
of TNF-α, which may be attributed to inhibition of NF-kB and AP-1 translocation to 
the nucleus and binding to DNA (Ivetic Tkalcevic, Bosnjak et al. 2006, Cigana, 
Assael et al. 2007, Zarogoulidis, Papanas et al. 2012). LPS-stimulated models also 
show reduction of TNF-α with AZM treatment (Ivetic Tkalcevic, Bosnjak et al. 2006, 
Zarogoulidis, Papanas et al. 2012). Research reports that AZM inhibits both TNF-
α secretion and neutrophil recruitment to the lung in a murine model (Tsai, 
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Rodriguez et al. 2004, Feola, Garvy et al. 2010). Following neutrophil mobilization 
and activation to the site of injury, they undergo apoptosis, initiating inflammation 
resolution (Kanoh and Rubin 2010). AZM enhances neutrophil apoptosis (Koch, 
Esteban et al. 2000, Kanoh and Rubin 2010), and promotes macrophage 
phagocytosis of apoptotic neutrophils, resulting in inflammation resolution.  This 
resolution is related to the alternatively activated macrophage state (Yamaryo, 
Oishi et al. 2003, Hodge, Hodge et al. 2006). 
1.1.4.1 Immunomodulatory and anti-inflammatory effects of AZM in sterile 
inflammatory diseases 
AZM modulates the inflammatory response through macrophage 
repolarization towards the reparative state (Murphy, Sundareshan et al. 2008, 
Cory, Birket et al. 2014), as demonstrated in models of inflammation and tissue 
injury such as spinal cord injury (Zhang, Bailey et al. 2015), lung inflammation 
(Feola, Garvy et al. 2010), and stroke (Amantea, Certo et al. 2016). In a model of 
lung inflammation, AZM reduces the production of pro-inflammatory cytokines (IL-
6 and IL-12) while increasing IL-10. Additionally, AZM significantly decreases the 
expression of iNOS and pro-inflammatory macrophage receptor (CCR7) while 
increasing arginase activity and anti-inflammatory macrophage receptor (MR and 
CD23) expression (Murphy, Sundareshan et al. 2008). In an ischemic stroke 
model, which induces a sterile inflammatory response similar to MI, AZM shifts 
macrophages towards the reparative phenotype, leading to a limited blood brain 
barrier injury and improved neurological recovery (Amantea, Certo et al. 2016). 
Likewise, in an experimental retinal ischemia/reperfusion model, AZM is protective 
against neuronal injury. This protection is attributable to the anti-inflammatory 
properties of the drug, as evidenced by reduced MMP-9/2 expression and activity 
(Varano, Parisi et al. 2017). Research in a  spinal cord injury model finds that pre-
injury AZM treatment induces macrophage repolarization to the reparative 
phenotype as demonstrated by increased M2 macrophage (CD206, Arginase 1) 
and reduced M1 macrophage (CD86) marker  expression (Zhang, Bailey et al. 
2015). Accompanying the immunomodulatory effects of AZM is an increase in 
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tissue sparing and functional recovery (Zhang, Bailey et al. 2015). In this report, in 
vitro experiments confirm a well-defined shift in cytokine profile towards the anti-
inflammatory state (IL-12 downregulation and IL-10 upregulation), indicating a 
more prominent M2 macrophage phenotype with AZM therapy. Subsequent work 
by the same group shows that post-injury AZM treatment significantly shifts 
macrophage state to the reparative phenotype (Gensel, Kopper et al. 2017) in 
macrophages isolated from spinal cord as well as in in vitro stimulated 
macrophages using a gene-array approach to provide a comprehensive and 
unbiased profiling of macrophage phenotype. Importantly, this work shows that 
AZM doses (10, 40, 160 mg/kg) suppress the expression of pro-inflammatory (M1) 
genes in macrophages, while two doses (10, 160 mg/kg) induce anti-inflammatory 
(M2) gene expression (Gensel, Kopper et al. 2017). These effects strongly suggest 
that AZM exerts its immunomodulatory effects in both high and low doses similarly, 
without causing off-target effects at higher doses. 
 
1.1.5 Liposomes 
Various therapeutic agents have attempted to alleviate cardiac remodeling 
post-MI through systemic administration, however; they achieved limited efficacy 
due to a lack of bioavailable cardiac tissue (Dasa, Suzuki et al. 2015). Furthermore, 
most drug delivery systems do not achieve sufficient accumulation in the damaged 
myocardium or in the cells of interest, which may increase potential off-target 
effects. Although local delivery may be an option in the setting of MI, it may require 
repeated catheterization, which is not an applicable and cost-effective procedure 
(Dasa, Suzuki et al. 2015). To avoid off-target effects and enhance efficacy, an 
encapsulated dosage form has been utilized successfully (Bornmann, Graeser et 
al. 2008, Dasa, Suzuki et al. 2015). 
Liposomal dosage form, an FDA approved drug delivery platform, is a self-
closed spherical structure made of one or more phospholipid bilayers surrounded 
by an aqueous core. Since they can hold both lipophilic and hydrophilic 
compounds, liposomes represent an attractive drug delivery system to achieve 
targeted drug delivery (Levchenko, Hartner et al. 2012).  They improve drug 
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pharmacokinetics, minimize systemic side effects, decrease required dose, 
prolong circulation half-life, and reduce time to reach steady state (Oh, Nix et al. 
1995). In addition, encapsulated therapeutic agents slowly release from the 
liposomes, providing continuous exposure to the targeted site and enhanced drug 
efficacy (Cheraghi, Negahdari et al. 2017). Non-cardiac applications show that 
liposomal delivery platforms can reduce doxorubicin drug toxicity by reducing the 
administered dose while keeping or enhancing antitumor effectiveness (Rose 
2005). In this study, liposomal doxorubicin reaches steady state level faster and 
with fewer doses due to promoted accumulation in the targeted organs (Charrois 
and Allen 2003). After infarct, cellular and vascular permeability increase in the 
injured myocardium, facilitating the accumulation of nanoparticles such as 
liposomes in the damaged zones (Takahama, Minamino et al. 2009). Liposomes 
are a proven potent drug delivery system that can serve as a carrier to achieve 
higher drug concentration at sites of cardiac injury (Mueller, Marcus et al. 1981). 
Liposomes can also augment the local distribution of tracers in the infarcted 
myocardium (Caride, Twickler et al. 1984).  
The post-infarction myocardium contains a large variety of diverse cells 
such as inflammatory phagocytes that may be successfully targeted, 
hypothetically,  by liposomal delivery platforms (Oh, Nix et al. 1995). After 
parenteral administration, mononuclear phagocytes naturally take up liposomes. 
Liposomes can harness the physiological function of these cells to mediate 
targeted delivery, therefore promoting therapeutic agent efficacy (Kelly, Jefferies 
et al. 2011). Stroke research shows that parentally administered gene therapy 
localizes in infiltrated macrophages in the infarcted brain (Tanaka, Kitagawa et al. 
2004). These observations replicate with macrophages in several studies (Scott, 
Rosano et al. 2009, Harel-Adar, Ben Mordechai et al. 2011, Cheraghi, Negahdari 
et al. 2017). Mononuclear phagocytes (neutrophils, monocytes, macrophages) 
play pivotal roles in the immunopathology of MI, and thus, represent an attractive 
target for liposomal drug delivery (Kelly, Jefferies et al. 2011), as demonstrated 
with liposomal celecoxib therapy (Margulis, Neofytou et al. 2015, Cheraghi, 
Negahdari et al. 2017). 
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In targeting cardiac macrophages with liposomes, research shows that 
parenteral administration of phosphatidylserine-presenting liposomes (PS-
liposomes) shifts cardiac macrophage phenotype to the reparatory state (Harel-
Adar, Ben Mordechai et al. 2011). These liposomes are taken up by macrophages 
both in vivo and in vitro, activating them to produce large amounts of anti-
inflammatory cytokines (TGF-β and IL-10) and reduce production of pro-
inflammatory cytokines (TNF-α). Moreover, mannose receptor, CD206, is 
upregulated, while pro-inflammatory macrophage marker, CD86, is 
downregulated, implicating a marked shift in the function from pro-inflammatory 
towards reparative state. This strategy is associated with significant improvement 
in scar size, angiogenesis, LV function, and cardiac remodeling in the PS-liposome 
treated group (Harel-Adar, Ben Mordechai et al. 2011).  
 
1.1.5.1 Liposomal AZM 
AZM precipitates in aqueous solution due to poor solubility, which has 
detrimental effects on drug efficacy (Peters, Friedel et al. 1992, Oh, Nix et al. 
1995). To prevent AZM hydrolysis during storage and to achieve easier 
administration without co-solvents, a lyophilized drug-phospholipid dosage 
formulation may be used. Hydrophobic drugs such as AZM reside in the acyl 
hydrocarbon chain of liposomes, while hydrophilic drugs locate mostly in the 
aqueous interior. Therefore, liposomal formulations may be effective in increasing 
solubility, extending half-life, and improving the therapeutic index and stability of 
AZM (Cheraghi, Negahdari et al. 2017). Consequently, liposomes alter the 
biodistribution and the clearance rate of encapsulated drugs (Gabizon, Shmeeda 
et al. 2003, Cheraghi, Negahdari et al. 2017). Our research indicates that 
liposomes increase AZM solubility 75 times, suggesting superior potency due to 
higher drug availability. In agreement with this strategy, studies show that the 
antibacterial effects of liposomal AZM against intracellular M. avium growth in 
macrophages is 41-fold higher than free AZM (Oh, Nix et al. 1995). This may 
explain the success of liposomal preparation in promoting the pharmacodynamic 
effects of the drug. Although lack of efficient assays to precisely determine the 
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intracellular concentration of AZM limits our ability to test this hypothesis, this 
strategy successfully enhances the intracellular deposition of other antibiotics 
(ciprofloxacine) (Oh, Nix et al. 1995). Additionally, AZM substantially spreads 
throughout the body due to the large volume of distribution (27 liters/kg) (Oh, Nix 
et al. 1995), and as such, developing a strategy that constrains it to target cells 
may improve efficacy and prevent non-specific distribution and accumulation. In 
conclusion, liposomes are valuable tools in enhancing the pharmacokinetics, 
reducing off target side effects, and achieving targeted delivery of drugs post-MI. 
Furthermore, these liposomes decrease the exposure of other systems to the drug 
and thus reduce the potential microbial resistance for AZM. 
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1.2. STATEMENT OF THE PROBLEM 
 
Myocardial infarction (MI) is a severe ischemic disease, causing sudden 
death and heart failure with prevalence rates promptly rising worldwide. Despite 
significant advances in medical care, mortality rate and comorbid complications 
remain high in MI patients. Heart failure is one of the most expensive chronic 
illnesses with medical costs constituting 1-2% of overall healthcare spending. Post-
MI inflammatory changes in the heart play a critical role in the pathophysiology of 
MI and its related complications. Likewise, these inflammatory pathways regulated 
healing and remodeling after MI. Accordingly, targeting suppression of post-MI 
inflammation is a potential therapeutic approach in MI treatment. However, multiple 
clinical trials fail to demonstrate the effectiveness of traditional anti-inflammatory 
drugs such as corticosteroids, cyclosporine, and non-steroidal anti-inflammatory 
drugs in treating patients with MI. Additionally, studies that selectively target one 
signaling pathway (cytokine and/or receptor) fail to demonstrate robust clinical 
benefits. 
A growing body of evidence suggests that modulation of post-MI 
inflammation via selective targeting of potential inflammatory mediators may hold 
the key in protecting the heart from adverse cardiac remodeling and chronic heart 
failure. However, the development of such therapies is a challenge as they must 
act as immunomodulatory rather than immunosuppressive agents since 
immunosuppressive agents have proven harmful in MI patients. Macrophages are 
key players in acute inflammation and chronic recovery, which present in MI in two 
activation states: pro-inflammatory and reparative. Pro-inflammatory macrophages 
contribute to adverse cardiac remodeling and heart failure while reparative 
macrophages enhance tissue healing. Recent research reveals that 
immunomodulation of the inflammatory response post-MI via macrophage 
repolarization towards the reparative state counterbalances pathophysiological 
mechanisms of adverse cardiac remodeling and prevents heart failure. However, 
translational approaches to harness this benefit are not clinically available. 
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In this work, we represent an approach to achieve this goal by using a small 
molecule drug. Research demonstrates that azithromycin (AZM) alters the 
inflammatory response and polarizes macrophages to the alternatively activated 
state in various inflammatory pathologies. AZM has an excellent safety profile and 
is approved for human use. We hypothesize that AZM therapy modulates the 
excessive inflammatory response post-MI, and thus, improves cardiac recovery.  
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1.3 Hypothesis 
Azithromycin is a potential immunotherapy to improve inflammation and adverse 
cardiac remodeling after MI. To test this hypothesis, we performed the following 
studies: 
1: Examine the immunomodulatory and cardioprotective effects of azithromycin 
post-MI (a proof-of-concept study). 
Hypothesis: AZM therapy modulates the potent inflammatory response, and thus, 
improves cardiac recovery after infarction. 
2: Determine the immunotherapeutic effects of low dose liposomal AZM delivered 
after infarction (clinically-relevant study). 
Hypothesis: Low dose liposomal AZM (Lazm) treatment, started immediately after 
MI, yields an enhanced immunomodulatory potential and cardiac recovery with low 
risk of adverse effects 
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Table 1.1: Innate immune mechanisms in MI: contribution of studies using 
transgenic mice (Liaudet and Rosenblatt-Velin 2013) 
 
Transgenic 
strain 
Model 
of MI 
Main findings 
TNF alpha 
pathway 
    
TNF alpha KO I/R (30'-
120') 
Reduced infarct size and contractile dysfunction. 
Reduced NF-kappaB activation, chemokine expression, 
PMN infiltration. 
TNF alpha KO P.O. (up 
to 7 D) 
Improved cardiac function. Reduced myocardial ICAM-1 
expression. 
TNFR1-R2 KO P.O. (24 
h) 
Increased infarct size, increased apoptosis of cardiac 
myocytes. 
TNFR1 (p55) 
KO 
P.O. 7-
28 D 
Reduced mortality, improved functional recovery. 
TNFR2 (p75) 
KO 
P.O. 7-
28 D 
Increased mortality, increased LV dysfunction. 
IL-1 beta pathway 
IL-1R KO I/R (1 
h/6 h to 
7 D) 
Reduced chemokine, cytokine and MMP expression. 
Reduced PMN infiltration, LV dilation and LV fibrosis. 
gp-130 mutant P.O. (up 
to 2 W) 
Persistent myocardial STAT3 activation, increased 
myocardial inflammation, LV dysfunction and LV rupture. 
IL-10 pathway     
IL-10 KO I/R (30'-
2-24 h) 
Increased PMN infiltration, ICAM-1/TNF expression and 
infarct size. 
IL-10 KO I/R (1 
h/6 h to 
7 D) 
Increased expression of TNF and CCL2. No effect on LV 
dysfunction and remodeling. 
TGF beta 
pathway 
    
Smad3 KO I/R (1 
h/6 h to  
D) 
Reduced PMN infiltration and chemokine expression. 
Reduced dilative LV remodeling and diastolic 
dysfunction. 
TSP-1 KO I/R (1 
h/3 h to 
7 D) 
Increased and prolonged expression of IL-1, IL-6 and 
TGF-beta. Enhanced LV adverse remodeling with 
increased fibrosis. 
CXCR4 KO P.O. (3 
W) 
No influence on LV systolic dysfunction and adverse 
remodeling 
IP-10 KO I/R (1 
h/6 h to 
7 D) 
Expansion of fibrosis, increased remodeling and systolic 
dysfunction 
Increased PMN (after 24 and 72 h) and macrophages 
(after 3 to 7 D). 
MCP-1 KO I/R (1 
h/6 h to 
7 D) 
Delayed macrophage recruitment and myofibroblast 
accumulation. Reduced cytokine expression. Reduced 
LV remodeling. 
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 Table 1.1 (Continued) 
CCR2 KO P.O. (up 
to 28 D) 
Reduced macrophage infiltration, MMP expression and 
collagen deposition. Reduced LV systolic dysfunction 
and LV remodeling. 
CCR1 KO P.O. (up 
to 21 D) 
Reduced PMN infiltration, decreased apoptosis, 
increased proliferation of myofibroblasts in the infracted 
tissue. Reduced LV remodeling. 
ICAM-1 KO I/R 
(30'/2 h-
3 W) 
Reduced reperfusion injury at 2 h. 
ICAM-1/P-sel 
KO 
I/R (30'-
1 h/3-24 
h) 
Reduced PMN infiltration at 24 h, but no change in infarct 
size. 
CD-18 KO I/R 
(30'/2 h) 
Reduced PMN infiltration and smaller infarct size (at 2 h 
reperfusion) 
Cardiac 
restricted 
mutated 
IkappaB 
P.O. (4 
W) 
Diminished NF-kB p65 activation and cytokine 
expression. Reduced LV remodeling, fibrosis and systolic 
function. 
Cardiac-
restricted 
mutated 
IkappaB 
P.O. (24 
h) 
Increased infarct size and apoptosis. Reduced 
expression of anti-apoptotic proteins (Bcl-2 and c-IAP1). 
p50 KO I/R 
(30'/24 
h) 
Reduced PMN infiltration, decreased infarct size 
p50 KO P.O. (up 
to 8 W) 
Reduced mortality, LV remodeling and systolic 
dysfunction 
p50 KO P.O. (4 
W) 
Increased expression of cytokines, chemokines and 
MMPs. Enhanced remodeling, fibrosis, hypertrophy and 
systolic dysfunction. 
TLR2 KO I/R 
(30'/60') 
(isolated 
hearts) 
Improved post-ischemic functional recovery. Blunted 
myocardial expression of TNF alpha and IL-1 beta. 
TLR2 KO P.O. (1 
to 4 W) 
Reduced TGF beta expression and fibrosis. Reduced LV 
remodeling and systolic dysfunction. 
TLR2 KO I/R 
(30'/60') 
Reduced myocardial PMN accumulation, ROS formation 
and IL-1 beta expression. Suppressed coronary 
endothelial dysfunction. 
TLR4 deficient 
(C3H/HeJ mice) 
P.O. (up 
to 4 W) 
Reduced remodeling and preserved systolic function. 
Reduced fibrosis and expression of cytokines. 
TLR4 KO P.O. (1-
4 W) 
Reduced systolic dysfunction and remodeling. 
Decreased TGF beta expression. Reduced lymphocyte 
infiltration and apoptosis. 
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Table 1.1 (Continued) 
TLR4 KO I/R (1 
h/24 h) 
Reduced infarct size, myocardial PMN infiltration and 
oxidative stress. 
MyD88 KO I/R (1 
h/up to 
7 D) 
Reduced infarct size, reduced LV dysfunction, reduced 
myocardial PMN infiltration, MCP-1 and ICAM-1 
expression. 
RAGE KO I/R 
(30'/48 
h) 
Reduced infarct size, myocardial inflammation and 
dysfunction. 
Inflammasome 
pathway 
    
Caspase-1 KO P.O. (up 
to 9 D) 
Reduced LV remodeling, MMP-3 and IL-18 expression 
and apoptosis. 
ASC KO I/R 
(30'/up 
to 2 W) 
Reduced infarct size at 48 h. Reduced LV fibrosis, 
remodeling and systolic dysfunction. Reduced 
myocardial cytokine expression. 
 
ASC: apoptosis-associated speck-like protein containing a caspase recruitment 
domain; Bcl-2: B-cell CLL/lymphoma 2;c-IAP-1: inhibitor of apoptosis protein-1; 
CCL: chemokine (C-C motif) ligand ; CCR: chemokine (C-C motif) receptor; 
CXCR: chemokine (C-X-C motif) receptor; D: Day; H: hour;ICAM-1: inter-cellular 
adhesion moelcule-1; IkappaB: inhibitor of KappaB; IL: interleukin; IL-1R: IL-1 
beta receptor; IP-10: Interferon-inducing protein 10; I/R: Ischemia/Reperfusion; 
KO: Knockout; LV: left ventricle; MCP-1: monocyte chemoattractant protein-1; 
MMP: matrix metalloproteinase; MyD88: myeloid 
differentiation primary response gene 88; NF-kappaB: nuclear factor kappaB; 
PMN: ploymorphonuclear cell; P.O.: permanent occlusion; P-sel: P-selectin; 
RAGE: receptor for advanced glycation end-products; ROS: reactive oxygen 
species; SDF-1: stromal cell-derived factor-1; STAT: signal transducer and 
activator of transcription; TGF beta: transforming growth factor beta; TLR: toll-like 
receptor; TNF alpha: tumor necrosis factor alpha; TNFR1: TNF receptor 1; 
TNFR2: TNF receptor 2; TSP-1: Thrombospondin-1; W: week. 
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Table 1.2: Gating strategies for immune cells (Ma, Mouton et al. 2018) 
Gating strategy Cells labeled Species 
Monocytes 
  
Ly6ChighCCR2highCX3CR1lowCD62 L+ Classical monocytes Mouse 
Ly6ClowCCR2lowCX3CR1highCD62L− Nonclassical 
monocytes 
Mouse 
CCR2+Ly6Chigh Inflammatory blood 
monocytes 
Mouse 
CD14+CD16−, CD14+CD16+ Blood monocytes Human 
B220−F4/80+CD115+Ly6C−, 
B220−F4/80+CD115+Ly6C+ 
Blood monocytes Mouse 
MHCIIlowCCR2+ Cardiac monocytes Mouse 
CD11 b+F4/80−Ly6G−Ly6Chigh, 
CD11 b+F4/80−Ly6G−Ly6Clow 
Monocytes Mouse 
Lineage−CD11 b+F4/80lowLy6C+ Cardiac monocytes Mouse 
CD11 b+CD11C−MHCII−CD68−Ly6Clow, 
CD11 b+CD11C−MHCII−CD68−Ly6Chigh 
Blood and cardiac 
monocytes 
Mouse 
Macrophages 
  
CD45+CD11 b+F4/80+CD206− M1 macrophages Mouse 
CD45+CD11 b+F4/80+CD206+ M2 macrophages Mouse 
CD45+CD11 b+F4/80+Ly6Clow Resident cardiac 
macrophages 
Mouse 
CD11 b+F4/80+CD206+ Alternatively 
activated 
macrophages 
Mouse 
CD11 b+F4/80+CD64+Ly6C+MHCII+/− M1 like 
macrophages 
Mouse 
CD11 b+F4/80+CD64+Ly6C−MHCII+/− M2 like 
macrophages 
Mouse 
F4/80+CD86+ M1 macrophages Mouse 
F4/80+CD206+ M2 macrophages Mouse 
F4/80+CD206− M1 macrophages Mouse 
CD45+CD68+ Cardiac, blood, and 
spleen 
macrophages 
Rat 
CD11 b+F4/80+CD68+Ly6Clow, CD11 
b+F4/80+CD68+Ly6Chigh 
Monocyte-derived 
cardiac 
macrophages 
Mouse 
CD14+CD64+MERTK+F4/80+CX3CR1+MHCII−, 
CD14+CD64+MERTK+F4/80+CX3CR1+MHCII+, 
CD14+CD64+MERTK+F4/80+CX3CR1−MHCII−, 
CD14+CD64+MERTK+F4/80+CX3CR1−MHCII+ 
Resident cardiac 
macrophages 
Mouse 
F4/80+CD11 b+Ly6Clow, F4/80+CD11 
b+Ly6Cmedium, F4/80+CD11 b+Ly6Clhigh 
Alternatively 
activated 
macrophages 
Mouse 
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Table 1.2 (Continued) 
CD45+CD11 b+F4/80+Ly6C−MHCIIhigh, 
CD45+CD11 b+F4/80+Ly6C−MHCIIlow, CD45+ 
CD11 b+F4/80+Ly6C+MERTK+CD206+, CD45+ 
CD11 b+F4/80+Ly6C+MERTK−CD206− 
Cardiac resident 
macrophages 
Mouse 
CD45+F4/80+MHC-IIlowCCR2−, 
CD45+F4/80+MHC-IIhighCCR2− 
Cardiac resident 
macrophages 
Mouse 
CD45+F4/80+MHCIIhighCCR2+ Monocyte-derived 
cardiac 
macrophages 
Mouse 
CD14+CD16+CD163+CD204+CD206+CD209− Anti-inflammatory 
M2c macrophages 
Human 
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Table 1.3: Properties of M1 and M2 macrophages post-MI (Ma, Mouton et al. 
2018) 
  
Pro-inflammatory Anti-inflammatory 
Stimuli GM-CSF, IFN-γ, TNF-α, IL-1β Hydrogen sulfide, IL-4, IL-10, 
IL-13, IL-33, TGF-β1, M-CSF 
Transcription 
factors 
AP-1, HIF-1α, IRF3, IRF5, NF-
κB, STAT1 
c-Maf, c-Myc, IRF4, JMJD3, 
KLF4, PPAR-γ, STAT3, 
STAT6 
Markers CCL2 (MCP1), CCL3 (MIP1a), 
CCL4 (MIP1b), CCL5 
(RANTES), CCL7, CCL8, 
CCR2, CD80, CD86, CXCL1, 
CXCL2, CXCL6, CXCL8 (IL-8), 
CXCL9, CXCL10, CXCL11, 
CXCL16, IL-1β, IL-6, IL-12, IL-
23, iNOS, MHCII, RNS, ROS, 
S100a8, S100a9, TNF-α 
Arg1, CCL1, CCL16, CCL17, 
CCL18, CCL22, CCL24, 
CXCL13, CXCL17, CXCL22, 
CXCL24, CXCR1, CXCR2, 
CD163, CD206 (MRC1), 
CD280 (MRC2), Cd301a 
(Clec10a, Mgl1), Cd301 b 
(Mgl2), Dectin-1, Fizz1 
(Retnla, Relmα), IL-10, 
PGE2, Spp1 (osteopontin), 
Stabilin1, TGF-β1, VEGF, 
Ym1 (Chi3l3) 
Cell 
physiology 
Pro-inflammation; proteolysis; 
phagocytosis of debris; 
antigen presentation to 
lymphocytes 
Anti-inflammation and 
resolution of inflammation; 
phagocytosis of apoptotic 
cells; pro-angiogenesis; 
ECM production and scar 
formation 
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Tabl1 1.4: Summary of markers of immune cells in humans and rodents 
(Ma, Mouton et al. 2018) 
Marker Location Expressed by Cell physiological 
function 
CCR2/CD192 Cell surface Monocytes, 
macrophages 
Mediates Ly6Chigh 
monocytes 
recruitment and 
migration 
CD11 b/ITGAM Cell surface Monocytes, 
macrophages, 
neutrophils, 
NK cells 
Couples with CD18 to 
form integrin αMβ2 
(also named Mac1 or 
complement receptor 
3) to initiate immune
response
CD14 Cell surface Human 
monocytes 
Mediates toll-like 
receptor 4 activation 
and production of IFN-
β 
CD16/FCGR3 Cell surface Human 
monocytes 
Binds to the Fc portion 
of IgG antibodies, 
antigen presentation, 
anti-inflammatory 
cytokine production 
CD64/FcγR1 Cell surface Monocytes, 
macrophages 
Antibody-dependent 
phagocytosis, 
recognizes the Fc 
region of IgG 
CD68/macrosialin Endosomal/l
ysosomal 
compartment
, cell surface 
Monocytes, 
macrophages 
Antigen processing 
and presentation, 
binds to oxidized low-
density lipoprotein 
CD163 Cell surface, 
secreted 
(soluble) 
Macrophages, 
neutrophils 
Hemoglobin/haptoglob
in scavenger receptor, 
anti-inflammatory 
CX3CR1 Cell surface Monocytes, 
macrophages 
Mediates Ly6Clo 
monocyte recruitment, 
inhibits proliferation of 
local macrophages 
F4/80/EMR1 Cell surface Macrophages Promotes pro-
inflammatory factor 
production, induces 
antigen-specific 
efferent Treg cells 
48 
Table 1.4 (Continued) 
Galectin 3/Mac2 Cell surface, 
secreted 
Macrophages Induces monocyte-
macrophage 
differentiation, 
interferes with 
dendritic cell fate 
decision, regulates T 
cell apoptosis, inhibits 
B-lymphocyte
differentiation into
plasma cells
Ly6C/Gr-1 Cell surface Monocytes A specific marker for 
pro-inflammatory 
monocytes 
Mac3 Cell surface Macrophages A glycoprotein 
MERTK Cell surface Macrophages, 
phagocytes 
Mediates 
phagocytosis, 
increases migration 
MHCII Cell surface Macrophages, 
dendritic cells, 
B cells 
Mediates antigen 
presentation 
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Table 1.5: Post-MI effect of perturbing inflammation components (Mouton, 
Rivera et al. 2018) 
 
Perturbation Effect Mechanism 
Reducing 
inflammation: 
↑LV physiology IL-1α null: ↓innate immune response in  
cardiac fibroblasts 
IL-1α null 
TREM1 null 
NF-κB null 
TLR4 null 
TRPV2 null 
PS-
presenting 
liposomes 
↓LV remodeling TREM1 null: ↓myeloid cell recruitment 
from the spleen and bone marrow; 
↓CCR2+  
Pro-inflammatory but not pro-reparative 
X3CR1+ monocyte infiltrationTLR4 null: 
↓neutrophil infiltration/activation TRPV2 
null: ↓macrophage migration PS-
liposomes: ↑macrophage secretion of IL-
10 and TGF-β 
Total 
neutrophil 
depletion 
↓LV physiology ↓Necrotic myocyte removal 
↑Fibrosis ↑Macrophage inflammatory response 
 ↑Myofibroblast activation 
Total 
macrophage 
depletion 
↓LV physiology Total: ↓necrotic/apoptotic cell removal 
↓Collagen 
deposition 
↓Fibroblast and endothelial cell activation 
M2-specific 
depletion 
↓Neovascularization M2: prolonged N1 neutrophil/M1 
macrophage activation 
Macrophage 
modulation: 
↑LV physiology Wntless: ↑reparative M2 macrophages, 
neovascularization 
Wntless null 
Macrophage 
EP3R null 
Macrophage 
EP3R 
transgenic 
CD5L null  
↓LV remodeling EP3R null: monocyte TGF-β 
signaling/↓CX3CR1 and VEGF signaling, 
↓Ly6Clo reparative monocyte activation 
EP3R transgenic: ↑angiogenesis CD5L 
null: ↓neutrophils, ↓collagen 
accumulation, ↓IL-1 receptor-associated 
kinase 4, NF-κB, myeloperoxidase, and 
inducible nitric oxide synthase 
 
MI, myocardial infarction; LV, left ventricular; ↑, increase; ↓, decrease. 
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Table 1.6: Summary of clinical outcomes with anti-inflammatory agents 
post-MI (Seropian, Toldo et al. 2014) 
Therapy Outcome 
Glucocorticoids conflicting results, associated with impaired 
healing, scar thinning, ventricular aneurysm, 
and increased risk of ventricular rupture 
NSAIDs  worse clinical outcome and ventricular rupture 
after AMI 
rhuMAb CD18 (humanized 
monoclonal antibody against 
CD18) 
failed to improve coronary reperfusion on 
angiography, ST-segment resolution, increased 
infections and bleeding complications 
Pexelizumab (humanized 
antibody against C5) 
failed to reduce infarct size or reduce major 
adverse cardiac events 
Tocilizumab (humanized 
monoclonal antibody against 
the IL-6 receptor ) 
conflicting and inconclusive results regarding 
the role IL-6 in ventricular remodeling 
Anakinra (competitive 
inhibitor of IL-1) 
a favorable effect on C-reactive protein (CRP) 
levels and trend toward more favorable left 
ventricular remodeling and reduced incidence 
of HF at 3 months 
Etanercept and infliximab 
(TNF-α blockers ) 
a dose-dependent increase in adverse cardiac 
events, significantly lowered the interest in 
these drugs for heart disease 
PI3K inhibitor no protective effect in ischemia-reperfusion 
model 
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Figure 1.1: Primary immune cells at the site of infarction. 
Neutrophil and macrophage responses after infarction. Shifting the response of 
M2 macrophage to the left by using AZM is beneficial in MI (Hypothesis).  
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Figure 1.2: The likely underlying molecular mechanisms for the 
immunomodulatory effects of macrolides. 
AP-1, activator protein 1; CaMK, calmodulin kinase; DAG, diacylglycerol; EGFR, 
epidermal growth factor receptor; ER, endoplasmic reticulum; ERK, extracellular 
signal-regulated kinase; GFR, cytokine receptor/growth factor receptor; GPCR, 
G-protein-coupled receptor; IKK, IκB kinase; IP3R, inositol triphosphate receptor; 
IRAK, IL-1 receptor-associated kinase; MEK, MAPK/ERK kinase; PKC, protein 
kinase C; TAK1, transforming growth factor-activated protein kinase 1; TLR, Toll-
like receptor. Big arrows, major pathways influenced by macrolides; dashed 
arrows, sub-pathways or cross-talk pathways; red lines, inhibition by macrolides; 
red arrows, levels are increased by AZM; AZM, azithromycin (Kanoh and Rubin 
2010). 
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CHAPTER II. SPECIFIC AIM 1 
Azithromycin therapy reduces cardiac inflammation and 
mitigates adverse cardiac remodeling after myocardial infarction: 
Potential therapeutic targets in ischemic heart disease 
Ahmed Al-Darraji, Dalia Haydar, Lakshman Chelvarajan, Himi Tripathi, Bryana 
Levitan, Erhe Gao, Vincent J. Venditto, John C. Gensel, David J. Feola, Ahmed 
Abdel-Latif  
Published: July 12, 2018 
https://doi.org/10.1371/journal.pone.0200474 
2.1 Summary 
Introduction: Acute myocardial infarction (MI) is  a  primary  cause  of  worldwide 
morbidity and mortality. Macrophages are fundamental components of post-MI 
inflammation. Pro-inflammatory macrophages can lead to adverse cardiac 
remodeling and heart failure while anti-inflammatory/reparative macrophages 
enhance tissue healing. Shifting the balance between pro-inflammatory and 
reparative macrophages post-MI is a novel therapeutic strategy. Azithromycin 
(AZM), a commonly used macrolide antibiotic, polarizes macrophages towards the 
anti-inflammatory phenotype, as shown in animal and human studies. We 
hypothesized that AZM modulates post-MI inflammation and improves cardiac 
recovery. 
Methods and results: Male WT mice (C57BL/6, 6–8 weeks old) were treated with 
either oral AZM (160 mg/kg/day) or vehicle (control) starting 3 days prior to MI 
and continued through day 7 post-MI. We observed a significant reduction in 
mortality with AZM therapy. AZM-treated mice showed a significant 
decrease in pro-inflammatory (CD45+/Ly6G-/F4-80+/CD86+) and increase in 
anti-inflammatory 
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(CD45+/Ly6G-/F4-80+/CD206+) macrophages, decreasing the pro-
inflammatory/anti-inflammatory macrophage ratio in the heart and peripheral blood 
as assessed by flow cytometry and immunohistochemistry. Macrophage changes 
were associated with a significant decline in pro- and increase in anti-inflammatory 
cytokines. Mechanistic studies confirmed the ability of AZM to shift macrophage 
response towards an anti-inflammatory state under hypoxia/reperfusion stress. 
Additionally, AZM treatment was associated with a distinct decrease in neutrophil 
count due to apoptosis, a known signal for shifting macrophages towards the anti-
inflammatory phenotype. Finally, AZM treatment improved cardiac recovery, scar 
size, and angiogenesis. 
Conclusion: Azithromycin plays a cardioprotective role in the early phase post-MI 
through attenuating inflammation and enhancing cardiac recovery. Post-MI 
treatment and human translational studies are warranted to examine the 
therapeutic applications of AZM. 
2.2 Introduction 
Acute myocardial infarction (MI) is a leading cause of mortality and 
morbidity in the western world(van der Laan, Nahrendorf et al. 2012). MI provokes 
a profound coordinated inflammatory response, a process mediated by 
inflammatory bone marrow (BM) and peripheral blood (PB) cells, which has been 
linked to the development of end stage heart failure (HF), a highly frequent 
complication post-MI (van der Laan, Nahrendorf et al. 2012). The peri-infarct zone 
demonstrates dynamic cellular changes with the infiltration of various inflammatory 
cells including neutrophils, monocytes, and macrophages (Epelman, Liu et al. 
2015). Monocytes infiltrate the peri-infarct zone and differentiate into 
macrophages, which play an important role in the initial inflammatory as well as 
the following reparatory phases (Dutta and Nahrendorf 2015). Two dominant 
patterns of macrophage activation are found: pro-inflammatory/classically 
activated macrophages (M1-like) and anti-inflammatory/alternatively 
activated/reparative macrophages (M2-like), with different cell markers and gene 
expression profiles (Epelman, Liu et al. 2015). In mice, the initial exaggerated 
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inflammatory response may actually confer long-term harm because reductions in 
the initial recruitment of inflammatory monocytes reduce infarct size and prevent 
adverse cardiac remodeling (de Couto, Liu et al. 2015, Protti, Mongue-Din et al. 
2016). Pro-inflammatory macrophages trigger inflammation, damage of extra 
cellular matrix (ECM)(Gibbs, Shanley et al. 1999), production of reactive oxygen/ 
nitrogen species and pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) 
(Martinez, Sica et al. 2008). In contrast, anti-inflammatory macrophages promote 
ECM repair, angiogenesis, and production of anti-inflammatory cytokines (IL-4, IL-
10, and IL-13) (Sunderkotter, Goebeler et al. 1991). 
Azithromycin (AZM), a clinically approved macrolide antimicrobial agent, 
has an excellent safety profile in humans. AZM modulates the inflammatory 
response through macrophage polarization towards the reparative state (Murphy, 
Sundareshan et al. 2008, Cory, Birket et al. 2014), as demonstrated in models of 
inflammation and tissue injury such as spinal cord injury (Gensel, Kopper et al. 
2017), lung infection (Feola, Garvy et al. 2010), and stroke (Amantea, Certo et al. 
2016). In these clinically relevant scenarios, AZM reduces the production of pro-
inflammatory cytokines (IL-6 and IL-12) and increases that of anti-inflammatory 
cytokines (IL-10)(Murphy, Sundareshan et al. 2008). Additionally, AZM 
significantly decreased the expression of iNOS and pro-inflammatory macrophage 
receptor (CCR7) while increasing arginase activity and anti-inflammatory 
macrophage receptors (MR and CD23) (Murphy, Sundareshan et al. 2008). In an 
ischemic stroke model, which induces a similar sterile inflammatory response to 
MI, AZM shifted macrophages from the pro-inflammatory to the reparative state 
leading to inhibition of blood brain barrier injury and improvement in neurological 
recovery (Amantea, Certo et al. 2016). Likewise, in a retinal ischemia/reperfusion 
experimental model, AZM was protective against neuronal injury. This protection 
was attributed to the anti-inflammatory properties of AZM, as evidenced by the 
reduction in MMP-9/2 expression and activity (Varano, Parisi et al. 2017). In 
addition to its immunomodulatory properties, AZM is well tolerated, achieves a 
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wide therapeutic index, and has well characterized pharmacokinetic and 
pharmacodynamic properties(Koch, Esteban et al. 2000). 
Here, we provide the first evidence that AZM reduces the inflammatory 
response and mediates cardioprotection against adverse cardiac remodeling and 
HF post-MI. AZM produces its positive effects through increasing neutrophil 
apoptosis and switching macrophage activation towards an anti-inflammatory 
phenotype. Our findings present an important step towards designing clinically 
relevant strategies to reduce the risk of cardiac remodeling and HF after MI. 
2.3 Materials and methods 
Study Design. 8–10 week old male C57BL/6 mice (Jackson Laboratory, 
BarHarbor, ME) were treated with either AZM (Azithromycin tablets, USP, 
Sandoze, NDC0781194133, Princeton, NJ), (crushed tablets suspended in 2% 
methylcellulose), orally using gastric gavage at 160 mg/kg/day or vehicle (2% 
methylcellulose), starting 3 days prior to MI or sham surgery through day 7 post-
MI (Fig 1A). Timing of AZM therapy was selected to ensure appropriate steady-
state levels at the time of injury (Feola, Garvy et al. 2010). AZM administration 
continued for 7 days after surgery to cover the entire duration of post-MI 
inflammatory response (Heidt, Courties et al. 2014, Ramirez, Iyer et al. 2014). AZM 
treatment was not associated with changes in liver or kidney function throughout 
the period of administration (S1 Fig). All procedures were conducted under the 
approval of the University of Kentucky IACUC in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals (DHHS publication No. [NIH] 85–23, 
rev. 1996). 
2.3.1 Murine model of myocardial infarction 
Mice were anesthetized with 1–3% isoflurane using a small animal 
vaporizer system. Pain reflexes were examined to make sure that the mouse was 
adequately anaesthetized prior to surgery. Following a left thoracotomy between 
the fourth and fifth ribs and removal of pericardial sac, the heart was exposed and 
pushed out of the thorax under direct visualization. The left anterior descending 
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coronary artery (LAD) was identified under a surgical microscope and permanently 
ligated 3 mm below its origin using a 6–0 silk suture as previously described (Gao, 
Lei et al. 2010, Klyachkin, Nagareddy et al. 2015). The sham group underwent the 
same surgical procedure except the suture was passed under the LAD but not tied. 
Following LAD ligation, the heart was placed back into the intrathoracic space and 
the pneumothorax was manually evacuated. After muscle closure, the skin was 
sutured using 4–0 Prolene running sutures. 
2.3.2 Humane endpoints 
Animals were treated with pain medications for 24–48 hours after surgery. 
This duration may be prolonged if animals showed signs of pain, discomfort or 
reduced food or water intake. Animals were followed every 8 hours for 24 hours 
followed by daily for 1 week, for any signs of clinical deterioration or overt heart 
failure. Their water and food consumption is monitored carefully. Any animals that 
show signs of decompensation were resuscitated and if this is unsuccessful, they 
were humanly euthanized. We also monitored mice for additional signs of distress 
or weight loss >15–20% from baseline weight; hunched posture; ruffled coat; etc. 
If the mice exhibited any of these signs, they were euthanized without any 
subsequent experimental procedures. Most of the mortality in our MI group 
occurred in the first week after surgery. Necropsy showed blood filled thoracic 
cavity suggesting myocardial rupture as the cause of death. 
The appearance of the surgical site is checked for signs of infection, undue 
sutures, and seroma formation. When possible, infection, sutures, or seroma 
formation is treated medically (antibiotics, if indicated) or surgically (replacing 
sutures or percutaneous drainage, respectively). In rare cases in which infection 
appears to have occurred, we consulted with DLAR veterinary for advise, 
treatment and management. In cases where complications are felt to be causing 
the animal significant distress, the animal is euthanized. 
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2.3.3 Method of euthanasia 
Mice were euthanized using high dose isoflurane followed by cervical 
dislocation to confirm their euthanasia. 
2.3.4 Flow cytometry 
Peripheral blood tubes containing 1:5 ratios of ethylene 
diaminetetraaceticacid (EDTA)/citrate-theophylline-adenosinedipyridamole 
(CTAD) were used to collect blood samples at 1, 3 and 7 days after MI (4 MI mice 
and 3 sham mice /treatment group). Whole blood was centrifuged at 700g for 5 
minutes, and plasma layer was collected in separated tubes and kept at -80°C. 
The remaining cell pack was incubated with 0.5 ml of 1X of red blood lysing buffer 
(BD pharm lyse) for 10 minutes with gentle agitation for RBC lysis followed by 
dilution using 0.5 ml of staining buffer (5% goat serum, 0.05% sodium azide in 
phosphate-buffered saline) to stop the reaction. The suspension was centrifuged 
at 400g for 5 minutes, and supernatant was discarded. This step was repeated if 
we observed residual red blood cells. The white blood cell pellet was resuspended 
in staining buffer, washed to remove any remaining lysis buffer, and centrifuged at 
400g for 5 minutes. Cells from individual blood samples were split into two portions 
for flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR) 
based on cell counts so that each sample contained ∼106 live (trypan blue-
negative) cells. Cells for rtPCR were lysed using cell lysis buffer (Life technologies) 
for 10 minutes with strong agitation and kept at -80°C for gene analyses. Cells for 
staining were immediately incubated on ice for 30 minutes with conjugated primary 
antibodies against FITC-conjugated Ly6G/C (BD Pharmingen), APC-CY7-
conjugated CD45 (Biolegend), PE-conjugated CD115 (Biolegend) for the 
monocyte panel. After incubation, cells were washed twice using flow buffer and 
analyzed using an LSR II (Becton Dickinson) in the University of Kentucky Flow 
Cytometry Core. Monocytes were classified as pro-inflammatory 
(CD45+/CD115hi/Ly6-Chi) and anti-inflammaory (CD45+/CD115hi/Ly6-Clo). 
Neutrophils were identified as CD45+/CD115lo/Ly6G/Clo. 
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Heart tissue collected at the same time points was rapidly removed and 
placed in ice cold PBS (VWR International). The heart was manually minced using 
razor blades. Minced heart tissue was transferred into 15 ml tube with Collagenase 
B (Roche, Indianapolis, IN) and Dispase II (Roche, Indianapolis, IN) solution for 30 
minutes in 37°C water bath, with manual agitation every 5–10 minutes. Then, the 
digestion reaction was terminated using cold staining buffer, and tubes were 
placed in ice. The digestion mixture was filtered through 70 μm cell strainers and 
centrifuged at 400g for 5 min at 4 0C, then the supernatant was aspirated and cells 
were resuspended in 0.5 ml of staining buffer. Cells from individual hearts were 
split into approximately three portions based on cell counting so that each sample 
contained ∼106 live (trypan blue-negative) cells for flow cytometry and RT-PCR as 
detailed above. Cells were incubated directly on ice for 30 minutes with conjugated 
primary antibodies against FITC-conjugated Ly6G (BD Pharmingen), PE-
conjugated CD206 (Biolegend), PerCP-CY5.5-conjugated CD86 (Biolegend), 
PECY7-conjugated F4/80 (Biolegend), and APC-CY7-conjugated CD45 
(Biolegend) for the macrophage panel, or the monocyte panel detailed above. After 
incubation, cells were washed twice using flow buffer and analyzed using an LSR 
II (Becton Dickinson). Macrophages were classified into pro-inflammatory 
(CD45+/Ly6G-/F4-80+/CD86+ cells) and ant-inflammatory (CD45+/Ly6G-/F4-
80+/CD206+ cells). Laser calibration and compensation were carried out for every 
experiment utilizing unstained and single fluorescent controls. 
Using the same protocols mentioned earlier, cells isolated from hearts and 
peripheral blood were incubated with APC-CY7-conjugated CD45 (Biolegend), 
FITC-conjugated Ly6G (BD Pharmingen), APC-conjugated Annexin 5 (Biolegend) 
and PE-conjugated propidium iodide (PI) (Biolegend) to identify apoptosis in 
neutrophils. Cells were considered apoptotic if they were PIlo/Annexin Vhi. For flow 
analyses in all experiments we utilized FlowJo (version 7) software to generate dot 
plots and analyze the data. 
 
 
 
 
60 
 
2.3.5 Histology 
Mice (N = 12-15/treatment group) were sacrificed 30 days after MI and 
hearts were collected in diastole by using saturated KCl and CdCl2 (100 mM) given 
through the apex into the left ventricular (LV) cavity. Then we cannulated the 
ascending aorta and perfused the heart with PBS (VWR International) followed by 
10% buffered formalin (VWR International) at 75 mmHg. Hearts were placed in 5 
ml of 10% neutral buffered formalin (VWR) and fixed overnight at room 
temperature. Hearts were then sectioned into 2-mm cross-sectional slices followed 
by paraffin embedding. Tissue was transferred to 70% ethanol for overnight 
followed by sectioning into 4-μm sections starting at the level of LAD ligation. 
Sections were then stained with Masson’s trichrome to evaluate scar size. Digital 
images were taken, and areas were evaluated using NIH ImageJ (version 7). We 
measured the LV area, LV cavity area, and infarct area in stained sections, as 
previously described (Klyachkin, Nagareddy et al. 2015). The scar size was 
presented as a percentage of LV myocardial volume. 
2.3.6 Immunohistochemistry 
Mice (N = 4/treatment group) were sacrificed 3 days after MI and hearts 
were collected. Immunohistochemical assessments were carried out on 
deparaffinized and rehydrated sections as previously described (Klyachkin, 
Nagareddy et al. 2015). After deparaffinization and washing, slides were incubated 
with primary antibodies: rat anti-mouse CD86 (1:100, BD Biosciences), goat anti-
mouse CD206 (1:1000, R and D Systems), rabbit anti-mouse YM1 (1:25, Stem 
Cell technologies), and goat anti-mouse IL-1β (1:200 R & D System) overnight at 
4°C. After washing, sections were incubated with secondary antibodies conjugated 
to Alexa Fluor 594,647 (1:500, Invitrogen, Carlsbad, CA), then incubated with 
Sudan Black B (Sigma Aldrich, St. Louis, MO) for 30 minutes. and subsequently 
incubated with DAPI nuclear counterstain. 10–15 adjacent areas in the pre-infarct 
and remote zones per section were analyzed (1–2 sections/animal) at 40x 
magnification using Nikon Confocal Microscope A1 in the University of Kentucky 
Confocal Microscopy facility. Only nucleated antibody positive cells were counted. 
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Calculations were performed using the Cell Counter plugin for ImageJ (version 
1.51d). Data were presented as total positive cells per high power field in the region 
of interest. 
A similar protocol was used to prepare heart sections from mice on day 30 
for angiogenesis assessment using FITC- isolectin B4 (FL1201, Vector Labs, 
Burlingame, CA). 10–15 adjacent areas in the pre-infarct per section were 
examined (1–2 sections/animal) at 40x magnification using Nikon Confocal 
Microscope A1 in the University of Kentucky Confocal Microscopy facility. Data 
were presented as total capillary density per mm2 in the peri-infarct region. All 
measurements were analyzed by blinded observers. 
To examine apoptosis in heart tissue, we used a TdT dUDP Nick-End 
Labeling (TUNEL) Assay and Caspase-3 staining. Caspase 3 staining was done 
in deparaffinized and rehydrated sections using antibody against cleaved caspase 
3 as previously described (Klyachkin, Nagareddy et al. 2015). TUNEL staining was 
performed in Biospecimen Procurement and Translational Pathology Shared 
Resource Facility (BPTP SRF) at the University of Kentucky. Only nucleated 
positive cells were counted in the peri-infarcted and infarcted areas. Calculations 
were done using the Cell Counter plugin for ImageJ (version 1.51d). Data were 
presented as total positive cells per high power field in the region of interest. All 
measurements were analyzed by blinded observers. 
2.3.7 Real-time polymerase chain reaction 
We utilized PureLink RNA Mini Kit (ThermoFisher Scientific) to collect total 
RNA from heart and blood cells according to the manufacturer’s protocol. The 
extracted RNA was quantified using NanoDrop 8000 spectrophotometer 
(Thermofisher). Then, cDNA was synthesized using SuperScript VILO cDNA 
synthesis kit (Invitrogen). Quantitative RT-PCR was performed using a 
QuantaStudio 7 Flex real-time thermocycler (Applied Biosystems by life 
technology) to quantify the mRNA expression of markers identifying: inducible 
nitric oxide synthases (iNOS), tumor necrosis factor alpha (TNF-α), monocyte 
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chemotactic protein-1 (MCP-1), transforming growth factor beta (TGF-β), 
interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-4 (IL-4), chitinase-like3 
Chil3 (YM1), Peroxisome proliferator-activated receptor gamma (PPARg). We 
used the comparative Ct method for relative estimation of mRNA expression which 
was normalized to 18s (a housekeeping gene). To overcome the possible errors 
due to augmentation of contaminated DNA: (a) we used primers adjusted to bridge 
an intron for specific cDNA augmentation; (b) we used proper negative control 
reactions (template free controls); (c) we reassessed the consistency of product 
augmentation through examination of the melting curve of augmented products 
(dissociation graphs); and (d) the melting temperature (Tm) was 57°C–60°C, and 
the probe Tm was at least 10°C more than the primer Tm. The primer sequences 
are listed in S1 Table. 
2.3.8 Echocardiography 
We used a Vevo 3100 system supplied with a 15-7-MHz linear broadband 
transducer and a 12-5-MHz phased array transducer to acquire Echocardiograms. 
We assessed cardiac function at baseline (before cardiac surgery) then at 48 hours 
after MI, and immediately before sacrifice at 30 days after MI. We utilized a heating 
pad to keep the body temperature at 37°C during the experiment; the temperature 
was measured using a rectal temperature probe. To determine the left ventricular 
function and volume in M-mode, two-dimensional and Doppler echocardiography 
modes we utilized modified parasternal long-axis and short-axis. We also used M-
mode tracings at the mid-papillary level to estimate the systolic and diastolic 
parameters, and Teichholz formula at end-systole and end-diastole to measure the 
LV volumes. All mice were anaesthetized using 1%–3% isoflurane during 
Echocardiography to maintain a heart rate of 450–500 BPM for all 
echocardiographic acquisitions. Echocardiography imaging and analysis was 
performed by a blinded investigator. 
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2.3.9 Cell culture and hypoxic exposure 
The murine macrophage cell line J774 (ATCC, Manassas, VA) was used 
for the in vitro studies on the anti-inflammatory effects of AZM. Cells were plated 
in 6 well plates at concentration 0.3×106 cells/well in media consisting of DMEM, 
10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, L-Glutamine, and 
Glucose. Following cell adhesion (4–6 hours) cells were treated with AZM (Sigma-
Aldrich, St. Louis, MO) at concentration 30 μM or DMSO (SIGMA-ALDRICH, St. 
Louis, MO) as control and incubated over night at 37 C with 5% CO2. To induce 
hypoxia-reperfusion injury, cultured cells were established in a gas-tight modular 
chamber (STEMCELL Technologies Inc., Seattle, WA) containing 1% O2, 5% 
CO2, 94% N2, or in normal oxygen tension with 20% O2, 5% CO2 as control for 
24 hours at 37°C followed by reperfusion with 21% O2, 5% CO2 for 24 or 48 hours. 
Supernatants were collected at the end of these time points to assess the 
cytokines level and their ratio (TNF-α and IL-10). 
2.3.10 ELISA assays 
Protein concentrations of TNF-α and IL-10 are measured using standard 
ELISA kits (BD Biosciences, San Deigo, CA) according to the manufacturer 
protocol. Data are presented as individual cytokine values and their ratio. 
2.3.11 Luminex assay 
Plasma was collected according to the above mentioned protocols at days 
3, and 7 post-MI. Inflammatory biomarkers (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-
1, MIP-1a and MIP-1b) were assayed using the Milliplex mouse cytokine magnetic 
kit (MILLIPLEX MAP for Luminex xMap Technology, Millipore, USA) according to 
the manufacturer’s protocol. 
2.3.12 Liver and kidney function tests 
Plasma was collected according to the above mentioned protocols at days 
1, 3, and 7 post-MI. Samples were sent to ANTEC diagnostic to assay blood urea 
nitrogen, alanine aminotransferase (ALT), albumin, and albumin/globulin ratio. 
64 
2.3.13 Statistical analysis 
Values are expressed as mean ± standard error of mean (SEM). We used 
unpaired Student t test or analysis of variance (one-way or multiple comparisons) 
to estimate differences, as appropriate. We utilized two-sided Dunnett or Dunn 
tests for post hoc multiple comparison procedures, with control samples as the 
control category. Throughout the analyses, a P value less than 0.05 was 
considered statistically significant. All statistical analyses were performed using 
the Prism 7 software package (GraphPad, La Jolla, CA). 
2.4 Results 
2.4.1 AZM shifts macrophages away from the pro-inflammatory towards the 
reparative state post-MI 
Macrophages are the predominant inflammatory cells type in cardiac tissue 
after cardiac injury, regulating its healing at multiple phases. It is well established 
that AZM can modulate inflammation through shifting macrophages towards the 
reparative phenotype (Murphy, Sundareshan et al. 2008, Feola, Garvy et al. 2010, 
Cory, Birket et al. 2014, Gensel, Kopper et al. 2017). To date, the effect of AZM on 
the inflammatory response after MI at the level of macrophages has not been 
characterized. We analyzed the phenotype of macrophages in cardiac tissue at 
several time points following induction of MI using flow cytometry (Figure 2.1A). 
We detected a significant reduction in the pro-inflammatory macrophages 
(CD45+/Ly6G-/F4-80+/CD86+) at 1 day following MI with AZM treatment (Figure 
2.1B). This effect was associated with a significant increase in the reparative 
macrophages (CD45+/Ly6G-/F4-80+/CD206+) at day 1 and 3 after MI (Figure 
2.1C). Overall, the ratio between pro- and anti-inflammatory macrophages was 
reversed towards an anti-inflammatory state with AZM treatment, particularly in the 
early phase after MI (Figure 2.1D). 
Under physiological conditions, resident macrophages maintain tissue 
homeostasis (Epelman, Liu et al. 2015). However, after injury such as MI, 
monocytes infiltrate the heart and differentiate into macrophages. Monocytes 
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contribute to tissue healing and repair through coordinated activities of different 
monocyte subpopulations (Ly6Chi vs. Ly6Clo) (Nahrendorf, Swirski et al. 2007, 
Swirski, Nahrendorf et al. 2009). We assessed monocyte subpopulations (Ly6Chi 
vs. Ly6Clo) after MI in the PB and heart (Figure 2.2A). While we did not notice 
significant differences between blood monocyte subsets in AZM vs. vehicle treated 
mice, we detected a significant reduction in the Ly6Chi (pro-inflammatory) 
monocytes (CD45+/Ly6C/Ghi/CD115hi) in cardiac tissue after MI with AZM 
treatment (Figure 2.2B). There was no significant difference in the Ly6Clo (anti-
inflammatory) monocytes in cardiac tissue with AZM treatment. This suggests a 
reduction in pro-inflammatory monocyte infiltration to the heart or a reduction in 
their polarization in the myocardium. Since maintained Ly6Chi monocytes impair 
healing after MI (Swirski, Nahrendorf et al. 2009), these results imply that AZM 
treatment reduces detrimental inflammatory response following myocardial 
ischemia. 
2.4.2 AZM downregulates pro-inflammatory cytokines while upregulating 
anti-inflammatory cytokines following cardiac injury 
Macrophages have distinctive cytokine profiles based on their inflammatory 
status. Pro-inflammatory macrophages are potent generators of toxic effector 
molecules (reactive oxygen species, nitric oxide) and pro-inflammatory cytokines 
(IL-1β, TNF-α, IL-6)(Martinez, Sica et al. 2008). Conversely, reparative 
macrophages produce anti-inflammatory molecules (TGF-β and IL-10) and 
express scavenger, mannose, and galactose-type receptors (Cynamon, Klemens 
et al. 1992, Song, Ouyang et al. 2000). We conducted in vitro studies to examine 
the effect of hypoxia/reperfusion injury on the phenotype of J774 macrophages in 
the presence or absence of AZM. Following 24 hours hypoxia and reperfusion, we 
noted significant shift in macrophage cytokine production towards a pro-
inflammatory phenotype with higher TNF-α levels compared to IL-10 levels. AZM 
treatment shifted the cytokine production towards an anti-inflammatory pattern with 
significant increase in IL-10/TNF-α ratio (Figure 2.3). We also examined the effect 
of AZM on cytokine expression following MI in the in vivo studies. Our data confirm 
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the change towards the anti-inflammatory state with AZM treatment. In heart 
tissue, AZM treatment was associated with significant reductions in the gene 
expression of iNOS and inflammatory cytokines (MCP-1, TNF-α, IL-6, and IL-1β) 
while the anti-inflammatory cytokines/macrophage modulatory factors (TGF-β and 
IL-4, PPARγ and YM1) were increased (Figure 2.4A).  
A similar trend was noted in the gene expression of pro- and anti-
inflammatory cytokines in PB cells at the same time points (Figure 2.4B). These 
gene expression results are corroborated by IHC and ELISA studies of the heart 
and plasma, respectively. Three days after MI, we quantified IL-1β and YM1 levels 
in the peri-infarct zone. IL-1β was remarkably downregulated with a concomitant 
elevation in YM1 in AZM treated mice compared to the control group (S2.2 Figure). 
In plasma, levels of inflammatory cytokines (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-
1, MIP-1a and MIP-1b) were suppressed on days 3 and 7 post-MI as assessed by 
the Luminex assay (S2.3 Figure). Overall, these results imply that AZM treatment 
modulates the inflammatory response following myocardial ischemia by 
attenuating the pro-inflammatory changes and enhancing anti-
inflammatory/reparative cytokine production. 
2.4.3 AZM treatment is associated with alternative macrophages activation 
in the peri-infarct region 
The balance between pro- and anti-inflammatory macrophages in the peri-
infarct region plays an important role in infarct expansion and adverse cardiac 
remodeling (Harel-Adar, Ben Mordechai et al. 2011, Ben-Mordechai, Palevski et 
al. 2015, de Couto, Liu et al. 2015, Epelman, Liu et al. 2015). To evaluate the 
impact of AZM on the activation state of macrophages in the peri-infarct region, we 
quantified pro-inflammatory (CD86+) and anti-inflammatory (CD206+) 
macrophages 3 days post-MI using immunohistochemistry. Our results confirmed 
the shift towards an anti-inflammatory state with AZM treatment. AZM-treated mice 
had significantly lower numbers of CD86+ cells and higher numbers of CD206+ 
cells (Figure 2.5). Importantly, the pro-inflammatory/reparative macrophage ratio 
was decreased robustly in the AZM treated compared to the vehicle group. Of note, 
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macrophage inflammatory state is a spectrum from the pro- to the anti-
inflammatory phenotypes. Nonetheless, we used the same strategy for assessing 
each population quantitatively to avoid any bias. We counted CD86 and CD206 
separately and this could have led to double counting of cells in each category. 
These findings are in agreement with our flow cytometry data and implicate a 
potential therapeutic role for AZM in reducing post-MI cardiac inflammatory 
changes. 
2.4.4 AZM reduces neutrophil counts after cardiac ischemia through 
enhancing apoptosis 
In acute inflammation, neutrophils are key players in removing pathogens 
and debris, thus contributing to the return of normal tissue homeostasis (Carbone, 
Nencioni et al. 2013). Evolutionary mechanisms have developed to limit the initial 
inflammatory response after MI. These pathways include a robust switch of 
macrophages towards anti-inflammatory phenotype following ingestion of 
apoptotic neutrophils (Serhan and Savill 2005). Indeed, prior studies have 
implicated the ingestion of apoptotic cells as a mechanism for the anti-
inflammatory changes observed with AZM (Hodge, Hodge et al. 2006). While our 
data as well as others have shown that AZM induces alternative polarization of 
macrophages towards the anti-inflammatory state, the mechanism of these 
changes is not entirely clear. We hypothesized that AZM promotes neutrophil 
apoptosis which likely initiates the anti-inflammatory changes. In support of this 
hypothesis, prior reports have confirmed the pro-apoptotic effects of macrolides on 
neutrophils (Aoshiba, Nagai et al. 1995, Rapp 1998). We therefore analyzed 
neutrophil numbers (CD45+/CD115lo/Ly6G/Clo) using the gating strategy outlined 
in Fig 2A in the heart and PB via flow cytometry. Treatment with AZM resulted in 
significant reductions of neutrophil counts in cardiac tissue and PB in the early 
phase after MI (Figure 2.6A). To further investigate the mechanism associated 
with neutrophil count reduction, we examined neutrophil apoptosis using Annexin 
V and PI staining in cardiac tissue using flow cytometry. AZM treatment was 
associated with a significant increase in the percentage of apoptotic neutrophils in 
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the early inflammatory phase after MI compared to vehicle-treated mice (Figure 
2.6B and 2.6C). Our findings indicate that AZM treatment reduces neutrophil 
numbers after cardiac injury through pro-apoptotic effects, which could account for 
its post-MI immunomodulatory effect. 
2.4.5 AZM diminishes cardiac cell death and scar size while promoting 
angiogenesis following cardiac ischemic injury 
Alternatively activated macrophages are master regulators of the healing 
process after MI by regulating cardiomyocyte apoptosis, collagen deposition, and 
angiogenesis in the peri-infarct regions (Aurora, Porrello et al. 2014). To determine 
the effect of AZM effects on programmed cell death in the heart post-MI, we 
investigated cleaved caspase-3 positive staining of cells in the infarct zone, peri-
infarct border, and remote (normal) zones 3 days post-MI. We found that apoptosis 
was significantly reduced within the infarct and border regions in the AZM-treated 
group compared to vehicle-treated group (Figure 2.7). In order to confirm our 
caspase 3 staining results, we performed TUNEL assay in the peri-infarct region. 
The results were consistent with the caspase 3 assay (S2.4 Fig), suggesting 
enhanced survival of cardiac cells, likely driven by AZM. These data corroborate 
the immunohistochemistry and real-time PCR results, demonstrating significant 
reduction in pro-apoptotic cytokines such as TNF-α. We then assessed the effect 
of AZM therapy on the infarct size using morphometric assessments on Masson’s 
trichrome-stained cross-sections from the hearts (30 days post-MI). We observed 
significantly smaller scar size in mice treated with AZM compared to those treated 
with vehicle (Figure 2.8A and 2.8B). These data indicate that AZM protects the 
infarcted heart from the adverse cardiac remodeling that occurs chronically after 
ischemia. Alternatively activated macrophages produce multiple cytokines 
(including pro-angiogenic factors) that can enhance regeneration (Sunderkotter, 
Goebeler et al. 1991, Song, Ouyang et al. 2000). Angiogenesis is regarded as a 
major stimulator of tissue recovery in the heart after ischemic injury. To examine 
the vessels density in the peri-infarcted areas between groups, we assessed 
quantified isolectin (a marker of endothelial cells in blood vessels) 30 days 
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following MI. Mice treated with AZM had significantly higher capillary density in the 
peri-infarct region compared to vehicle-treated mice (Figure 2.8C and 2.8D). 
Taken together with the results detailed in Fig 7, AZM treatment reduces scar size 
after MI, which could be explained by the reduction in cellular apoptosis and 
enhanced angiogenesis in the ischemic heart. 
2.4.6 AZM preserves cardiac function, reduces adverse remodeling and 
improves survival post-MI 
Loss of balance between inflammatory and reparative phases post-MI can 
result in adverse cardiac remodeling and eventually systolic HF (de Couto, Liu et 
al. 2015). Our data suggest an immunomodulatory role for AZM on the heart post-
MI. To examine the translation of these cellular effects on cardiac function, 
echocardiography was carried out on AZM and vehicle treated mice at baseline, 
and 2 and 30 days after MI. We observed preservation of LV ejection fraction as 
well as fractional shortening in AZM treated compared to vehicle mice (Figure 
2.9A-9C). We also observed similar effects on parameters of LV remodeling such 
as LV end-systolic and end-diastolic diameters (Figure 2.9D-9E). In agreement 
with the noted reduction in scar size, we observed significantly less deterioration 
in infarct wall thickness in AZM treated group compared to controls (Figure 2.9F). 
Therefore, the beneficial effect of AZM extends beyond the enhancements in the 
inflammatory balance after MI to a favorable recovery of LV functional and 
remodeling parameters as summarized in S2.2 Table. Additionally, survival rates 
reflect these AZM-mediated functional improvements with a marked reduction in 
mortality in AZM-treated mice (Figure 2.9G). 
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2.5. Discussion 
Cardiac inflammation is a crucial component of the recovery phase after MI. 
However, a tug-of-war between pro- and anti-inflammatory forces in the ischemic 
myocardium impacts cardiac recovery. Reversing the pro-inflammatory forces 
after MI can enhance cardiac recovery and survival. In this study, we provide first 
evidence that the macrolide, AZM, exerts immunomodulatory effects on 
macrophages after MI shifting them towards anti-inflammatory phenotype. This is 
demonstrated by significant reduction in pro-/anti-inflammatory macrophage ratio 
and pro-inflammatory genes expression in parallel with significant elevation in anti-
inflammatory gene expression. These immunomodulatory effects resulted in 
reduced apoptosis and scar size, enhanced cardiac functional recovery, and 
improved survival. Taken together, AZM represents a novel and clinically available 
target for reducing cardiac inflammation and damage following MI. 
The immunomodulatory effects of AZM after MI appear to be multifactorial 
including direct effects on macrophages as well as pro-apoptotic effects on 
neutrophils. It is well accepted that neutrophils play a critical role in tissue healing 
following MI through debris clearance from the injury site (Ortega-Gomez, Perretti 
et al. 2013). However, prolonged neutrophil accumulation in the heart post-MI is 
considered deleterious (Chia, Nagurney et al. 2009, Guasti, Dentali et al. 2011). 
On the other hand, aggressive neutrophil depletion following MI can disturb the 
healing process, leading to impaired functional recovery (Horckmans, Ring et al. 
2017). Clinical data suggest that a delay in neutrophil apoptosis after MI 
contributes to the exaggerated inflammatory response (Garlichs, Eskafi et al. 
2004). Here, we show that AZM enhances neutrophil apoptosis in cardiac tissue 
after MI, which could explain the reduction in neutrophil counts in our studies. This 
is in agreement with other reports in the literature that suggest a pro-apoptotic 
effect of macrolides on neutrophils (Aoshiba, Nagai et al. 1995, Inamura, Ohta et 
al. 2000). The pro-apoptotic effect of AZM is most noticeable on the first day after 
MI. Importantly, studies have shown that AZM is more concentrated in 
polymorphonuclear leukocytes, which will induce apoptosis in these cells through 
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arresting cell cycle in G2/M (Ribeiro, Hurd et al. 2009). Engulfing apoptotic 
neutrophils by macrophages stimulates the anti-inflammatory response through 
blocking pro-inflammatory cytokines and enhancing anti-inflammatory cytokines 
(IL-10 and TGF-β) and pro-resolving lipid mediators(Soehnlein and Lindbom 
2010). 
In addition to its effects on neutrophil apoptosis, AZM can have direct effects 
on macrophages. Our in vitro results indicate that AZM therapy attenuates the 
inflammatory changes seen in macrophages subjected to hypoxia/reperfusion 
injury. In addition, induction of programmed cell death in neutrophils results in 
decrease in the production of inflammatory cytokines and chemokines (Soehnlein, 
Zernecke et al. 2008), as demonstrated in our study. Indeed, our experiments 
show that AZM treatment decreased the expression of MCP-1 which promotes 
Ly6Chi cells recruitment to the infarcted tissue. Ly6Chi monocytes differentiate into 
pro-inflammatory macro phages in the peri-infarct border which eventually 
contribute to adverse cardiac remodeling (Panizzi, Swirski et al. 2010). 
Furthermore, through the reduction in neutrophil count and modulation of 
macrophage phenotype, the production and deleterious effects of pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-6 were diminished (Saini, Xu 
et al. 2005). In parallel to the decreased pro-inflammatory cytokines, we observed 
significant increase in anti-inflammatory cytokines such as TGF-β and IL-4 which 
have been linked to favorable cardiac remodeling and functional recovery after MI 
(Lambert, Lopez et al. 2008). 
The immunomodulatory effects of AZM have been demonstrated in various 
inflammatory and tissue injury scenarios (Zhang, Bailey et al. 2015, Gensel, 
Kopper et al. 2017). Among them, acute stroke and spinal cord injury have close 
resemblance to the inflammatory reactions (biphasic macrophage response and 
chemokine profile) happening post-cardiac injury (Gensel and Zhang 2015, 
Amantea, Certo et al. 2016). AZM treatment after spinal cord injury led to 
significant decrease in pro-inflammatory macrophages and increase in anti-
inflammatory macrophages (Zhang, Bailey et al. 2015, Gensel, Kopper et al. 
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2017). Interestingly, and in accordance with our data, the shift in macrophage 
phenotype was associated with marked functional improvements in mice. The 
exact molecular mechanisms through which AZM exerts its immunomodulatory 
effects are not fully understood. However, transcription factors such as NF-kB and 
AP-1 are likely targets (Kanoh and Rubin 2010) Our unpublished data suggest that 
AZM reduces NF-kB activation through decreasing the translocation of phospho-
p65 to the nucleus. Furthermore, there is a simultaneous increase in IKKβ and 
IκBα with AZM therapy. This does not exclude immunomodulatory actions 
mediated through other intracellular signaling pathways (Kanoh and Rubin 2010). 
Macrophages are essential players in the myocardial environment post-MI 
and their role extends beyond the inflammatory phase to tissue regeneration and 
healing (Godwin, Pinto et al. 2013, Petrie, Strand et al. 2014). The heart possesses 
a remarkable regenerative capacity in the early stages of postnatal life, an ability 
lost by day 7 after birth (Porrello, Mahmoud et al. 2011, Porrello, Mahmoud et al. 
2013). It has been postulated that this regenerative capacity is related to the 
naivety of the immune system in which macrophage modulation plays a central 
role (Song, Ouyang et al. 2000). Indeed, anti-inflammatory macrophages have 
been shown to interact with stem cells following cardiac injury leading to enhance 
cardiac recovery (de Couto, Liu et al. 2015). Overall, AZM therapy is associated 
with higher numbers of anti-inflammatory macrophages (CD206+ cells) after MI 
with the majority of changes occurring in the peri-infarct region as shown in our 
immunohistochemistry data. This phenotypic shift is associated with smaller scar, 
better cardiac function, and enhanced angiogenesis after MI. Additionally, we 
observed a significant reduction in apoptotic heart cells in both infarct and peri-
infarct areas at day 3 post-MI, which could be attributed to the survival factors 
released from reparative macrophages (Lambert, Lopez et al. 2008, Murray, Allen 
et al. 2014) . In summary, the early shift in macrophages towards the reparative 
phenotype by AZM treatment can limit acute ischemic damage and promote 
chronic cardiac recovery. 
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The balance between macrophage phenotypes is reversible (Ben-
Mordechai, Palevski et al. 2015) and can be therapeutically harnessed to enhance 
cardiac healing after ischemic injury. Animal studies show that early interventions 
aimed at altering macrophage activation state or shifting the balance towards the 
anti-inflammatory phenotype can substantially reduce the risk of HF development 
(de Couto, Liu et al. 2015, Kain, Liu et al. 2017). Kain et al initiated a phenotypic 
switch in macrophages after myocardial injury by using either free or encapsulated 
15-epi-Lipoxin A4. They demonstrated upregulation of the reparative 
macrophages as well as the anti-inflammatory/macrophage modulatory genes 
(Mrc-1, Ym-1, Arg-1). Moreover, cardiac function was improved in 15-epi-Lipoxin 
A4 treated mice compared to controls (Kain, Liu et al. 2017). These findings were 
confirmed in multiple studies using different therapeutic approaches, including 
formyl peptide receptor 2 (Heo, Kwon et al. 2017), cardiosphere-derived cells(de 
Couto, Liu et al. 2015), and endogenous Annexin-A1(Qin, Finlayson et al. 2017). 
However, studies on alternative macrophage activation in MI utilized experimental 
therapeutics with limited safety data in humans. Conversely, our strategy of using 
AZM is more clinically relevant and can be safely translated to human studies. 
Healing and remodeling after MI are fundamentally regulated by the 
inflammatory pathways. Modulating the inflammatory response post-MI is an 
elusive target as studies have shown that complete inhibition of inflammation is 
rather harmful (Frangogiannis 2014). Indeed, therapeutic interventions targeting 
the systemic inflammatory pathways have yielded limited success in pre-clinical 
and clinical studies (Frangogiannis 2014). Delayed healing and development of 
ventricular aneurysm were reported with glucocorticosteroids, and their uses 
should be avoided post-MI (Bulkley and Roberts 1974). On the other hand, 
NSAIDs use in coronary artery disease patients has been correlated with higher 
mortality and recurrent myocardial infarction (Schjerning Olsen, Fosbol et al. 
2011). Selective targeting of inflammatory mediators such as IL-1β using selective 
monoclonal antibodies demonstrated success in clinical studies, albeit with high 
cost and modest benefit (Seropian, Toldo et al. 2014). Therefore, strategies aimed 
74 
at modulating the inflammatory response rather than its suppression provides 
promising therapeutic modalities. In this study, we show that AZM as a small 
immunoregulatory molecule provides more specific modulation to the post-MI 
inflammation through increasing the abundance of anti-inflammatory macrophages 
without completely blunting the pro-inflammatory mediators. 
In this study, we initiated AZM 3 days prior to MI to ensure appropriate 
steady-state levels at the time of injury (Feola, Garvy et al. 2010). Based on 
published literature(Kanoh and Rubin 2010), we anticipate rapid accumulation of 
AZM in macrophages and fast immunomodulatory actions. Hence, initiating AZM 
following MI could be beneficial as well and this is currently being studied in our 
lab. Another limitation in our study is the use of relatively higher dose of AZM 
(160mg/kg/day) than the clinically prescribed dose (10-45mg/kg)(Zhang, Bailey et 
al. 2015). As a proof of concept, we aimed to achieve a dose consistent with our 
in vitro studies. However, multiple human studies have demonstrated AZM safety 
at higher doses and its wide therapeutic window. Given the allometric scaling on 
AZM, lower doses than those used in our study may be effective in humans (Rapp 
1998, Petrie, Strand et al. 2014). Finally, we sought to examine the extremes of 
macrophage polarization by quantifying the pro- and anti-inflammatory 
macrophages based on gene expression and surface markers. While this is a 
helpful approach for examining the effects of AZM, we acknowledge that it 
oversimplifies the macrophage landscape and categorizes them into only two main 
groups (pro- and anti-inflammatory) which may lead to overestimating either of the 
categories(Nahrendorf and Swirski 2016). Future studies are warranted to provide 
a comprehensive examination of the effect of AZM on the various macrophage 
subtypes after MI. 
Conclusions 
Cardiac inflammatory changes following MI are mediated, at least in part, 
by pro-inflammatory macrophages, which have detrimental effects on cardiac 
function and survival. This is the first study to demonstrate the efficacy of AZM as 
an immunomodulatory pharmacological agent for macrophages after MI. Our 
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results indicate that the anti-inflammatory effects of AZM are related to its direct 
effects on macrophages and its pro-apoptotic effects on neutrophils. Systematic 
assessment of cardiac and systemic changes demonstrates that the beneficial 
effects of AZM result in significant reduction in scar size, adverse cardiac 
remodeling, cardiac function, and survival post cardiac ischemia. AZM has a wide 
therapeutic window, can be administered orally, has low side effect profile and has 
been approved for human use. These criteria make it an ideal agent for novel and 
effective therapeutic interventions to improve survival and reduce HF following MI 
in humans. 
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Figure 2.1. AZM therapy shifts macrophages towards the anti-inflammatory 
phenotype in the heart after myocardial infarction. 
Experimental design for the in vivo study (Panel A). Representative FACS plots 
demonstrating the gating strategy for pro-inflammatory (CD45+/Ly6G+/F4-80+/CD86+) and 
anti-inflammatory (CD45+/Ly6G+/F4-80+/CD206+) macrophages (Panel B). Quantitative 
analyses of pro-inflammatory subpopulations (CD86+) and anti-inflammatory 
subpopulations (CD206+) are presented in Panels C and D, respectively, at different time 
points following MI in AZM and vehicle treated groups. There is a significant reduction in 
the inflammatory macrophages in the first day after MI in AZM-treated mice, which is 
associated with a significant increase in anti-inflammatory ones. These changes translate 
into a significant reduction in the pro-/anti-inflammatory (CD86+/ CD206+) ratio at days 1 
and 3 after MI (Panel E) (n = 4 MI and 3 sham mice/group/time point, *P<0.05, **P<0.01 
and ****P<0.001 compared to vehicle controls). Data presented as mean ± SEM. AZM, 
azithromycin; IHC, immunohistochemistry; LAD, left anterior descending coronary artery; 
rtPCR, real-time Polymerase Chain Reaction. 
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Figure 2.2. AZM therapy reduces cardiac inflammatory monocytes after MI. 
Representative FACS plots demonstrating the gating strategy for 
Ly6Chi(CD45+/CD115hi/Ly6-Chi) and Ly6Clo (CD45+/CD115hi/Ly6-Clo) monocytes (Panel 
A). Quantitative analyses of monocyte subpopulations in PB and heart tissue 
demonstrating no significant changes in PB monocyte subpopulations but significant 
reduction in cardiac Ly6Chi population throughout the different time points after MI in AZM 
treated mice (Panel B) (n = 4 MI and 3 sham mice/group/time point, *P<0.05 and **P<0.01 
compared to vehicle controls). Data presented as mean ± SEM. AZM, azithromycin; PB, 
peripheral blood. 
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Figure 2.3. AZM therapy reduces the production of inflammatory cytokines in 
macrophages subjected to ischemia/reperfusion injury. 
Quantitative analyses of pro-inflammatory cytokine, TNF-α, and the anti-inflammatory 
cytokine, IL-10, production from J774 macrophages subjected to 24 hypoxia followed by 
24 and 48 hours of reperfusion. The analysis demonstrates reduction of TNF- α compared 
to vehicle both at 24 and 48 hours. No significant changes were noted in IL-10 production. 
Overall, the IL-10/TNF-α ratio was significantly higher in macrophages treated with AZM 
(Panel B) (two independent experiments and 4 replicates/time point, *P<0.05, ***P<0.001 
and **** P<0.0001 compared to vehicle controls). Data presented as mean ± SEM. AZM, 
azithromycin; IL-10, interleukin 10; TNF-α, tumor necrosis factor-alpha. 
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Figure 2.4. AZM treatment exerts immunomodulatory effects on cytokines 
expression following MI. 
mRNA expression of pro-inflammatory cytokines in HT (Panel A) and PB (Panel B), 
demonstrate significant reduction in gene expression of these cytokines in the early 
inflammatory phase following injury with AZM therapy compared to vehicle controls (red 
line demarcates the level of gene expression in sham operated mice). The mRNA 
expression of anti-inflammatory cytokines is augmented with AZM therapy compared to 
vehicle control (n = 4 mice/group/time point, *P<0.05, **P<0.01, ***P<0.001 and **** 
P<0.0001 compared to vehicle controls). Data presented as mean ± SEM. AZM, 
azithromycin; HT, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-4, interleukin 4; 
iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; PB, 
peripheral blood; PPARγ, peroxisome proliferator-activated receptor gamma; TGF-1β, 
tissue growth factor 1 beta; TNF-α, tumor necrosis factor-alpha; YM1 (Chil3), chitinase-
like 3. 
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Figure 2.5. AZM treatment enhances alternative macrophage activation in the peri-
infarct border of the injured heart. 
Immunohistochemical assessment of the content of pro-inflammatory (CD86+) and 
reparative macrophages (CD206+) markers 3 days post-MI. Panel A shows representative 
images from vehicle- and AZM-treated mice demonstrating higher density of CD86+ 
compared to CD206+ cells in the peri-infarct border in vehicle-treated mice. White line 
demarcates the infarct border. Panel B shows quantitative assessment of CD86+, CD206+ 
and the markers ratio 3 days post-MI. The difference in pro-inflammatory and anti-
inflammatory macrophages lead to a significant shift towards an anti-inflammatory state 
and the reduction in their ratio in AZM-treated mice (n = 4 animals/group, *P<0.05 and 
****P<0.0001 compared to vehicle controls). Scale bars represent 50 μm. Data presented 
as mean ± SEM. AZM, azithromycin; HPF, high power field. 
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Figure 2.6. Cardiac neutrophils are reduced with AZM treatment due to apoptosis. 
Panel A summarizes the quantitative assessment of neutrophil (CD45 +/CD115lo/
Ly6G-Clo) numbers and demonstrates significant reduction in the AZM-treated group 
relative to controls in the heart and peripheral blood during the early inflammatory 
stage post-MI. Panel B illustrates the flow cytometry analyses of neutrophil populations 
stained against annexin V and PI showing higher percentage of early apoptotic 
neutrophils in AZM-treated mice. Panel C summarizes the quantitative assessment of 
early apoptotic neutrophils and demonstrates significantly higher percentage in the heart 
in the AZM-treated group during the early stage following MI (n = 4 mice/group/time 
point, *P<0.05 compared to vehicle controls). Data presented as mean ± SEM. AZM, 
azithromycin; HT, heart; PB, peripheral blood; PI, propodium Iodide. 
82 
Figure 2.7. AZM reduces apoptosis post-infarction. 
Panel A shows representative light microscope images of cleaved caspase-3 staining for 
infarcted and border regions in AZM- and vehicle-treated mice 3 days after MI. 
Quantitative analyses (Panel B) of apoptosis reveal a remarkable reduction in caspase-3 
activation in the infarct and border regions of AZM-treated group compared to the control 
group (n = 4 animals/group, **P<0.01 compared to vehicle controls). Scale bars represent 
100 μm. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power field. 
83 
Figure 2.8. AZM treatment reduces scar size and enhances angiogenesis after 
myocardial injury. 
Representative Masson's trichrome staining at 30 days after myocardial injury in vehicle- 
and AZM-treated groups (Panel A). Quantitative analysis of scars as percentage of LV 
area shows significant reduction in AZM group relative to the control group (Panel B) 
(vehicle-treated, n = 15 vs. AZM-treated, n = 12, **P<0.01 compared to vehicle controls). 
Representative isolectin staining (Green) for capillary density in the peri-infarct region in 
AZM- and vehicle-treated animals demonstrates higher capillary density in AZM group 
compared to control (Panel C). Quantitative analysis of capillary density confirms the 
higher angiogenesis rate and capillary density in AZM-treated group (Panel D) (n = 4 
animals/group, **P<0.01 compared to vehicle controls). Scale bars represent 50 μm. Data 
presented as mean ± SEM. AZM, azithromycin; MI, acute myocardial infarction; LV, left 
ventricular. 
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Figure 2.9. AZM treatment improves chronic cardiac remodeling and survival post-
MI. 
30 day following MI, transthoracic echocardiography using M-Mode (Panel A) and 2D 
echocardiography was performed on AZM- and vehicle-treated animals to evaluate left 
ventricular function and remodeling parameters. Quantitative analyses demonstrate 
significant recovery in LV function as assessed by ejection fraction (LVEF) (Panel B) and 
fractional shortening (FS) (Panel C). Data also shows significant improvements in LV 
adverse remodeling parameters such as end-systolic diameter (LVESD) (Panel D) and 
end-diastolic diameter (LVEDD) (Panel E). Additionally, we observed significantly thicker 
infarct walls suggesting of enhanced recovery and regeneration (Panel F). Survival curves 
of AZM and vehicle-treated mice 30 days post-MI demonstrate a significant improvement 
in survival with AZM treatment (Panel G). (Echo data: vehicle-treated, n = 15 vs. AZM-
treated, n = 12; survival data: vehicle-treated, n = 48 and AZM-treated, n = 53; *P<0.05, 
**P<0.01 and ****P<0.001 compared to vehicle control). Data presented as mean ± SEM. 
AZM, azithromycin; MI, acute myocardial infarction. 
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Supplemental Figure 2.1. AZM does not alter kidney or liver function with prolonged 
use after myocardial infarction. The levels of plasma Albumin, Albumin/Globulin, 
Blood Urea Nitrogen or ALT all these parameters were not significantly different between 
vehicle and AZM-treated groups. (n=4/group/time point). ALT, alanine aminotransferase; 
AZM, azithromycin. 
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Supplemental Figure 2.2. AZM treatment reduces IL-1β and increases YM1 
expression in the peri-infarct border of the injured heart. Immunohistochemical 
assessment of cells expressing IL-1β and YM1 3 days post-MI. Panel A shows 
representative images from vehicle and AZM-treated mice demonstrating higher density 
of IL-1β compared to YM1 in the peri-infarct border in vehicle-treated mice.  Yellow arrows 
point to positive cells. Panel B shows quantitative assessment of IL-1β and YM1 3-days 
post-MI, which indicate significant reduction in IL-1β and elevation in YM1 positive cells. 
(n=4 animals/group/time point, ****P<0.0001 compared to vehicle controls). Scale bars 
represent 50 m. Data presented as mean ± SEM. AZM, azithromycin; HPF, high power 
field; IL-1β, interleukin 1 beta; YM1 (Chil3), chitinase-like 3. 
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Supplemental Figure 2.3.  AZM therapy reduces the secreted inflammatory 
cytokines. Quantitative analyses of cytokines (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-1, 
MIP-1a and MIP-1b) in vehicle and AZM-treated mice. The analysis demonstrates 
reduction of pro-inflammatory cytokines on days 3 and 7 post MI compared to vehicle. 
(n=4 mice/group/time point, *P<0.05 and **P<0.01 compared to vehicle controls). Data 
presented as mean ± SEM. AZM, azithromycin; IL-1, interleukin 1; IL-12, interleukin 12; 
MCP-1, monocyte chemoattractant protein-1; MIP, Macrophage Inflammatory Proteins; 
N.D., non-detectable; TNF-α, tumor necrosis factor-alpha.
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Supplemental Figure 2.4. AZM reduces apoptosis in the infarcted heart. Panel A 
shows representative light microscope images of a TdT dUDP Nick-End Labeling Assay 
(TUNEL) for the border regions in AZM and vehicle-treated mice 3 days after MI. 
Quantitative analyses (Panel B) of apoptosis reveal a reduction in TUNEL positive cells 
in the border regions of AZM-treated group compared to the control group (n=4 animals/ 
group, ****P<0.0001 compared to vehicle control). Scale bars represent 100 m. Data 
presented as mean ± SEM. AZM, azithromycin. 
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S2.1 Table. Forward and reverse primer sequence used in the experiments. 
Prime
r 
Forward Reverse 
18S CCAGTGGTCTTGGTGTGCTG GGAGAACTCACGGAGGACGA 
i-NOS CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 
IL-6 CTTCCATCCAGTTGCCTTCTTG AATTAAGCCTCCGACTTGTGAAG 
MCP-
1 
CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
TNF- TGGAACTGGCAGAAGAGG AGACAGAAGAGCGTGGTG 
IL-1 CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 
TGF- CGGAGAGCCCTGGATACCACCTA 
GCCGCACACAGCAGTTCTTCT
CT 
IL-4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA 
PPAR
 GCCAGTTTCGATCCGTAGAA AATCCTTGGCCCTCTGAGAT 
Chil3 
(YM1) AGGCTTTGCGGTCCTGAT CCAGCTGGTGAAGTAGCAGA 
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S2.2 Table. Echocardiographic morphometric parameters at 30 days post-MI. 
Primer Vehicle AZM P value 
Left ventricular 
ejection fraction 27.97.4 46.84.9 0.04 
Fractional 
shortening 14.14 23.92.6 0.049 
Left ventricular end-
systolic diameter 4.60.4 3.30.2 0.02 
Left ventricular end-
diastolic diameter 5.30.3 4.30.2 0.01 
Left ventricular end-
systolic volume 108.821.7 48.410.5 0.02 
Left ventricular end-
diastolic volume 136.217.8 84.78.7 0.01 
Infarct wall 
thickness 0.780.09 1.10.07 0.02 
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CHAPTER III. SPECIFIC AIM2 
Liposomes Enhance the Immunotherapeutic Efficacy of Azithromycin 
in Myocardial Infarction and Reduces the Risk of Adverse Effects 
3.1 Summary 
Introduction: There is a growing body of evidence showing that altering 
the inflammatory response by alternative macrophage polarization towards 
the reparative phenotype is protective against acute ischemic injury and 
improves cardiac functional recovery. Research shows that AZM, a macrolide 
antibiotic, alters inflammation and polarizes macrophages to the alternatively 
activated state in inflammatory conditions. We demonstrated that free AZM 
treatment (160 mg/kg/day, orally), initiated 3 days pre-MI, enhances post-MI 
cardiac recovery as a result of shifting macrophages to the reparatory state. Due 
to the limited clinical translational perspective (pre-MI treatment and relatively 
high dose of AZM) of our initial proof-of-concept study, we planned this study 
using a liposomal formulation of AZM (Lazm) to achieve rapid onset of action 
via targeted accumulation in inflammatory phagocytes.  Based on our 
preliminary studies with Lazm, we hypothesized that Low dose of liposomal 
AZM (Lazm) treatment, started after MI, yields enhanced immunomodulatory 
potential and cardiac recovery with low risk of adverse effects.  
Methods and results: Low dose free and liposomal AZM (40 or 10 mg/kg, IV) 
were administered immediately post-MI. We observed a significant shift 
favoring anti-inflammatory/reparatory macrophages with both AZM 
formulations (free and liposomal). A significant decrease in cardiac 
inflammatory neutrophils with AZM treatment was paralleled with significant 
reduction in the infiltration of inflammatory monocytes. Modulation of the 
inflammatory cell response was associated with a significant reduction in pro-
inflammatory and an equivalent increase in anti-
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inflammatory gene expression. Taken together, AZM treatment induced a systemic 
shift in post-MI inflammatory response. AZM effects resulted in reduced cardiac 
cell death and scar size, and enhanced angiogenesis. These protective effects let 
to improvement of the functional/structural complications usually seen post-MI. 
Importantly, the liposomal formulation of AZM was protective from its cardiac off-
target effects. 
Conclusion: We demonstrate that AZM is a potent immunomodulatory agent for 
the detrimental post-MI inflammatory response. Moreover, our studies are the first 
to demonstrate that targeted AZM delivery using liposomal formulations achieves 
more effective immunomodulatory effects with less cardiac side effects. To our 
knowledge, this is the first evidence of the immune modulation properties of 
liposomal AZM. Our findings strongly support clinical trials using AZM as a novel 
and clinically relevant therapeutic target to improve cardiac recovery and reduce 
heart failure post-MI in humans. 
3.2 Introduction 
Myocardial infarction (MI) remains a primary cause of morbidity and 
mortality globally, albeit hospitalization rates reduced in the last 15 years (Spatz, 
Beckman et al. 2016). Heart failure resulting from post-infarction remodeling is a 
major driver of cardiac death (Lindsey, Saucerman et al. 2016, Spatz, Beckman et 
al. 2016). Cardiomyocyte death and extracellular matrix (ECM) breakdown at the 
area of cardiac injury induce a potent and poorly controlled inflammatory response 
(Timmers, Pasterkamp et al. 2012), interfering with healing and scar formation 
processes (Entman and Smith 1994, Frangogiannis, Youker et al. 1998, Mehta 
and Li 1999). Innate immune cells such as neutrophils, monocytes, and 
macrophages are key players in this response (Hulsmans, Sam et al. 2016). After 
infarction, neutrophils are the first inflammatory cells to infiltrate the infarcted 
myocardium (Reimer, Murry et al. 1989). While neutrophils play an important role 
in removing dead cells and debris, their byproducts may exacerbate cardiac 
damage (Reimer, Murry et al. 1989, Ortega-Gomez, Perretti et al. 2013). A recent 
study reveals that there are two activation states of neutrophils in the post-ischemic 
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heart: pro-inflammatory (N1) and anti-inflammatory (N2) neutrophils (Ma, 
Yabluchanskiy et al. 2016). N1 neutrophils dominate the heart immediately after 
infarction and contribute to the development of adverse cardiac remodeling and 
heart failure, while N2 neutrophils increase gradually after MI and have cardio-
protective effects (Ma, Yabluchanskiy et al. 2016). Additionally, neutrophils can 
negatively impact post-MI healing through preferential recruitment of pro-
inflammatory (Ly6Chi)  (Soehnlein, Zernecke et al. 2008), rather than anti-
inflammatory monocytes (Ly6Clo) (Nahrendorf, Swirski et al. 2007).  
Macrophages are essential in organizing the early post-MI inflammatory 
and subsequent reparative phases. General classification of macrophages is into 
pro-inflammatory/classically activated/M1 and anti-inflammatory/alternatively 
activated/reparative/M2 macrophages based on gene profile and function 
(Nahrendorf and Swirski 2016, Ma, Mouton et al. 2018). Pro-inflammatory 
macrophages are dominant days 1-3 post-MI (Ma, Mouton et al. 2018) and 
mediate the inflammatory process (Sica, Matsushima et al. 1990, Ma, Mouton et 
al. 2018). Following this early inflammatory phase, on days 5-7, reparative 
macrophages are the most prevalent and are characterized by high expression 
levels of IL-10, IL-1Ra, and decoy type II receptors (Dinarello 2005, Yan, Anzai et 
al. 2013, Ma, Mouton et al. 2018). Due to the production of these mediators, M2 
macrophages play a central role in inflammation resolution and demonstrate robust 
anti-inflammatory effects, potentially involved in tissue remodeling and 
angiogenesis (Gombozhapova, Rogovskaya et al. 2017). There is a growing body 
of evidence showing that repolarization of macrophages to the reparative 
phenotype is protective against early development of ischemic lesion and its 
subsequent cardiac remodeling (Schnoor, Cullen et al. 2008, Harel-Adar, Ben 
Mordechai et al. 2011, de Couto, Liu et al. 2015, Kain, Liu et al. 2017, Qin, 
Finlayson et al. 2017). Previous research from our lab demonstrates that 
azithromycin (AZM), a commonly used antibiotic with immunomodulatory effects, 
alters post-MI inflammation through repolarization of macrophages to a reparative 
phenotype, which ultimately leads to increased  protection against adverse cardiac 
remodeling and heart failure (Al-Darraji, Haydar et al. 2018). However, these 
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findings have limited clinical translation given the pre-MI treatment and relatively 
high dose, which our non-targeted delivery of AZM dictated (Al-Darraji, Haydar et 
al. 2018). It remains unclear whether low dose AZM immediately after cardiac 
injury is effective in shifting macrophage phenotype or enhancing cardiac recovery 
post-MI. The goal of this translational study is to demonstrate pre-clinical findings 
showing the efficacy of AZM as immunotherapeutic agent in a clinically translatable 
model of MI therapy.  
Liposomes are formed of one or more phospholipid bilayers surrounded by 
an aqueous core (Levchenko, Hartner et al. 2012), which can hold both lipophilic 
and hydrophilic compounds. Given their biocompatibility and ease of use, they 
rapidly became an attractive drug delivery system (Levchenko, Hartner et al. 
2012). Research shows that liposomes reduce the ED50 of the cytotoxic drug, 
doxorubicin, in preventing drug toxicity while promoting anti-tumor efficacy (Rose 
2005). Doxorubicin liposomes reach steady state faster and with fewer doses due 
to intensified localization at targeted organs (Charrois and Allen 2003). 
Additionally, liposomes are highly effective carriers, achieving higher drug 
concentration at sites of cardiac injury (Mueller, Marcus et al. 1981). Increased 
cellular and vascular permeability in the injured myocardium enhances the specific 
capacity of liposomes to deliver therapeutic agents to the site of injury (Takahama, 
Minamino et al. 2009). Research shows that liposomes facilitate the local 
distribution of tracers in infarcted myocardium (Caride, Twickler et al. 1984). 
Additionally, post-infarction medium contains a large variety of diverse cell types, 
which can be targeted to improve outcomes of the accumulated therapeutics 
(Dasa, Suzuki et al. 2015) . Liposomal dosage forms are effective as a drug 
delivery strategy for phagocyte-targeted therapy, producing lower immunogenic 
reaction, higher biocompatibility and specificity, and greater drug stability. After 
parenteral administration, liposomes are naturally taken up by mononuclear 
phagocytes (Kelly, Jefferies et al. 2011). Liposomes can harness the physiological 
function of these cells to mediate a targeted delivery and promote the therapeutic 
efficacy of the agent (Kelly, Jefferies et al. 2011). Therefore, we designed this 
study to overcome the limitations of our previous work and to improve outcomes 
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of AZM cardioprotective therapy. Additionally, we expect the encapsulated dosage 
form to reduce potential off-target effects of AZM.  In this report we test the 
hypothesis that low dose liposomal AZM (Lazm) treatment, started immediately 
post-MI, yields an enhanced immunotherapeutic potential and cardiac recovery 
with low risk of adverse effects. 
3.3 Materials and methods 
3.3.1 Study Design 
C57BL/6 male mice (Jackson Laboratory, BarHarbor, ME), age 6-8 weeks, 
were treated with one of two doses of liposomal or free AZM (10mg/kg/day or 
40mg/kg/day) or vehicle (PBS or empty liposomes) using retro-orbital injection, 
starting immediately after MI or sham surgery for 7 days (Fig 3.1A). The doses 
used represent commonly prescribed comparable human dosages (Evans, Smith 
et al. 2005, Evans, Rogers et al. 2011), as well as provide effective distribution and 
tissue accumulation in animals (Shepard and Falkner 1990). Treatment continued 
for 7 days to span the duration of the post-MI inflammatory period (Heidt, Courties 
et al. 2014). All procedures were conducted under the approval of the University 
of Kentucky IACUC in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals (DHHS publication No. [NIH] 85–23, rev. 1996). 
3.3.2 Murine model of myocardial infarction 
Anesthesia was induced through a small animal vaporizer system with 1–
3% isoflurane. Pain reflexes were appropriately tested to confirm adequate 
anesthesia before and during the surgical procedure. Lateral thoracotomy between 
the left fourth and fifth ribs was performed, the pericardial space was accessed, 
and the heart protruded from the intercostal space. The left anterior descending 
coronary artery (LAD) was identified and permanently ligated with 6–0 silk suture 
3 mm distal to its origin, as previously described (Al-Darraji, Haydar et al. 2018). 
Sham surgery consisted of the same procedure without LAD ligation. The heart 
was immediately returned to the intrathoracic cavity and air manually evacuated to 
96 
prevent pneumothorax. Finally, the muscle and skin were sutured using a 4–0 
Prolene running suture. 
3.3.3 Preparation of liposomes 
Liposomal formulations were prepared according to previously established 
protocol (Kierstead, Okochi et al. 2015), using the thin film hydration method with 
equal molar ratios of distearyl phosphatidylcholine (DSPC), distearyl 
phosphatidylglycerol (DSPG) and cholesterol (Avanti polar lipids). AZM was 
included at 10 and 30 mol% based on phospholipid content. Formulations 
containing fluorophores were prepared in the same manner using 0.5 mol% of the 
lipophilic dye with 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine (DiD). 
Lipids and AZM were mixed in chloroform and methanol at the desired ratio and 
the organic solvents removed by rotary evaporation to yield a thin film. After placing 
under a vacuum overnight, the lipid/drug films were hydrated in phosphate buffered 
saline (pH 7.4) and sonicated at 65°C for 30 min. The resulting unilamellar vesicles 
were extruded through 200 nm polycarbonate membranes to obtain uniform 
particle size. Liposome size, polydispersity and stability over time were determined 
by dynamic light scatter testing. 
3.3.4 Flow cytometry 
3.3.4.1 Blood 
Cell phenotype, in addition to gene profile, analyses of monocytes and 
neutrophils were investigated in peripheral blood as previously described (Al-
Darraji, Haydar et al. 2018). Briefly, blood was collected in tubes with a 1:5 ratio of 
ethylene diaminetetraacetic acid (EDTA)/citrate-theophylline-
adenosinedipyridamole (CTAD) on days 1, 3 and 7 post-MI. Whole blood was 
centrifuged for 5 minutes at 500 x g, and the plasma layer was separated and 
reserved at -80°C. To lyse red blood cells, the residual cell pellet was incubated 
with 0.5 ml of diluted red blood lysing buffer (BD pharm lyse) for 10 minutes with 
mild agitation. To end the lysis process, 0.5 ml of staining buffer (5% goat serum, 
0.05% sodium azide in phosphate-buffered saline) was added to the suspension 
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of red blood cell lysed blood. Then, the suspension was centrifuged at 400 x g for 
5 minutes, and the supernatant was removed. This step was repeated if the red 
blood cells were still detectable in the cell pellet. White blood cell pellet was 
washed twice in staining buffer to remove any residual lysis buffer. After 
supernatant removal, the pellet was resuspended in a pre-determined volume of 
staining buffer and counted. Cells of each blood sample were divided into two parts 
depending on cell count to have ∼106 live (trypan blue-negative) cells in each part. 
One portion was collected for surface marker staining, and the other part incubated 
with cell lysis buffer (Life technologies) to lyse cells for 10 minutes with multiple 
aggressive agitations, and then kept at -800C for further gene expression analysis. 
Cells for staining were incubated immediately with conjugated primary antibodies 
against PERCPCY5.5-conjugated Ly6G/C (BD Pharmingen), PECY7-conjugated 
F4/80 (Biolegend), brilliant violet 421-conjugated CD11b (Biolegend), APC-CY7-
conjugated CD45 (Biolegend), and PE-conjugated CD115 (Biolegend) for 30 
minutes on ice. Following incubation, cells were washed twice with staining buffer 
and analyzed by an LSR II (Becton Dickinson) in the University of Kentucky Flow 
Cytometry Core. Using unstained cells and single fluorescent controls, laser 
calibration and compensations were performed for all experiments. We identified 
monocytes with the CD45hi/CD115hi/Ly6-Chi profile as classical (pro-inflammatory), 
and cells with the CD45hi/CD115hi/Ly6-Clo profile were identified as non-classical 
(anti-inflammatory). Neutrophils were identified as CD45 hi/CD115 lo /Ly6-C/Glo.  
3.3.4.2 Heart 
Phenotypic cell analysis of macrophages and neutrophils and gene 
expression analysis was conducted in the heart as previously described (Al-
Darraji, Haydar et al. 2018). Briefly, mice were sacrificed, and hearts were rapidly 
isolated and placed in ice cold PBS (VWR International). Using a razor blade, the 
heart was manually minced. After mincing, tissue was incubated with a 
Collagenase B (Roche, Indianapolis, IN) and Dispase II (Roche, Indianapolis, IN) 
mixture at 37°C for 30 minutes, with gentle agitation every 5-10 minutes. Tissue 
digestion ceased using cold staining buffer and the suspension was placed on ice 
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and filtered using a 70 μm cell strainer, followed by centrifugation at 400 x g for 5 
mins at 4°C. Supernatant was discarded and the pellet was resuspended in 0.3 ml 
of staining buffer. Individual heart cells were divided into approximately three equal 
portions depending on cell count with ∼106 live (trypan blue-negative) cells in each. 
Two portions were used for cell staining while the remainder was incubated with 
cell lysis buffer (Life technologies) using multiple aggressive agitations, for 10 
minutes and reserved at -800C for further gene expression analysis. Cells for flow 
cytometry were incubated immediately with conjugated primary antibodies against 
FITC-conjugated Ly6G (BD Pharmingen), PE-conjugated CD206 (Biolegend), 
PECY7-conjugated F4/80 (Biolegend), brilliant violet 421-conjugated CD11b 
(Biolegend), brilliant violet 510-conjugated CD11c (Biolegend), APC-CY7-
conjugated CD45 (Biolegend), or  PERCPCY5.5-conjugated Ly6G/C (BD 
Pharmingen), PECY7-conjugated F4/80 (Biolegend), brilliant violet 421-
conjugated CD11b (Biolegend), APC-CY7-conjugated CD45 (Biolegend), and PE-
conjugated CD115 (Biolegend) for 30 minutes on ice. Cells were then washed 
twice with staining buffer and analyzed by an LSR II (Becton Dickinson) in the 
University of Kentucky Flow Cytometry Core. Using unstained cells and single 
fluorescent controls, laser calibration and compensations were performed for all 
experiments. CD45hi/Ly6Glo/F4-80hi cells were identified as macrophages and 
further classified as pro-inflammatory or reparative based on the expression of 
CD206 and CD11c. Neutrophils were defined as CD45 hi/CD115 lo /Ly6-C/Glo, 
CD206 was used to further identify N1 neutrophils. 
3.3.5 Histology 
Histological analysis was performed on deparaffinized and rehydrated 
sections as previously described (Al-Darraji, Haydar et al. 2018). Briefly, 30 day 
post-MI mice (N = 6-10/treatment group) were sacrificed under isoflurane 
anesthesia and hearts were isolated. Hearts were perfused first with PBS (VWR 
International), then by 10% buffered formalin (VWR International). Perfused hearts 
were placed in 10% neutral buffered formalin (VWR) overnight at room 
temperature, then sectioned into 3-mm cross-sections starting at the level of 
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coronary ligation then embedded in paraffin and sectioned into 4-μm sections. 
Sections were stained with Masson’s trichrome to evaluate scar size as previously 
described (Al-Darraji, Haydar et al. 2018). Digital images of stained sections were 
acquired, and areas of interest were assessed using NIH ImageJ (version 7) 
software. The LV area, LV cavity area, and infarct area were measured as 
previously described (Al-Darraji, Haydar et al. 2018). Scar size was presented as 
a percentage of the total LV volume. 
3.3.6 Immunohistochemistry 
Heart sections (N = 4/treatment group) were prepared as described in the 
previous section. Immunostaining of heart sections was performed on 
deparaffinized and rehydrated sections as previously described (Al-Darraji, Haydar 
et al. 2018). Briefly, sections were incubated with primary antibodies: rabbit anti-
mouse IBA1 (Wako), goat anti-mouse CD206 (R and D Systems), and/or goat anti-
mouse IL-1β (R & D Systems) overnight at 4°C, then washed and incubated with 
secondary antibodies conjugated to Alexa Fluor 488 or 594 (Invitrogen), followed 
by incubation with DAPI. In the peri-infarct area, 10-15 adjacent zones per section 
(1–2 sections/animal) were imaged at 40x magnification utilizing a Nikon Confocal 
A1 Microscope in the University of Kentucky Confocal Microscopy facility. 
Nucleated cells that were antibody-positive were quantified using Cell Counter 
plugin for Nikon NIS-Elements (version AR 3.2). Findings are presented as total 
number of positive cells per high power field in the area of interest.  
By using a similar protocol to the above, heart sections (N=5-7/treatment 
group) were prepared from mice sacrificed at day 30 post-MI. Sections were 
stained with FITC-conjugated isolectin B4 (FL1201, Vector Labs, Burlingame, CA). 
In the peri-infarct region, 10-15 adjacent zones per section (1–2 sections/animal) 
were imaged at 40x magnification utilizing Nikon Confocal Microscope A1. 
Quantification was performed using Cell Counter plugin for Nikon NIS-Elements 
(version AR 3.2). Findings are presented as total capillary density per mm2 in the 
peri-infarct zone. All measurements were performed in the peri-infarcted areas 
only and analyzed by blinded observer. 
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Cell apoptosis was examined on deparaffinized and rehydrated sections 
from mice (N = 4/treatment group) sacrificed at day 3, as previously described (Al-
Darraji, Haydar et al. 2018). TUNEL and caspase-3 staining was performed in the 
Biospecimen Procurement and Translational Pathology Shared Resource Facility 
(BPTP SRF) at the University of Kentucky. Nucleated positively stained cells were 
estimated. Quantification was performed using Cell Counter plugin for ImageJ 
(version 1.51d). Findings are presented as total positive cells per high power field 
in the peri-infract region. All measurements were obtained in the peri-infarcted 
areas only and analyzed by blinded observer. 
 
  3.3.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR).  
PureLink RNA Mini Kit (ThermoFisher Scientific) was used to isolate total 
mRNA from heart and blood cells according to manufacturer protocol. Isolated 
RNA was quantified using a NanoDrop 8000 spectrophotometer (Thermofisher). 
Next, cDNA was generated using the SuperScript VILO cDNA synthesis kit 
(Invitrogen). Using a QuantaStudio 7 Flex real-time thermocycler (Applied 
Biosystems by life technology), Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) was performed to measure the mRNA expression of markers 
identifying: inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha 
(TNF-α), monocyte chemotactic protein-1 (MCP-1), transforming growth factor 
beta (TGF-β), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-4 (IL-4), 
chitinase-like3 Chil3 (YM1), interleukin-10 (IL-10), arginase-1 (ARG-1), and 
Peroxisome proliferator-activated receptor gamma (PPARg). We used the 
comparative Ct method for relative estimation of mRNA expression, which was 
normalized to 18s (a housekeeping gene). Certain strategies to avoid bias and 
error inducible by contaminated DNA were taken: (a) primers were adjusted to 
bridge an intron for specific cDNA augmentation, (b) appropriate negative control 
reactions (template free controls) were used, (c) careful examination of the melting 
curve of augmented products (dissociation graphs) for consistency was performed, 
and (d) the probe Tm was at least 10°C more than the primer Tm , while the melting 
temperature (Tm) was 57°C–60°C. 
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3.3.8 Echocardiography 
Mice were anaesthetized using 1–3% isoflurane during echocardiography 
to maintain a heart rate of 450-500 BPM during imaging. A Vevo 3100 system 
coupled with a 15-7-MHz linear broadband transducer and a 12-5-MHz phased 
array transducer was used to perform echocardiogram analyses. Heart function 
was examined at baseline (before cardiac surgery) and then remeasured at one 
and 4 weeks post-MI. During acquisition, a heating pad was used to preserve the 
body temperature at 37°C and the temperature was continuously assessed by 
rectal temperature probe. Using modified parasternal long-axis and short-axis 
probe placement, two-dimensional and Doppler echocardiography was used to 
assess the LV function and volume in M-mode. Tracings at the mid-papillary level 
were used to investigate the systolic and diastolic parameters and Teichholz 
formula was applied to quantify LV function. Echocardiographic imaging and 
analyses were carried out by a blinded investigator.  
3.3.9 Luminex assay 
At 1 and 3 days post-MI, plasma was collected using the PB collection 
protocol detailed earlier. Inflammatory biomarkers (IL-12, IL-1β, IL-1α ITNF-α, 
MIP-1, MIP-1α, MIP1β, MIP2, IP-10, G-CSF, RANTES, and KC) were quantified 
using the Milliplex mouse cytokine magnetic kit (MILLIPLEX MAP for Luminex 
xMap Technology, Millipore, USA) according to the manufacturer’s protocol. 
3.2.10 Maestro in vivo fluorescence imaging 
Mice were placed inside the Maestro imaging system under isoflurane anesthesia. 
They were positioned so that the chest and abdomen of the animal were in the 
field of view. We used an orange filter (excitation 605nm, emission 675nm long 
pass) to capture the APC signal that comes from liposomes. Acquisition settings 
were in range from 640 to 820nm in 10-nm steps.  To enhance the quality of the 
images we adjusted various variables like stage height, focus, and exposure 
length, within time points. Images were taken with side-by-side Lazm and vehicle-
102 
injected control animals and were analyzed using Maestro software (Cambridge 
Research & Instrumentation, INC. (CRI), USA). 
3.3.11 Cell culture  
We used a murine macrophage cell line, J774 monocyte/macrophage cell 
line (ATCC, Manassas, VA), for in vitro experiments examining the 
immunomodulatory effects of free and liposomal AZM. Using DMEM media 
(supplemented with 10% FBS, 1% penicillin/streptomycin, 1% sodium pyruvate, L-
Glutamine, and Glucose), cells were plated in 6 well plates at a concentration of 
0.3×106 cells/well. After adhesion, cells were treated with 30 μM free or liposomal 
AZM (Sigma-Aldrich, St. Louis, MO) and 20 ng/ml IFNγ (eBioscience 14-8311-63) 
diluted in DMEM. Following overnight incubation at 37°C with 5% CO2, cells were 
stimulated using 100 ng/ml of LPS (Invivogen) diluted in DMEM. Supernatant was 
collected 48 hours after stimulation to quantify pro- and anti-inflammatory cytokine 
(TNF-α and IL-10) concentration.  
3.3.12 ELISA assays 
Levels of TNF-α and IL-10 were assessed in the supernatant from in vitro 
cell culture experiments using standard ELISA kits (BD Biosciences, San Deigo, 
CA) according to the manufacturer protocol. Results are presented for each 
cytokine (picogram/ml) with different treatments.  
3.3.13 Non-invasive electrocardiogram (ECG) system 
Mice were anesthetized with 2% isoflurane, then placed on the ECG 
platform. Electrodes were placed through the skin on the torsos followed by ECG 
recording for 2-3 minutes. Once the recording was completed, the data were 
analyzed using Chart software (PhysioTel).  
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3.3.14 Statistical Analysis 
Data are presented as mean ± standard error of the mean (SEM). Unpaired 
Student t test or analysis of variance (one-way or multiple comparisons) were used 
for group comparisons, as appropriate. Two-sided Dunnett or Dunn tests for post 
hoc multiple comparison procedures were used, with control samples as the 
control category. P value less than 0.05 was considered statistically significant 
during the analyses. Statistical analyses were performed using the Prism 8 
software package (GraphPad, La Jolla, CA). 
3.4 Results 
3.4.1 Lazm formulation accumulates in the injured myocardium, particularly 
in immune cells. 
Several therapeutic agents have been tested to alleviate cardiac 
remodeling post-MI through systemic administration; however, they suffer limited 
efficacy due to poor bioavailability in the heart or dose-limiting adverse effects 
(Dasa, Suzuki et al. 2015). The increased vascular permeability post-MI facilitates 
the accumulation of nanocarriers such as liposomes in the injured myocardium 
(Takahama, Minamino et al. 2009). In our studies, we elected to use non-
PEGylated liposomes which are readily engulfed by phagocytes at sites of tissue 
injury (Oh, Nix et al. 1995). First, we were interested in determining whether Lazm 
accumulates in the injured heart after parenteral administration. We utilized a 
Maestro EX in vivo imaging system in combination with APC-labeled liposomes for 
visualization (Figure 3.1B). We found that Lazm accumulates in the injured heart 
as early as the first day after infarct and peaks at day 3 after injury (Figure 3.1B). 
The ex vivo imaging shows that these liposomes more likely accumulate in the 
infarct and peri-infarct regions of the heart, which is consistent with geographic 
accumulation of infiltrating phagocytes (Figure 3.1B). Importantly, no signal was 
determined in the heart of sham-operated mice either in vivo or ex vivo.  
Post-infarcted myocardium contains diverse cell populations that may be 
targeted therapeutically to enhance cardiac recovery (Dasa, Suzuki et al. 2015). 
Liposomal formulations have been extensively tested as targeted delivery tools for 
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phagocytic cells, with lower immunogenicity, higher bioavailability and specificity, 
and greater drug stability (Kelly, Jefferies et al. 2011). We examined liposomal 
accumulation in the heart at a cellular level using flow cytometry. FACS analysis 
of labeled Lazm shows that liposomes concentrate in phagocytes such as 
neutrophils and macrophages beginning on day 1 post-MI. Importantly, less than 
1% of non-immune cells in the heart show liposomal uptake, implying preferential 
liposomal accumulation in our cells of interest (Figure 3.2). We confirmed these 
observations using Celigo analyses, which show an enhanced liposomal 
colocalization with phagocytic cells isolated from the heart after MI (Figure 3.3). 
These findings strongly indicate that our designed non-PEGylated liposomes 
accumulate at the peri-infarct region, particularly in phagocytic cells, early after MI. 
Liposomal accumulation exhibits temporal trends consistent with infiltration of 
inflammatory cells.  
3.4.2 Liposomal formulation reduces the risk of AZM side effects. 
Studies show that AZM produces a negative inotropic effect and delays 
ventricular repolarization. These hemodynamic effects of AZM are likely mediated 
by a Ca+2 channel-independent pathway and delayed rectifier K+ current (Ohara, 
Nakamura et al. 2015). Additionally, the cardiac action potential is much shorter in 
mice compared to humans  (Perlman 2016). Therefore, we were interested in 
examining the potential arrhythmogenic and hemodynamic effects of AZM in the 
heart when administered post-MI. Baseline parameters do not differ among the 
monitored groups. The retro-orbital administration of free AZM at 40mg/kg 
remarkably reduces heart rate, RR, ejection fraction, and cardiac output interval 
compared with baseline (Figure 3.4A and B). Moreover, we note that the QT 
interval is also prolonged after free AZM administration (Figure 3.4C). In contrast, 
administration of Lazm at the same dose does not induce any noticeable 
conduction or electrical changes in vivo (Figure 3.4A, B, and C). These findings 
imply that the liposomal dosage form of AZM is indeed protective against 
hemodynamic drug modifications, which is most likely attributed to the specific 
delivery of AZM to immune cells, avoiding cardiomyocytes. It is likely that 
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encapsulation of AZM rescues other adverse drug effects as well, making it an 
attractive method of delivery for clinical practice, especially in high risk patients. 
3.4.3 Lazm therapy recruits reparative macrophages to the infarcted 
myocardium. 
Macrophages are the primary cardiac immune cells during steady state and 
after ischemic injury, where they organize the ensuing inflammatory and healing 
events (Hulsmans, Sam et al. 2016) ((Ben-Mordechai, Palevski et al. 2015). We 
previously identified a cardioprotective role of oral free AZM in the setting of MI via 
its immunomodulatory effects on macrophages in post-MI inflammation. However, 
the pre-MI administration and high dose of AZM limit the clinical translation of this 
study. Therefore, here we used an encapsulated dosage form in an attempt to 
promote early cardiac bioavailability of AZM therapy. This is the first study to 
examine the anti-inflammatory and immunomodulatory properties of liposomal 
AZM, which may potentially expand to other inflammatory pathologies. First, we 
find significantly lower heart weight in Lazm treated groups, suggestive of less 
tissue edema and potentially less inflammatory change (Figure 3.5). In our 
investigation of macrophage phenotype in the injured heart at multiple timepoints 
after injury using flow cytometry (Figure 3.6), we observe a decrease in pro-
inflammatory macrophages (CD45+/Ly6G-/F4-80+/CD11c+) at day 1 with a more 
profound effect on day 3 post-MI in Lazm treated groups compared to free AZM 
and control groups (Figure 3.6A). Conversely, reparative macrophages 
(CD45+/Ly6G-/F4-80+/CD11c-/CD206+) significantly increase at day 3 in Lazm 
treated groups compared to free AZM and control groups (Figure 3.6B). 
Collectively, these changes translate into a significant reduction in the ratio of pro-
/anti-inflammatory macrophages in Lazm groups, indicating a shift in macrophage 
phenotype towards the reparative state (Figure 3.6C). 
Repolarizing macrophages towards the anti-inflammatory activation state in 
peri-infarct zones can protect more cardiomyocytes from death, reducing infarct 
expansion and the subsequent adverse cardiac remodeling (de Couto, Liu et al. 
2015) (Ben-Mordechai, Palevski et al. 2015). To confirm the immunomodulatory 
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effects of AZM on macrophages in the peri-infarct zone, we quantified cells 
expressing a general macrophage marker (Iba1), a reparative macrophage marker 
(CD206+), and IL-1β as a marker of pro-inflammatory macrophages on day 3 post-
MI using immunohistochemistry. We found a significant increase in reparative 
(CD206+) macrophages in free and liposomal AZM treated mice compared to 
control groups (Figure 3.7A). At the same time, we observe significantly higher 
numbers of pro-inflammatory (Iba1+IL-1β+) macrophages in the control groups 
(Figure 3.8A). Generally, the total number of macrophages (Iba1+ cells) were not 
different between groups, implying that Lazm therapy does not affect total 
macrophage count, but rather influences polarization in favor of the reparative 
phenotype, and this effect is increased with liposomal AZM (Figure 3.7B). This 
shift in alternatively activated macrophages in AZM treated groups is observed in 
both our immunohistochemical and flow cytometric data. These effects may be 
therapeutically harnessed to resolve the detrimental inflammation post-MI.  
Monocytes dominate the infarcted heart following MI, providing a rich 
source of macrophages  (Zlatanova, Pinto et al. 2016).  Recruitment of the two 
subsets of monocytes (Ly6Chi and Ly6Clo) to the heart occurs in two waves: a first 
wave of Ly6Chi and a subsequent wave of Ly6Clo. These subpopulations mediate 
essential activities in early inflammation and the later reparative process (Swirski, 
Nahrendorf et al. 2009)  (Nahrendorf, Swirski et al. 2007). In the heart (Figure 
3.9A), we find that the Ly6Chi (CD45+/Ly6C/Ghi/CD115hi) monocytes (pro-
inflammatory) significantly decrease in the first day after injury in liposomal and 
free AZM treated groups, an effect that disappears at later timepoints. In the blood 
(Figure 3.9B), the Ly6Chi monocytes were considerably low on day 3 with 
comparable numbers on other days in the Lazm groups. These observations 
suggest that the liposomal and free AZM treatments can modulate other members 
of the immune response to MI both locally in the heart and systemically. 
3.4.4 Lazm treatment reduces neutrophils, particularly N1.   
Neutrophils orchestrate the clearance of dead cells and debris  (Ortega-
Gomez, Perretti et al. 2013). Additionally, apoptotic neutrophils initiate anti-
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inflammatory changes in macrophages and hence contribute to the resolution of 
inflammation  (Horckmans, Ring et al. 2017). Neutrophil 
(CD45+/CD115lo/Ly6G/Clo) analysis in the heart and blood using flow cytometry 
reveals that Lazm treatment significantly reduces neutrophil counts during their 
peak at day 1 (Figure 3.10A). However, we did not see significant changes in mice 
treated with free AZM.  
To further investigate the immunomodulatory actions of AZM, we examined 
the distribution of N1 neutrophils (CD11b+/Ly6G+/CD206-) in the heart over time. 
We found a substantial decrease in N1 neutrophils at day 1 in Lazm treated groups 
(Figure 3.10C), which may explain the reduction in total neutrophil number. These 
findings may represent a novel therapeutic avenue in the treatment of MI patients 
who experience prolonged neutrophilia after infarct.  
 
3.4.5 Lazm treatment shifts inflammatory gene expression towards the anti-
inflammatory state.  
The gene expression profile of macrophages relates to the activation status 
of these cells. Pro-inflammatory macrophages produce large amounts of pro-
inflammatory cytokines (IL-1β, TNF-α, IL-6) and toxic effector molecules (reactive 
oxygen species, nitric oxide)  (Martinez, Sica et al. 2008). On the other hand, 
reparative macrophages are potent generators of anti-inflammatory cytokines 
(TGF-β and IL-10) in addition to the expression of scavenger, mannose, and 
galactose-type receptors  (Song, Ouyang et al. 2000). To identify whether 
liposomal formulation enhances the anti-inflammatory effects of AZM, we 
conducted in vitro experiments to identify the production of pro-inflammatory/anti-
inflammatory cytokines in the J774 macrophage cell line. After 48 hours of 
stimulation, we observed accentuated immunomodulatory effects with liposomal 
AZM, confirmed through significant shift in the production of TNF-α and IL-10 
towards the anti-inflammatory pattern (Figure 3.11).  
We also assessed the mRNA expression of inflammatory and reparative 
genes in the heart and blood cells using RT-PCR. We observed a significant shift 
in the gene expression profile towards the anti-inflammatory state associated with 
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liposomal/free AZM treatment. In cardiac tissue, mRNA levels of a pro-
inflammatory macrophages (iNOS) and pro-inflammatory cytokines (MCP-1, TNF-
α, IL-6, and IL-1β) are substantially downregulated in mice treated with free and 
liposomal AZM, particularly on days 1 and 3 post-infarct (Figure 3.12A). 
Conversely, the expression of anti-inflammatory cytokines and reparative 
macrophages (TGF-β and IL-10; IL-4, ARG, Fizz1, PPARγ and YM1) are 
significantly upregulated in the same groups of mice with consistent effects up 
through day 7 (Figure 3.12B). Interestingly, we observe a similar trend in the gene 
expression of cytokine and macrophage markers in PB cells in the same groups 
(Figure 3.12C and D), suggesting systemic anti-inflammatory and 
immunomodulatory effects of Lazm therapy in addition to local effects at the site 
of injury. Additionally, we observe that inflammatory cytokine and chemokine (IL-
12, IL-1β, IL-1α ITNF-α, MIP-1, MIP-1α, MIP1β, MIP2, IP-10, G-CSF, RANTES, 
and KC) concentrations are reduced in plasma of AZM treated groups (Figure 
3.13).  Based on our prior published studies, we see no changes at day 7 so we 
did not run that analysis. Collectively, these consistent results from multiple in vitro 
and in vivo studies suggest that AZM may have therapeutic clinical potential in MI 
patients. 
 
3.4.6 Lazm therapy reduces cell death and scar size, and increases 
angiogenesis in the infarcted heart. 
To identify the pro-survival effect of AZM therapies on cardiac cells post-MI, 
we assessed apoptosis in peri-infarct borders 3 days post-MI using caspase-3 
(early apoptosis) and TUNEL (late apoptosis) assays. We observed that free and 
liposomal AZM therapy markedly reduce apoptosis in comparison to controls 
(Figure 3.14A and 3.15A respectively), likely related to pro-survival factors 
produced by reparative macrophages  (Aurora, Porrello et al. 2014). We next 
assessed the infarct size 30 days post-MI using Masson’s trichrome-stained 
sections from the heart. We found that Lazm treatment significantly reduced scar 
size in comparison to controls (Figure 3.16). These data indicate that AZM 
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preserves the heart from acute injury after ischemia as well as reduces 
susceptibility to chronic scar enlargement. 
Reparative macrophages, through secretion of protective cytokines and 
pro-angiogenic factors such as VEGF, may promote reparative power  (Aurora, 
Porrello et al. 2014).  To determine blood vessel density at the infarct borders, we 
quantified isolectin-positive cells (a marker for endothelial cells) in the peri-infarct 
region 30 days post-MI. We observed a significant increase in density of newly 
formed blood vessels in the Lazm groups compared to controls (Figure 3.17). This 
is another important factor in AZM/Lazm therapy that may contribute to reduced 
scar size. The- shift in macrophage phenotype may explain the reduction in 
apoptotic cells and enhanced angiogenesis and provide the mechanism for 
reduced scar size observed in these groups. 
3.4.7 Lazm therapy enhances cardiac functional recovery after MI. 
Adverse cardiac remodeling and the ensuing heart failure post-MI are likely 
related to an imbalance between pro-inflammatory and pro-reparative phases after 
injury (de Couto, Liu et al. 2015). By modulating the inflammatory response, we 
investigated the role of AZM in cardiac recovery after MI. We performed 
echocardiography at 1- and 4-weeks post-MI and analyzed cardiac function and 
remodeling. We observed a significant attenuation of LV functional decline in Lazm 
treated groups compared to controls (Figure 3.18A). We noted a similar trend in 
other cardiac remodeling parameters such as LV end-systolic and LV end-diastolic 
diameters in the same groups (Figure 3.18B and C). Finally, survival rates indicate 
that the cardioprotective effects of free/liposomal AZM translated into a remarkable 
reduction in mortality (Figure 3.19). 
Collectively, the immunomodulatory effects of Lazm therapy were potent at 
inducing favorable resolution of the overactive and/or extended pro-inflammatory 
cascades and their associated cardiac damage and impaired recovery. As a result, 
we found significant improvement in the structural/functional complications post-
MI.
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3.5 Discussion  
Macrophages are the primary immune cells in the heart post-MI, organizing 
the early inflammatory stage and the later reparative events. The two activation 
states of macrophages (pro-inflammatory vs. reparatory) make them an attractive 
therapeutic target to induce earlier resolution of post-MI inflammation. We recently 
found that azithromycin (AZM) improves cardiac remodeling and recovery post-MI 
through a shift in macrophages to the reparatory state using a proof-of-concept 
experimental model. In this study, we utilized a clinically relevant experimental 
design using targeted liposomal AZM delivery to potentiate its bioavailability and 
immunomodulatory effects post-MI. Lazm enhanced resolution of post-MI 
inflammation as evidenced by a shift of pro-inflammatory to reparatory 
monocytes/macrophages. Neutrophils were substantially decreased as well, 
particularly the pro-inflammatory N1 neutrophils. These observed cellular changes 
occurred primarily at the site of cardiac injury and were paralleled by a shift towards 
anti-inflammatory cytokine production and cellular preservation, leading to reduced 
scar size, enhanced angiogenesis, and improved cardiac functional recovery. In 
addition to these findings, we observed that the liposomal formulation is protective 
from adverse drug effects such as conduction abnormality. These findings imply 
that post-MI treatment with low dose Lazm is a promising therapeutic target in 
patients with MI. 
Several therapeutic agents have been tested to alleviate cardiac 
remodeling post-MI through systemic administration, however; they had limited 
efficacy due to poor accumulation in the target site/cells, incompatible 
pharmacokinetic properties with MI, or dose-limiting adverse effects (Dasa, Suzuki 
et al. 2015). As a result, an optimal drug delivery system capable of favorably 
accumulating therapeutic agents in the injured myocardium while upholding a 
reservoir that is not intensely processed by other non-targets (Dasa, Suzuki et al. 
2015) is urgently needed. In the present work, in vivo imaging and flow cytometric 
analyses confirm that liposomes accumulate preferentially in the peri-infarct and 
infarct regions post-MI beginning in the first 24 hours after infarct, indicating 
specific localization to the damaged myocardium. Flow cytometric analysis 
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investigating the accumulation of liposomes in cardiac cells indicates that 
liposomes concentrate in immune cells, with less than 1% of non-immune cells 
testing positive for liposomes. This distribution strongly suggests that liposomes 
increase the on-target effects (enhanced efficacy), as well as reduce the off-target 
effects (less potential of adverse effects). Indeed, our in vivo electrophysiological 
monitoring of the heart confirmed the observed reduction of conduction 
abnormalities with Lazm formulation compared to free AZM. By using non-
PEGylated liposomes, inflammatory cells phagocytize Lazm in the leaky 
vasculature of the infarcted myocardium. However, more studies are needed to 
further refine drug delivery and release in the setting of MI. 
We previously demonstrated the immunomodulatory effectiveness of AZM 
as a potential therapy for cardioprotection after ischemic injury (Al-Darraji, Haydar 
et al. 2018). In this earlier proof-of-concept study, pre-MI treatment provided time 
for the drug to reach steady levels before MI induction (Feola, Garvy et al. 2010). 
We also used a relatively high dose of AZM (160 mg/kg/day), consistent with 
previous animal studies (Feola, Garvy et al. 2010, Zhang, Bailey et al. 2015). We 
are currently working with our collaborators to prepare a biotinylated form of AZM 
for both in vivo and in vitro experiments to enable its quantitative tracking in cells 
and tissue using different encapsulation strategies.  However, AZM administration 
may be related to cardiac conduction and hemodynamic changes. Therefore, we 
stopped pursuit of a long-term follow up study with free AZM due to profound 
adverse effects (Fig 3.4). 
To avoid these translational barriers and warrant post-MI low dose AZM, we 
considered an encapsulated dosage form of AZM, which may enhance the 
immunomodulatory efficacy and facilitate faster mode of action of drugs as 
previously shown with other compounds (Cynamon, Klemens et al. 1992, Oh, Nix 
et al. 1995). Our data confirm enhanced pharmacological effects with low dose of 
Lazm compared to free AZM. Furthermore, our studies reveal that liposomal 
formulation is protective against adverse effects of free AZM such as the observed 
reduction in heart performance, presumably by reducing the uptake of AZM in non-
immune cells in the heart.  
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It is widely accepted that neutrophils are the first immune cells to infiltrate 
the infarcted heart and their extended existence is associated with exacerbation of 
cardiac injury after ischemia. We showed in our first study that neutrophil counts 
substantially decrease in mice receiving AZM, due to enhanced apoptosis (Al-
Darraji, Haydar et al. 2018). Recently, research shows that there are two activation 
states of neutrophils in the ischemic heart: early pro-inflammatory (N1) and late 
anti-inflammatory (N2)  (Ma, Yabluchanskiy et al. 2016). Interestingly, PB 
neutrophils are CD206-, becoming CD206+ in the heart, which indicates the 
plasticity of neutrophils and their ability to change in response to the surrounding 
microenvironment. Here, we observed that N1 neutrophils significantly decrease 
with Lazm therapy, perhaps attributable to the apoptotic effects of AZM or reduced 
neutrophil recruitment due to suppressed production of chemokines such as 
Macrophage Inflammatory Protein (MIP) and Keratinocyte Chemoattractant (KC). 
It is possible that removal of apoptotic cells from the injured myocardium is an 
essential cellular mechanism to resolve inflammation by shifting macrophage 
phenotype (Huynh, Fadok et al. 2002, Nathan and Ding 2010). Additionally, we 
observed a significant reduction in cardiac Ly6Chi monocytes with liposomal and 
free AZM, suggesting a possible mechanism for the reduced number of pro-
inflammatory macrophages. This phenomenon is most likely related to the 
diminished expression of MCP-1 in the heart and blood.  
The post-MI healing phase is primarily organized by reparative 
macrophages (Ma, Mouton et al. 2018). This could explain the attenuated cardiac 
recovery with macrophage depletion and the improved outcomes with adoptive 
transfer of alternatively activated macrophages (Leor, Rozen et al. 2006, van 
Amerongen, Harmsen et al. 2007). Furthermore, multiple studies demonstrated 
the therapeutic utility of shifting macrophages to the reparative phenotype post-MI 
(Weirather, Hofmann et al. 2014, ter Horst, Hakimzadeh et al. 2015). We found 
that liposomal and free AZM treatment were associated with higher anti-
inflammatory (Iba1+CD206+ cells) and lower pro-inflammatory (Iba1+IL-1β+) 
macrophages after MI in peri-infarct regions. Additionally, we observed a 
significant reduction in apoptosis at day 3 post-MI in the same regions, possibly 
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attributable to pro-survival factors released from reparative macrophages (Lenardo 
and Baltimore 1989, Lakshminarayanan, Beno et al. 1997). These data confirm 
our observations and analysis in flow cytometry and inflammatory mediators. 
Changes in post-MI inflammation translate into smaller scar, better cardiac 
function, and more newly formed blood vessels after MI. Collectively, we observed 
a global trend with both AZM and Lazm in shifting immune cells to the anti-
inflammatory state. 
Immune cell modulation was associated with significant downregulation in 
the inflammatory genes, and upregulation in the anti-inflammatory genes. 
Inflammatory cytokines IL-1β, TNF-α, IL-6, and MCP-1, as well as M1 
macrophages marker, iNOS, were markedly reduced in the early time points post-
MI. These changes could explain the reduced infiltration of inflammatory cells into
the heart. As an example, MCP-1 drives mobilization of Ly6Chi monocytes to the
heart after infarction where they differentiate into M1 macrophages. Furthermore,
reduction of MCP-1 promotes alternative activation of macrophages (Carbone,
Nencioni et al. 2013). Moreover, IL-1β promotes generation of chemotactic
mediators inducing myocardial injury via increased recruitment of immune cells to
the heart (Bujak and Frangogiannis 2009). Recent, data shows that targeting IL-
1β with the monoclonal antibody, canakinumab, significantly decreases
cardiovascular event reoccurrence (Ridker, Everett et al. 2017). In agreement, we
observed a robust decrease in the expression of IL-1β, which contributes to the
improvement of outcomes in this study, at least partially.
Simultaneously, anti-inflammatory genes such as TGF-β, IL-4, and IL-10, 
as well as M2 macrophage markers FIZZ1, YM1, PPAR-ɣ, and ARG are 
upregulated by free and liposomal AZM treatments. These mediators have been 
shown to exert multiple beneficial functions in the myocardium following MI. IL-10 
modifies monocyte-macrophage function, morphology, and phenotype. Secretion 
of IL-1α, IL-1β, TNF-α, IL-6, and IL-8 is inhibited by IL-10 in activated monocytes 
(Frangogiannis 2012). Furthermore, IL-10 could participate in matrix remodeling 
via enhancement of tissue inhibitor of metallopeptidase 1 (TIMP-1) synthesis, thus 
stabilizing the ECM (Lacraz, Nicod et al. 1995, Frangogiannis 2012). TGF-β is an 
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essential regulator of both the transition from inflammation to healing and 
organized scar formation (Bujak and Frangogiannis 2007). Through activation of 
endothelial mononuclear cells, TGF-β inhibits production of various pro-
inflammatory cytokines and chemokines (Frangogiannis 2012). Additionally, TGF-
β stimulates fibroblasts to produce ECM proteins (collagen, fibronectin, tenascin, 
and proteoglycans) (Bassols and Massague 1988). Moreover, TGF-β reduces the 
expression of proteinases (plasminogen activator and collagenase) and enhances 
the production of proteinase inhibitors (plasminogen activator inhibitor and TIMP-
1), suppressing matrix breakdown and helping scar maturation (Laiho, Saksela et 
al. 1986, Frangogiannis 2012). We noticed increased expression of IL-10 and 
TGF-β with free and liposomal AZM therapy, which may explain the reduction in 
heart failure and mortality observed in our study. Interestingly, changes in pro-
inflammatory and anti-inflammatory genes are consistent between heart and 
peripheral blood, suggesting a systemic effect moderating the severity of  post-MI 
inflammation. This feature is also important from a clinical prospective since it 
provides a more feasible way to monitor the pharmacological effects of AZM.  
Conclusion 
The present study is the first to demonstrate the immunomodulatory 
properties of liposomal AZM, which has wide therapeutic applications beyond the 
cardiovascular field. It is expected that liposomal AZM will be beneficial as a  carrier 
and anti-inflammatory drug in other sterile inflammatory diseases that share a 
similar inflammatory profile with MI, such as ischemic stroke and spinal cord injury 
(Zhang, Bailey et al. 2015, Amantea, Certo et al. 2016). Immunomodulatory effects 
of AZM are time-and dose-dependent and are enhanced by improving the 
pharmacokinetics and pharmacodynamics of the drug through liposomal 
formulation. We note that low dose Lazm, started after MI, effectively resolves 
post-MI inflammation and improves adverse cardiac remodeling with lower risk of 
adverse effects. Interestingly, we observe also that the liposomal encapsulation is 
truly protective from the potential unwanted effects of AZM, which is of utmost 
importance to clinical application. The facts that AZM is a widely prescribed 
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antibiotic and liposomes are effective drug delivery systems for multiple 
therapeutic agents promotes rapid clinical translation of our findings. Finally, 
researchers can harness the method of preparing liposomes used in this studyto 
deliver other therapeutic agents to the injured myocardium. Our findings strongly 
support clinical trials using AZM as a novel and clinically relevant therapy to 
improve cardiac recovery and reduce heart failure post-MI in humans.   
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Figure 3.1. Experimental design and targeting myocardium with labeled Lazm after 
infarction. 
(A) Experimental design for the in vivo study. (B) Imaging system images of mice (in vivo)
injected with labeled Lazm 1, 2, 3, and 6 days after infarction. Hearts were collected 24
hours after injection and imaged (ex vivo). Images show that Lazm liposomes are
accumulated in the heart starting the first day after infarction, an effect persisting during
the time of follow-up (6 days). No signal was determined from the heart of the mouse with
sham surgery either in vivo or ex vivo. The ex vivo imaging show s that liposomes are
preferably accumulated in the infarct and peri-infarct regions of the heart (red arrow). (C)
Represents quantitative assessments of signal intensity emitted from the infarcted heart
day 1, 2, 3, and 6 after infarction in comparison to the control (CON) (a mouse injected
with vehicle), which shows a marked increase in the intensity of the signal during all time
points. Lip, labeled liposomal azithromycin.
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Figure 3.2. Targeting immune cells with labeled Lazm after infarction.  
FACS analysis with labeled Lazm at days 1 and 3 post-MI shows liposomes are 
accumulated in cardiac immune cells after IP or IV administration, with more significant 
effect after IV administration. Data suggests that Lazm liposomes begin to concentrate in 
the immune cells on day 1 post-MI using IV but not IP route. No significant accumulation 
was noted in non-immune cells (N = 3 animals/group/timepoint, *P<0.05, **P<0.01, and 
***P<0.001, and ****P<0.0001 compared to sham). Data presented as mean ± SEM. IV, 
intravenous; IP, intraperitoneal; Lazm, liposomal azithromycin; Macs, macrophages; 
Control, mice did not receive liposomes. 
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Figure 3.3. Liposomes co-localize with cardiac macrophages.  
Representative images from Celigo of heart cells of Lazm- treated mice show spatial 
localization of macrophages (orange) and liposomes (purple). Images show a remarkable 
localization of macrophages with liposomes. Lazm, liposomal azithromycin.  
In this experiment, a similar protocol to flow cytometry was used to prepare cell 
suspension; however, Celigo was used instead of flow cytometry to identify co-localization 
of different cell populations with liposomes (N=3 mice). 
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Figure 3.4. Hemodynamic Effects of free and liposomal AZM. 
Changes in heat rate (Panel A), RR interval (Panel B), QT interval (Panel C), ejection 
fraction (Panel D), and cardiac output (Panel E) after retro-orbital administration of 
various doses of Lazm or free AZM. Data shows that the liposomal formulation of AZM 
is protective against hemodynamic changes induced by free AZM. (N=3, **P<0.01 and 
*** P<0.001 compared to baseline of the corresponding group). Data presented as 
mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin. 
121 
Figure 3.5. Lazm therapy rescues heart and spleen from inflammatory induced 
hypertrophy.  
Quantitative assessment of spleen (Panel A) and heart (Panel B) as a percent of 
body weight suggests that Lazm therapy is protective against heart and spleen 
enlargement after infarction, indicative of less potent inflammation.  (n = 4 
animals/group/timepoint, *P<0.05 and **P<0.01 compared to the vehicle control). 
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; 
HT, heart.  
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Figure 3.6.  Lazm treatment shifts macrophages to the reparatory phenotype in the 
injured myocardium. 
Immunomodulation of macrophages by Lazm in heart tissue post-MI. FACS analyses 
of the relative expression of macrophage markers to assess their activation state in 
vehicle, free AZM, and Lazm treated groups. Quantitative data suggests that 
inflammatory (F4/80+/CD11c+) macrophages markedly decrease in Lazm treated 
groups relative to controls starting at day1, with a more profound effect on day 3 post-
MI (Panel A).  In contrast, the reparatory macrophages (CD206+) increase significantly 
at day 3 post-MI in the same groups of mice (Panel B). The immunomodulatory effects 
translate into a substantial reduction in the pro-/anti-inflammatory (CD11c+/ CD206+) 
ratio at all tested timepoints post-MI (Panel C). Less powerful immunomodulatory 
changes were noted with free AZM treatments. (N = 4 animals/group/timepoint, 
**P<0.01, ***P<0.001, and ****P<0.0001 compared to the vehicle control). Data 
presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; Ht, 
heart.  
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Figure 3.7. Lazm shifts macrophages towards the anti-inflammatory phenotype  
Immunohistochemical assessment of general and reparative macrophages (IBA1+ and 
CD206+, respectively) 3 days post-MI. Panel A shows representative images from 
controls, free AZM, and Lazm treated mice illustrating IBA1 (green) and CD206 (red) 
positive macrophages in peri-infarct zones. Images show increased expression of CD206 
by macrophages in free and liposomal AZM treated groups compared to controls. Panel 
B represents quantitative assessment of IBA1and CD206 3-days post-MI (n = 4 
animals/group, ***P<0.001 and ****P<0.0001 compared to vehicle control). Scale bars 
represent 50 μm. Data presented as mean ± SEM.  
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Figure 3.8. Lazm reduces pro-inflammatory macrophages in the ischemic heart. 
Immunohistochemical assessment of a general macrophage marker (IBA1) co-localized 
with a pro-inflammatory cytokine (IL-1β) 3 days post-MI. Panel A shows representative 
images from controls, free AZM, and Lazm treated mice illustrating IBA-1 (green) and IL-
1β (red) positive macrophages in peri-infarct zones. Images indicate a marked reduction 
in the expression of IL-1β in macrophages with free and liposomal AZM treatments 
compared to controls. Panel B represents quantitative assessment of IBA-1 and IL-1β 3-
days post-MI (n = 4 animals/group, *P<0.05 **P<0.01, and ****P<0.0001 compared to 
vehicle control). Scale bars represent 50 μm.  Data presented as mean ± SEM.  
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Figure 3.9.  Lazm reduces inflammatory monocytes after infarct. 
Immunomodulation of monocytes by free and liposomal AZM in Ht and blood post-MI. 
FACS analyses for the relative expression of Ly6C to assess monocyte activation state 
in controls, free AZM, and Lazm treated groups of mice. Quantitative data indicate that 
inflammatory monocytes (Ly6CHi) markedly decrease in liposomal and free AZM treated 
mice, with a more powerful effect in Lazm groups (PanelA). Very little change was noted 
in the blood (Panel B). (N = 4 animals/group/time point, **P<0.01, ***P<0.001, and 
****P<0.0001 compared to vehicle control). Data presented as mean ± SEM. AZM, 
azithromycin; Lazm, liposomal azithromycin; Ht, heart.  
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Figure 3.10. Lazm treatment reduces neutrophil counts, in particular N1 neutrophils. 
FACS analyses suggest that neutrophil counts are significantly decreased in the Ht 
(Panel A), specifically N1 (CD11b+Ly6G+CD206-) neutrophils in Lazm treated mice 
on day 1 post-MI (Panel C). No changes in neutrophils were noted with free AZM 
treatment. Neutrophils were reduced on day 7 in Lazm groups in blood (Panel C) (N = 
4 animals/group/time point, **P<0.01 and ***P<0.001 compared to vehicle control). 
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; 
Ht, heart; PB, peripheral blood.  
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Figure 3.11. Liposomal azithromycin produces a more significant shift in macrophage 
response towards the anti-inflammatory state. 
This figure shows quantitative analyses of pro-inflammatory cytokine, TNF-α, and anti-
inflammatory cytokine, IL-10, production from J774 macrophages subjected to LPS 
stimulation for 48 hours. The analyses demonstrate a more significant reduction of 
TNF- α with Lazm compared to free AZM at 48 hours post-MI. Moreover, IL-10 
production is additionally enhanced with Lazm. Treatment (two independent 
experiments and 4 replicates/time point, ***P<0.001 and **** P<0.0001 compared to 
free AZM). Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal 
azithromycin; IL-10, interleukin 10; TNF-α, tumor necrosis factor-alpha. 
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Figure 3.12A. Lazm modulates pro- and anti-inflammatory cytokine expression. 
Heart homogenate (Ht) cells were used to quantify pro-inflammatory cytokine secretion 
via RT-PCR. Pro-inflammatory cytokine expression, including iNOS, TNF-α, MCP-1, 
IL-1β and IL-6c(A). Data shows significant reduction in inflammatory cytokines at days 
1 and 3 with Lazm treatment in Ht (n = 4 animals/group/time point, *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change relative 
to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal 
azithromycin; Ht, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; iNOS, inducible 
nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor 
necrosis factor-alpha. 
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Figure 3.12B. Lazm modulates pro- and anti-inflammatory cytokine expression. 
Heart homogenate (HT) cells were used to quantify anti-inflammatory cytokine 
secretion via RT-PCR. Anti-inflammatory IL-10, TGF-β, Fizz1, and YM1, ARG, PPARg, 
IL-4 expression (B). Data shows significant increase in anti-inflammatory cytokines on 
days 1, 3 and, 7 with Lazm treatment in HT (n = 4 animals/group/time point, *P<0.05, 
**P<0.01 , ***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change 
relative to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm, 
liposomal azithromycin; HT, heart; IL-4, interleukin 4; ARG, arginase; Fizz1, found in 
inflammatory zone 1; PPARγ, peroxisome proliferator-activated receptor gamma; TGF-
1β, tissue growth factor 1 beta; YM1 (Chil3), chitinase-like 3; IL-10, interleukin-10. 
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Figure 3.12C. Lazm modulates pro- and anti-inflammatory cytokine expression. 
Peripheral blood cells were used to quantify pro-inflammatory cytokine secretion via 
RT-PCR. Pro-inflammatory cytokine expression, including TNF-α, MCP-1, IL-1β and 
IL-6(C). Data show significant reduction in inflammatory cytokines at days 1 and 3, and 
7 with Lazm treatment in blood (n = 4 animals/group/time point, *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 compared to the vehicle control). Fold change relative 
to sham control. Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal 
azithromycin; HT, heart; IL-1β, interleukin 1 beta; IL-6, interleukin 6; MCP-1, monocyte 
chemoattractant protein-1; PB, peripheral blood; TNF-α, tumor necrosis factor-alpha. 
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Figure 3.12D. Lazm modulates pro- and anti-inflammatory cytokines expression. 
Peripheral blood cells were used to quantify anti-inflammatory cytokine secretion via 
RT-PCR. Anti-inflammatory TGF-β, Fizz1, and YM1 expression (D). Data show 
significant increase in anti-inflammatory cytokines in days 1, 3 and, 7 with Lazm 
treatment in blood (n = 4 animals/group/time point, *P<0.05, **P<0.01, ***P<0.001, and 
****P<0.0001 compared to the vehicle control). Fold change relative to sham control. 
Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; 
HT, heart; IL-4, interleukin 4; Fizz1, found in inflammatory zone 1; PB; TGF-1β, tissue 
growth factor 1 beta; YM1 (Chil3), chitinase-like 3. 
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Figure 3.13. Lazm modulates pro-inflammatory cytokine and chemokine production. 
Plasma quantification of pro-inflammatory cytokine and chemokine secretion via Luminex 
assay. Data shows significant reduction in inflammatory cytokines and chemokines at 
days 1 and 3 with Lazm therapy (n = 4 animals/group/time point, *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 compared to the vehicle control). Data presented as mean 
± SEM. AZM, azithromycin; Lazm, liposomal azithromycin; IL-1, interleukin 1; TNF-α, 
tumor necrosis factor-alpha; RANTES, regulated on activation, normal T cell expressed 
and secreted; Il-12, interleukin 12; MIP, macrophage inflammatory protein; KC, 
Keratinocyte chemoattractant; IP, Inducible protein; LIX, Lipopolysaccharide-induced 
CXC chemokine ; G-MCSF, Granulocyte-Macrophage Colony-Stimulating Factor. 
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Figure 3.14. AZM reduces apoptosis in the heart post-infarction. 
Panel A shows representative light microscope images of TUNEL staining of peri-
infarct regions in controls, free AZM, and Lazm treated mice 3 days post-MI. Panel B 
represents quantitative analysis of apoptosis which reveals a remarkable reduction of 
TUNEL positive cells in free and liposomal AZM treated groups compared to the vehicle 
control group (n = 4 animals/group, **P<0.01 and ***P<0.001 compared to vehicle 
control). Scale bars represent 100 μm. Data presented as mean ± SEM. AZM, 
azithromycin; Lazm, liposomal azithromycin 
134 
Figure 3.15. AZM reduces apoptosis in the heart post-infarct. 
Panel A shows representative light microscope images of caspase-3 staining for peri-
infarct regions in controls, free AZM, and Lazm treated mice 3 days post-MI. Panel B 
represents quantitative analyses of apoptosis which reveal a remarkable reduction of 
caspase-3 positive cells in free and liposomal AZM treated groups compared to the 
vehicle control group (n = 4 animals/group, **P<0.01 and ****P<0.0001 compared to 
vehicle control). Scale bars represent 100 μm. Data presented as mean ± SEM. AZM, 
azithromycin; Lazm, liposomal azithromycin. 
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Figure 3.16. Lazm therapy reduces scar size after infarct.  
Panel A shows representative Masson's trichrome staining at 30 days post-MI in 
control, free AZM, and Lazm treated groups, indicating a marked reduction in scar size 
with liposomal and free AZM. Panel B represents quantitative analysis of scar as a 
percentage of LV area, which shows significant reduction in liposomal and free AZM 
treated groups relative to the vehicle control group (n = 6-10 animals/group, **P<0.01, 
***P<0.001 and ****P<0.0001 compared to the vehicle control). Scale bars represent 
1000 μm.  Data presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal 
azithromycin. 
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Figure 3.17. Lazm therapy promotes angiogenesis after infarct. 
Panel A shows representative isolectin staining (Green) at 30 days post-MI for capillary 
density in the peri-infarct region in control, free AZM, and Lazm treated animals.  This 
data demonstrates higher capillary density in Lazm groups compared to vehicle control. 
Panel B is quantitative analysis of capillary density, which confirms a higher rate of 
angiogenesis and capillary density in Lazm treated groups (n = 5-10 animals/group, 
****P<0.0001 compared to the vehicle control). Scale bars represent 50 μm. Data 
presented as mean ± SEM. AZM, azithromycin; Lazm, liposomal azithromycin. 
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Figure 3.18. Lazm therapy improves adverse cardiac remodeling. 
30 days following MI, echocardiography was performed on control, free AZM, and Lazm 
treated animals to evaluate left ventricular function and remodeling parameters. 
Quantitative analyses demonstrate significant recovery in LV function as assessed by 
ejection fraction (LVEF) (Panel A), which significantly improved in Lazm groups. Data 
also show significant improvements in LV adverse remodeling parameters such as end-
systolic diameter (LVESD) (Panel B) and end-diastolic diameter (LVEDD) (Panel C). (n 
= 6-10 animals/group, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 compared to 
the vehicle control). Data presented as mean ± SEM. AZM, azithromycin; Lazm, 
liposomal azithromycin. 
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Figure 3.19. AZM therapies enhance survival.  
Survival curves of free/liposomal AZM and vehicle-treated mice 35 days post-MI 
demonstrate a marked improvement in survival with Lazm and low-dose free AZM 
treatment. Mortality in 40 mg/kg IV AZM group occurs during the drug administration due 
to severe changes in cardiac conduction and hemodynamic parameters. While mice in 
other groups died of cardiac rupture, a common complication after MI surgery. (vehicle 
group, n =34, 40 mg/kg IV AZM group, n=33, 40 mg/kg Lazm group, n=35, 10 mg/kg Lazm 
group, n=31, 10 mg/kg IV AZM, n=35). AZM, azithromycin; Lazm, liposomal azithromycin. 
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CHAPTER IV. General discussion 
4.1 Summary 
The purpose of the work in this dissertation is to determine the role of 
azithromycin (AZM) as an immunomodulatory therapeutic agent in reducing the 
inflammatory response and related adverse cardiac remodeling after infarction. 
The ultimate goal of our research is to provide a clinically translatable approach 
with rapid onset of action and low off-target effects by using a liposomal 
formulation. To achieve our goals, we adopted a comprehensive approach utilizing 
various in vivo and in vitro models to examine the effects of free and liposomal 
encapsulation formulations of AZM in an established murine MI model. 
First, we sought to investigate the efficiency of AZM as an 
immunomodulatory and anti-inflammatory drug in switching macrophage 
phenotypes towards the reparative state, and thus, alleviating the exaggerated 
post-MI inflammation. These studies are based on a growing body of evidence 
showing that altering the inflammatory response by repolarizing macrophages to 
the reparative phenotype is protective against acute ischemic injury and improves 
cardiac recovery. Research has shown that AZM, a macrolide antibiotic, alters 
inflammation and polarizes macrophages to the alternatively activated state in 
inflammatory conditions. Therefore, we hypothesized that AZM therapy reduces 
cardiac inflammation and mitigates adverse cardiac remodeling after MI. We 
treated mice with either AZM (160 mg/kg/day, oral) or vehicle, starting 3 days prior 
to MI. We selected the timing of AZM therapy to ensure appropriate steady state 
levels at the time of injury. We found that AZM treatment significantly decreased 
inflammatory macrophages while increasing reparative ones. Neutrophils also 
decreased with AZM treatment via enhanced apoptosis. Furthermore, AZM 
treatment significantly reduced infiltration of inflammatory monocytes to the heart, 
while anti-inflammatory monocytes were increased. Immune cell modulation was 
associated with significant downregulation of pro-inflammatory genes, and 
upregulation of anti-inflammatory genes. Taken together, AZM treatment resulted 
in a systemic and local shift in the post-MI inflammatory response. The 
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immunomodulatory effects of AZM translated into reduced cardiac cell death and 
scar size, and enhanced angiogenesis. Finally, these protective effects led to 
improved cardiac functional recovery and reduced adverse remodeling (Figure 
4.1).   
Due to limited clinical translational perspective (pre-MI treatment and 
relatively high dose of AZM) of our initial proof-of-concept study, we executed a 
follow-up study using a liposomal formulation of AZM (Lazm) to achieve rapid 
onset of action via targeted accumulation in the damaged myocardium. Liposomes 
are a valuable tool in producing a faster mode of action since they  extensively 
localize in the injured myocardium and are specifically taken up by phagocytes. 
Furthermore, liposomal formulation is an efficient tool to enhance on-target and 
reduce off-target effects. Based on our preliminary studies with Lazm, we 
hypothesized that low dose of liposomal AZM (Lazm) treatment, started after MI, 
yields enhanced immunomodulatory potential and cardiac recovery with low risk 
of adverse effects. Therefore, we treated mice with low doses of encapsulated 
AZM immediately after infarction. We observed that Lazm induces early resolution 
of the post-MI inflammatory response as evidenced by switching of the activation 
state of monocytes/macrophages towards the reparatory phenotype. Neutrophils 
were substantially decreased, particularly pro-inflammatory neutrophils. Cytokine 
profiles also shifted to the anti-inflammatory status with Lazm therapy. 
Inflammation-resolving effects of Lazm were associated with reduced apoptosis in 
the injured heart, as well as improved scar size, angiogenesis, and LV function in 
our long-term studies. These findings imply that low dose, post-MI treatment with 
Lazm improves outcomes post-MI through early resolution of inflammation and 
initiation of the repair phase (Figure 4.1). Besides the immunomodulatory effects 
of Lazm, we observed that encapsulation of AZM substantially reduces the risk of 
off-target effects as well. 
This work is early evidence demonstrating the efficacy of free and liposomal 
AZM as an immunomodulatory pharmacological agent after MI. Our results 
indicate that the anti-inflammatory effects of AZM relate to its direct effects on 
immune cells, which lead to alleviation of post-MI inflammation. Assessments of 
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cardiac and systemic changes demonstrate that the beneficial effects of AZM 
result in significant improvements in scar size, adverse cardiac remodeling, cardiac 
function, and survival post cardiac ischemia. Additionally, this is the first study 
demonstrating the immune modulation properties of liposomal AZM, which have 
potential wide therapeutic applications beyond the cardiovascular field. In addition, 
this work is the first to demonstrate that liposomal encapsulation is significantly 
protective from adverse drug effects such as hemodynamic changes, which are 
previously unexamined. These data introduce a novel and clinically relevant 
immunomodulatory therapy for ischemic heart and other sterile inflammatory 
diseases. AZM has a wide therapeutic window, allows oral administration, has a 
low side effect profile, and has clinical approval in humans. These criteria make it 
an ideal candidate for drug repurposing to improve survival and reduce heart 
failure following MI in humans.  
 
4.2 Inflammation after infarction 
Coronary artery occlusion of prolonged duration results in a time-dependent 
increase in cardiomyocyte death, particularly in the peri-infarct zones of the injured 
myocardium, and thus, restoration of blood flow plays a crucial role in 
cardiomyocyte protection and prevention of further deterioration in heart function 
(Lucchesi, Werns et al. 1989). With progression of cardiomyocyte death and tissue 
degradation, there is increased activity of the complement system, production of 
chemotactic factors, and a pro-inflammatory cytokine storm. All these events 
mediate propagation of post-MI inflammation, which is an essential element to 
replace the nonfunctional injured myocardium with scar of fibrotic nature to 
maintain the integrity of the heart (Romson, Hook et al. 1983). Following the initial 
heightened inflammatory response, a phase characterized by inflammation 
resolution starts. This phase includes removal of damaged tissue and dead cells, 
inhibition of inflammatory mediators, activation of healing mechanisms, and 
induction matrix turnover (Frangogiannis 2012). However, the detrimental effects 
of the initial inflammatory phase may persist (days) even when inflammation has 
been resolved (Lucchesi, Werns et al. 1989). 
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Data from clinical studies suggests that elevated levels of inflammatory cells 
and chemokines in MI patients increase the likelihood of developing impaired 
cardiac recovery and poor clinical outcome on long-term follow up. The profound 
recruitment of inflammatory cells to the ischemic heart forms the background to 
conclude that post-MI inflammation contributes to further infarct expansion after 
the initial insult (Frangogiannis 2014). Moreover, prolonged presence of pro-
inflammatory macrophages (M1) in the damaged myocardium may result in infarct 
expansion (ter Horst, Hakimzadeh et al. 2015). Indeed, high numbers of 
inflammatory cells in the heart negatively relate to the degree of myocardial 
salvage (Maekawa, Anzai et al. 2002, Tsujioka, Imanishi et al. 2009). Therefore, 
timely resolution of inflammation is critical in infarct expansion prevention and 
reduction of adverse cardiac remodeling. We note that AZM mediates an earlier 
resolution of post-MI inflammation and enhanced healing, as demonstrated by 
phenotypic cell analyses of immune cells and gene expression of inflammatory 
mediators, inducing better protection against post-MI complications. 
   
4.2.1 Anti-inflammatory therapies in MI 
The major contributing mechanism to the pathophysiology of MI is the 
inflammatory response (Frangogiannis 2014). The inflammatory pathways 
primarily regulate heart healing and remodeling after infarction. Literature suggests 
that the involvement of the inflammatory response in the pathogenesis of cardiac 
remodeling may include the following mechanisms: a) damaged matrix proteins 
via cytokine-induced MMP activation diminish tensile strength of the injured 
myocardium, accompanied with slippage of myocytes and loss of stimuli that 
supports cardiomyocyte function; b) a prolonged uncontrolled inflammatory 
reaction could activate apoptosis in surviving cardiomyocytes, forming new 
jeopardized regions (Frangogiannis 2014). Therefore, therapeutic interventions 
targeting inflammation represent attractive strategies after infarction 
(Frangogiannis 2014). However, multiple clinical trials fail to demonstrate the 
effectiveness of traditional anti-inflammatory drugs such as corticosteroids, 
cyclosporine, and non-steroidal anti-inflammatory drugs in treating patients with 
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MI. (Bulkley and Roberts 1974, Akgur, Brown et al. 2000, Schjerning Olsen, Fosbol 
et al. 2011). 
Furthermore, inhibition of other inflammatory mediators (integrin, PI3K, and 
C5) was not successful in clinical trials, despite success in animal experiments 
(Frangogiannis 2014, Seropian, Toldo et al. 2014). More selective targeting of 
inflammatory mediators such as IL-1β showed some promise in improving clinical 
outcomes in high-risk patients with ischemic heart disease, albeit with high cost 
and modest benefits (Seropian, Toldo et al. 2014). Blocking of pro-inflammatory 
signals such as IL-1 and MCP-1 could add benefits in patients who have prolonged 
post-MI inflammation (Christia and Frangogiannis 2013). However, these venues 
have not been tested in large clinical trials of post-MI patients (Hartman, Groot et 
al. 2018). Heart failure has a complex pathophysiology; hence it is unlikely to be 
reversed by the manipulation of one receptor, cytokine or pathway (Hartman, Groot 
et al. 2018). It is important to mention that  some studies targeting cytokines and/or 
their receptors yielded contradictory results due to limitations in these kinds of 
studies (Hartman, Groot et al. 2018). Limitations in translating pre-clinical studies 
are discussed in more detail later.  
Taken together, targeting inflammation after MI has proven an elusive goal 
in clinical trials and there is unmet need for clinically relevant therapies. The 
exacerbated inflammatory response after myocardial injury creates difficult 
challenges to develop therapies that govern this response without altering its 
beneficial effects, mainly clearing dead cells and tissues and preparing the 
myocardium for the healing phase. Modulation of the inflammatory response at the 
cellular level, instead of its complete suppression, may represent a promising 
therapeutic avenue in treating MI as demonstrated by multiple studies  (de Couto, 
Liu et al. 2015, Kain, Liu et al. 2017) (will be discussed in more detail in modulation 
of the inflammatory response). However, limited data exists on similar approaches 
with proven safety in humans. Here, we observed that AZM is successful in 
reducing the intensity and duration of the inflammatory phase and inducing an 
earlier transition to the reparatory phase through reprogramming of, rather than by 
a profound suppression of, post-MI inflammation. Our findings show that AZM 
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reduces the expression of pro-inflammatory cytokines and M1 markers and 
simultaneously raises anti-inflammatory genes and M2 markers. Changes in pro-
inflammatory and anti-inflammatory genes are consistent between heart and 
blood, suggesting systemic immunomodulatory actions. Interestingly, AZM 
substantially reduces the expression of IL-1 and MCP-1, which is an attractive 
therapeutic aim in clinical practice. In addition, repurposing AZM is more clinically 
relevant and can be a safe and cost-effective immunotherapy for post-MI patients.  
In another direction, it could be an interesting avenue to examine the effect 
of AZM on immune response post-MI in MCP-1 and/or IL-1 knock out mice in order 
to explore mechanisms of these modified immune cells’ recruitment to the injured 
myocardium. These experiments can be potentially extended to include more 
chemokines and cytokines such as IL-6 knock out mice, since IL-6 is involved in 
trafficking of inflammatory cells in the first day after infarction (de Couto, Liu et al. 
2015).   
Studies confirm a second inflammation phase peaking 8 days after the initial 
inflammatory response but limited data has been published about the specifics of 
this phase (Moro, Jouan et al. 2007). The etiology of the second wave of 
inflammatory cells and cytokines has not been studied but could be related, at least 
in part, to wall stress caused by adverse remodeling of the left ventricle. Therefore, 
the therapeutic utility of AZM in the second inflammatory wave after MI warrants 
further examination. 
 
4.2.2 Modulation of the post-MI inflammatory response 
Early activation of inflammatory cells and production of 
cytokines/chemokines are important for removing tissue debris and dead cells, as 
well as for successful initiation of the subsequent reparative response 
(Frangogiannis 2014). Uncontrolled and/or extended pro-inflammatory cascades 
are associated with more severe damage, worsened cardiac remodeling, and 
impaired cardiac recovery (Frangogiannis 2014). Even though the role of 
inflammation in the progression of cardiomyocyte death is controversial, 
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involvement of the inflammatory and fibrotic cascades in adverse cardiac 
remodeling and the ensuing heart failure is well-established (Frangogiannis 2014).  
 Macrophages are essential players in inflammation and fibrotic processes 
post-MI (Chen and Frangogiannis 2017). Macrophages mediate cardioprotection 
through their phagocytic properties, suppression of pro-inflammatory cascades, 
promotion of cytoprotective signaling, activation of reparative fibroblasts and 
angiogenic cells, and stimulation of regenerative pathways (Chen and 
Frangogiannis 2016). Furthermore, macrophages may enhance cardiomyocyte 
survival through production of myeloid-derived growth factor (MYDGF) (Korf-
Klingebiel, Reboll et al. 2015). Considering the activation state of macrophages, 
the reparative phenotype (M2) is the most abundant phenotype in the heart during 
post-MI healing. Animal experiments show that early intervention aimed at altering 
the macrophage activation state or shifting the balance towards the anti-
inflammatory phenotype can substantially reduce the risk of heart failure 
development (de Couto, Liu et al. 2015, Kain, Liu et al. 2017). Kain et al. (need 
year) initiated a phenotypic switch in macrophages after myocardial injury by using 
either free or encapsulated 15-epi-Lipoxin A4. They demonstrated upregulation of 
reparative macrophages, as well as anti-inflammatory/macrophage modulatory 
genes (Mrc-1, Ym-1, Arg-1). Furthermore, cardiac function improved in 15-epi-
Lipoxin A4 treated mice compared to controls (Kain, Liu et al. 2017). Multiple 
studies confirmed these findings using different therapeutic approaches, such as 
cardiosphere-derived cells (de Couto, Liu et al. 2015) and endogenous Annexin-
A1 (Qin, Finlayson et al. 2017). However, previous studies on alternative 
macrophage activation in MI utilized experimental therapeutics that had limited 
safety data in humans. Conversely, our strategy of using AZM is more clinically 
relevant and translatable to clinical trials since AZM is already approved and widely 
used in humans. 
In this work, we used AZM for the first time in the setting of MI to enhance 
inflammation resolution via repolarization of macrophages towards the reparative 
phenotype. We demonstrated that inflammatory macrophages significantly 
decrease with AZM treatments, while reparatory cells increase. Inflammatory 
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neutrophils also decrease with AZM treatments. Furthermore, infiltration of 
inflammatory monocytes to the heart are significantly reduced with AZM treatment, 
while anti-inflammatory monocytes are increased.  Immune cell modulation is 
associated with significant downregulation in pro-inflammatory genes (TNF-α, IL-
1β, MCP-1, and IL-6), and upregulation of anti-inflammatory genes (TGFβ and IL-
10). Therefore, AZM treatment is associated with a global trend of shifting immune 
cells to the reparatory state. These results are in agreement with the observed 
immunomodulatory effects of AZM in spinal cord injury and lung infection (Feola, 
Garvy et al. 2010, Zhang, Bailey et al. 2015). The immunomodulatory effects of 
AZM translate into reduced cardiac cell death and scar size, and enhanced 
angiogenesis. Finally, these outcomes reduce adverse cardiac remodeling and, 
thus, improve cardiac function. This is early evidence of a promising and clinically-
relevant approach to modulate post-MI inflammation via the repolarization of 
macrophage phenotypes. In addition, AZM has an excellent safety profile and is 
approved for use in humans. All these specifics make it an ideal agent for novel 
and effective therapeutic interventions to improve survival and reduce heart failure 
following MI in humans. 
4.2.3 Resolution of inflammation through phagocytosis of apoptotic cells 
Timely resolution of inflammatory signals is a prerequisite for successful 
initiation of healing and cardiac recovery. Phagocytosis of apoptotic cells is an 
essential component in suppressing these signals (Frangogiannis 2015). It has 
been shown that cardiomyocyte efferocytosis markedly reduces post-MI 
inflammation (Wan, Yeap et al. 2013), and inhibition of this process produces an 
extended inflammatory response and more severe adverse cardiac remodeling 
(Frangogiannis 2015). It is also reported that macrophage myeloid-epithelial-
reproductive tyrosine kinase (MERTK) in cardiac macrophages is an important 
mediator for the efficient removal of apoptotic cardiomyocytes (Maekawa, Anzai et 
al. 2002).  
Neutrophils are extensively recruited to the injured myocardium, and are 
then cleared by apoptosis. There is a well-established relationship between 
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reduced myocardial neutrophil infiltration and rescue of the heart from ischemic 
injury (Hansen 1995). However, the use of neutrophils as a therapeutic target to 
reduce adverse cardiac remodeling after MI is controversial. On one hand, 
inefficient clearance of neutrophils post-MI leads to matrix breakdown, collagen 
malposition, and increased risk of cardiac rupture (Lorchner, Poling et al. 2015). 
On the other hand, complete or near complete neutrophil depletion after MI is 
detrimental and is associated with poor healing and cardiac rupture (Horckmans, 
Ring et al. 2017) . Apoptosis is much less significant than necrosis post-MI as 
shown in clinical studies, which is the proposed mechanism of uncontrolled post-
MI inflammation, causing further tissue destruction (Garlichs, Eskafi et al. 2004). 
Although the effect of apoptotic neutrophil clearance on initiating the anti-
inflammatory phase was not investigated, timely removal of infiltrated immune cells 
is necessary for post-MI inflammation resolution (Frangogiannis 2012).  
Here, we show that AZM treatment results in a statistically significant 
decrease in neutrophil counts. We postulate that this reduction is related to a 
reduced neutrophil lifespan since macrolides can stimulate programmed cell death 
in activated neutrophils (Inamura, Ohta et al. 2000). Interestingly, we find that AZM 
enhances apoptosis in neutrophils after infarction. These findings suggest a 
potential mechanism to modulate macrophages and to alter the inflammatory 
response after MI. Engulfment of apoptotic neutrophils by macrophages stimulates 
the anti-inflammatory machinery by blockade of  pro-inflammatory cytokine 
production and generation of IL-10, TGF-β, and pro-resolving lipid mediators 
(Horckmans, Ring et al. 2017).  
We are planning future in vitro studies to explore the interaction between 
neutrophils and macrophage polarization. These studies include:  
a) Treating stimulated macrophages, pre-exposed to AZM or vehicle, with
conditional media from stimulated neutrophils, also pre-exposed to AZM or vehicle, 
then examining M1 and M2 macrophage markers. These experiments explore 
whether neutrophils produce certain mediators that influence the activation state 
of macrophages. 
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b) Co-culturing macrophages with neutrophils pre-exposed to AZM to examine 
neutrophil apoptosis and macrophage phenotype. This approach could determine 
whether AZM directly affects promotion of neutrophil apoptosis, and whether the 
expected apoptotic effect drives macrophage polarization to the alternative 
activation state. 
 
Additionally, we can test the relationship between neutrophils and 
macrophages in vivo. These experiments could include:  
a) Depleting neutrophils in groups of mice, except a group treated with AZM, 
then resupplying them with neutrophils treated with AZM after MI induction to 
examine macrophage polarization.  This offers a tool to test whether resorption of 
neutrophils, either apoptotic or not (control), regulates macrophage polarization 
and cardiac recovery. There are limitations to this study since neutrophil depletion 
is associated with undesirable effects on cardiac recovery, as mentioned earlier, 
which could complicate any analysis. 
 
b) We can test the role of AZM-induced neutrophil apoptosis by examining the 
effect of AZM in MPO knock out mice since these mice have a depleted ability for 
induction of programmed cell death in infiltrated neutrophils (Milla, Yang et al. 
2004). It would be of interest if these studies were repeated in an I/R model since 
the role of neutrophils in MI pathogenesis in this model is more profound (Baxter 
2002).  
 
Research in an ischemic stroke model shows that preferentially increased 
numbers of N2 neutrophils induced by using the PPARg agonist, rosiglitazone, 
decrease the volume of brain infarction (Cuartero, Ballesteros et al. 2013). 
Increment of N2 and/or decrement of N1 neutrophil count may be a promising 
therapeutic strategy in MI patients (Ma, Yabluchanskiy et al. 2016). We find that 
AZM profoundly reduces N1 (pro-inflammatory) neutrophils, which could represent 
a novel therapeutic avenue in treatment of MI patients who experience prolonged 
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neutrophilia after infarction. This feature is likely to have wider therapeutic 
applications in other inflammatory diseases in which neutrophils are key players. 
Moreover, N1 neutrophil and M1 macrophage states could be activated by linked 
mechanisms. It is also likely that reduction in N1 neutrophils relates to increased 
protection against cardiomyocyte death. It is also highly possible that the enhanced 
apoptosis by AZM is specific for N1 neutrophils, suggesting potential differences 
in the metabolism/fate between the N1 and N2 neutrophils, which needs more 
investigation. 
4.3 Studies to explore the immunotherapeutic mechanisms of AZM in MI 
It is important to study the underlying mechanisms of the 
immunotherapeutic effects of AZM. They likely represent cornerstones for a more 
complete understanding of MI immunopathology and roles of immune cells in this 
process, as well as for ultimate development of successful immunomodulatory 
therapies for ischemic heart disease. These potential studies include: 
a) Tribbles homolog 1 (Trib1) knock out mice: Trib1 protein modulates the
MAPK pathway through binding to MAPKK. These mice are unable to generate 
M2 macrophages after infarction, with a preserved ability to produce M1 
macrophages (Mahbub, Deburghgraeve et al. 2012). We can use this model to 
explore whether M2 macrophages are principle mediators of the cardioprotective 
effects of AZM in MI. We hypothesize that AZM cardioprotection will attenuate or 
disappear in these mice. We can extend these experiments to examine M2 
macrophage source (bone marrow derived and/or derived from cardiac resident 
macrophages) by generating Trib1 cardiac or bone marrow derived specific knock 
out mice. These experiments will help to elucidate the local, systemic, or 
combinatorial nature of AZM’s effects. 
b) Inhibition of colony stimulating factor 1 (CSF-1): CSF-1 stimulates
monocyte and macrophage survival and enhances macrophage activation towards 
the M2 phenotype, which can be blocked by using an inhibitor (GW2580) (Leblond, 
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Klinkert et al. 2015). Similar to the above experiments, if the immunotherapeutic 
effects of AZM are modified by this antagonist, it reinforces the importance of M2 
macrophages in mediating cardioprotective effects of AZM in MI. This experiment 
would provide additional insights into the protective mechanisms of AZM, 
specifically its effects on alternative macrophage polarization. 
 
c) Ex vivo polarization of macrophages: Using adoptive transfer of 
macrophages for phenotype reconstitution can define the role of shifted 
macrophages by AZM and exclude the contribution of various endogenous factors 
like other immune cells to certain levels. This experiment can be achieved by 
treating bone marrow derived macrophages with AZM then transfusing them 
intravenously into mice, which were previously treated with clodronate-containing 
liposomes to deplete endogenous phagocytes and macrophages (Weisser, van 
Rooijen et al. 2012). Depletion of systemic macrophages could also be achieved 
by crossing back mice onto a CD11b- inducible diphtheria toxin (DTR) background. 
Although this approach is useful, it is expensive and time consuming (Weisser, van 
Rooijen et al. 2012).  
 
4.4 Potential signaling pathways related to AZM effects in MI 
The current understanding of molecular mechanisms mediating 
macrophage polarization to a specific activation state remains inadequate and 
requires further study. Such studies would enable us to reprogram macrophages 
efficiently to the reparative phenotype, prevent harmful interventions, and improve 
outcome after infarction. Production of cytokines, chemokines, and adhesion 
molecules is primarily regulated by NF-kB and IkBα complex (Lenardo and 
Baltimore 1989). Stimuli like cytokines (TNF-α, IL-1β), ROSs, and TLR-stimulated 
ligands can activate the expression of NF-kB (Frangogiannis 2006). In the steady 
state, NF-kB dimers bind to an inhibitory molecule, IkBα, and reside in the 
cytoplasm. In the disease state, IkBα is phosphorylated, ubiquitinylated, and then 
degraded by proteolytic cleavage in the proteasome. Cleavage of NF-kB from IkBα 
leads to NF-kB activation and translocation to the nucleus, inducing transcription 
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of effector genes (Figure 1.2). It is suggested that NF-kB has a primary role in 
initiating and maintaining the inflammatory response in an experimental model of 
MI (Kupatt, Habazettl et al. 1999, Frangogiannis 2006). Reduction of infarction 
results from in vivo transfer of NF-kB decoy oligodeoxynucleotides to inhibit its 
activity, which suggests an important role for NF-kB in regulating post-MI 
inflammation (Morishita, Sugimoto et al. 1997). It is also shown that NF-kB 
depletion reduces adverse cardiac remodeling post-MI by decreasing the severity 
of post-MI inflammation and collagen deposition (Frantz, Hu et al. 2006). 
Interestingly, NF-kB has a dual role in MI since mice with mutated IkBα, that inhibits 
NF-kB translocation to the nucleus in cardiomyocytes, had larger infarction with 
increased cardiomyocyte apoptosis (Misra, Haudek et al. 2003).  
Unpublished data from Dr. Feola’s lab clearly demonstrates that AZM 
inhibits the translocation of p65 to the nucleus and elevates IKKβ kinase levels. 
Inhibited translocation is associated with suppression of negative feedback 
mechanisms which block IKKβ kinase expression. They also show that using IKKβ 
kinase inhibitor blocks Arg-1 expression, which infers that IKKβ kinase is an 
important effector molecule in the signaling pathway modulated by AZM. 
Moreover, this study suggests that AZM inhibits STAT-1 phosphorylation, which is 
also dependent on IKKβ kinase. Collectively, AZM modulates NF-kB and STAT-1 
pathways, connected by cross talk including IKKβ kinase, which could explain the 
immunomodulatory and anti-inflammatory effects of AZM. 
We conducted in vitro studies to examine the effect of hypoxia/reperfusion 
injury on the phenotype of J774 macrophages in the presence or absence of AZM. 
Following 24 hours of hypoxia and reperfusion, we noted high levels of TNF-α 
compared to IL-10 levels. AZM treatment shifted the cytokine production back 
towards the anti-inflammatory pattern with a significant increase in IL-10/TNF-α 
ratio. These findings demonstrate results from Dr. Feola’s lab. 
Based on the findings mentioned above, we can test key decision nodes 
that may be involved in inflammation resolution and macrophage polarization in 
vivo. The potential molecular targets in the immunomodulatory effects of AZM 
include: 
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a) NF-kB: We can examine the effects of NF-kB by using mice with targeted 
disruption of NF-kB signaling. If the immunomodulatory properties of AZM reduce 
or are completely lost in these mice, it would suggest that NF-kB is an important 
regulator in the molecular events induced by AZM. Moreover, a study like this also 
addresses whether NF-kB mediates macrophage phenotype transition. We can 
extend these experiments to include adaptive transfer of immune cells from NF-kB 
knock out mice to WT or vice versa to restore the immunomodulatory effects and 
exclude the diverse effects of NF-kB in different cells, as discussed earlier.  
 
b) IKKβ and IkBα: After testing the effect of NF-kB, we can test upstream 
molecules in the signaling cascade of NF-kB like IKKβ and IkBα by using mice with 
targeted disruption of these molecules. 
 
d) STAT1: Based on our observation that AZM upregulates IKKβ which 
inhibits phosphorylation of STAT1, we can determine the effect of STAT1 in the 
immunomodulatory properties of AZM using STAT1 knock out mice.  
 
By the end of these studies, we can clarify roles of these molecules in 
repolarizing macrophages to the anti-inflammatory state and determine if they are 
potential mediators of AZM effects. 
 
4.5 Liposomal AZM 
Liposomal research bridges urgent intellectual gaps between clinical 
targeting of post-MI inflammation and the optimal drug delivery system in MI. We 
are the first to demonstrate the immunomodulatory and anti-inflammatory 
properties of liposomal AZM, which has wide therapeutic potential beyond the 
cardiovascular field. Our work opens doors for more advanced studies to improve 
outcomes with AZM or other therapeutic agents post-MI using encapsulated 
formulation.  
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In addition to the cardioprotective effects of Lazm, we observe that 
liposomal packaging of AZM is indeed protective against the drug’s conduction 
changes. These findings clearly imply that the liposomal dosage form of AZM is 
indeed protective against the drug’s hemodynamic modifications, which is more 
likely attributed to the specific delivery of AZM to the immune cells, avoiding  
cardiomyocytes. It is very likely that encapsulation of AZM reduces the risk of other 
adverse effects related to this drug, which is something that needs to be earnestly 
considered in clinical practices of high risk patients. 
Liposomes are modifiable in terms of the surface attached groups. 
PEGylation of liposomes stabilizes them and prevents their opsonization by serum 
proteins and phagocytosis by Kupffer cells and hepatocytes. This results in 
liposomes with longer half-life, and thus, more accumulation in the injured 
myocardium caused by blood vessel leakage in the infarct areas (Takahama, 
Minamino et al. 2009). Due to the dynamic and progressive nature of the injured 
myocardium, this strategy may exhibit protective benefits with fewer doses or even 
a single dose following MI, improving patient tolerance. We observe potent 
immunomodulatory effects with a low dose of AZM encapsulated in liposomes, so 
examination of the relationship between immunomodulatory properties and the 
dosing interval of AZM using this approach could be an interesting avenue for 
future studies.  
Additional modulation can be achieved by attaching specific antibodies onto 
the surface of the liposomes (immunoliposomes), which is a potential therapeutic 
strategy for efficiently targeting certain kinds of cells. For instance, research shows 
that incorporating TLR ligands into liposomes promotes the efficacy of vaccines 
and the targeting of drugs (Ramirez, Iyer et al. 2014). With liposomal AZM, we can 
incorporate a macrophage marker (F4/80), or neutrophil marker (Ly6G) to enhance 
the targeted delivery of AZM, and therefore its efficacy. As a broader target, we 
can also use fluorescent immunoliposomes to enable monocyte/macrophage 
tracking to identify their distribution, function and kinetics in tissue injury. 
Expansion of liposomal work can include other therapeutic agents such as gene 
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therapy or small interfering RNA (siRNA) for targeting innovative biological 
pathways in resolving post-MI inflammation. 
AZM was prepared previously in liposomal formulations for antibiotic 
purposes. It has been shown that liposomal encapsulation promotes the 
antibacterial activities of AZM (Oh, Nix et al. 1995). When comparing the 
antibacterial effects of free AZM and liposomal AZM against intracellular M. avium 
growth in macrophages, it was found that the encapsulated formulation is 41-fold 
more potent than free AZM. Although there is a lack of efficient assays to precisely 
determine intracellular concentrations of AZM with liposomal formulation, these 
liposomes enhance the intracellular deposition of other antibiotics such as 
ciprofloxacin (Oh, Nix et al. 1995). Encapsulated formulations of antibiotics 
promote the antibacterial effectiveness both in vivo and in vitro (Cynamon, 
Klemens et al. 1992, Oh, Nix et al. 1995). Our data from in vitro experiments 
implies a similar trend regarding the immunomodulatory and anti-inflammatory 
effects of encapsulated dosage form. We find that liposomal AZM induces a more 
significant shift in macrophage response towards the anti-inflammatory state than 
free AZM. These findings are significant because they strongly suggest that 
liposomal AZM not only favorably modifies pharmacokinetic characteristics, but 
also augments pharmacodynamic effects, which are of great importance and 
require further exploration. We are currently working with our collaborators to 
prepare biotinylated AZM that can be traced both in in vivo and in vitro. 
 
4.6 Clinical applications 
Experimental animal models do not recapitulate the heterogeneity of 
pathology of complicated diseases like MI and heart failure. Much less is known 
about the macrophage phenotypes and functions in humans under normal 
physiological conditions and disease states. More studies are needed to 
understand human macrophage function, gene expression, and other properties 
to improve translation from bench to the bedside (Chen and Frangogiannis 2016). 
Therefore, targeting monocytes as precursors of macrophages (ter Horst, 
Hakimzadeh et al. 2015) may be more feasible to modulate macrophage 
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phenotypes. Harnessing isolated monocytes from MI patients can investigate the 
effectiveness of immunotherapies such as AZM and determine the destiny of 
monocytes after infiltration to the injured myocardium.  
We demonstrate that AZM is a potent immunomodulatory agent of the 
exaggerated post-MI inflammatory response. We find that AZM alters monocyte 
response in the injured heart via shifting the balance towards anti-inflammatory 
monocytes. Similar findings are simultaneously observed in peripheral blood.  We 
also find that AZM treatment reduces neutrophil counts. Moreover, AZM 
significantly suppresses pro-inflammatory cytokine and chemokine levels in 
plasma. These effects are important from a clinical prospective as they provide an 
effective tool to track the immuno-dynamic characteristics of AZM and its related 
cardioprotective properties in humans. Besides these effects, we observe a robust 
decrease in M1 macrophages with AZM therapy, suggesting additional advantage 
for considering AZM as immunotherapy in MI patients, who are mostly elderly. 
Research shows that M1 macrophages increase with age, while M2 macrophages 
show a decrease. Reducing M1 activation state may be a promising therapeutic 
target for MI patients.  
 
4.7 AZM and oxidative stress in MI 
ROS generation is increased in cardiovascular diseases such as MI, in 
particular after reperfusion, through enhanced expression of cytokines and growth 
factors. ROSs promote production and activity of proteases that control ECM 
breakdown and turnover and induce cardiomyocyte and blood vessel cell death 
(Frangogiannis 2018). Free radical scavengers which reduce ROSs, such as 
enzymes superoxide dismutase and catalase, show beneficial effects in reducing 
scar size (Jolly, Kane et al. 1984). Cytokine-related MAPK activation and stress-
responsive protein kinases, at least partially induced by redox, participate in 
activation master transcription factors like NF-kB and AP-1, which induce MMP 
transcription (Siwik and Colucci 2004).  
Macrolides, in general, reduce production of free radicals, in addition to their 
anti-inflammatory effects. AZM downregulates the expression and activity of GST 
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by up to 40% in cystic fibrosis cell lines (IB3-1 and 2CFSMEo cells). The anti-
inflammatory mediator, IL-10, also decreases GST activity to a similar extent, 
indicating a possible link between antioxidant and anti-inflammatory pathways 
(Zarogoulidis, Papanas et al. 2012). Studies show that AZM modifies MAPK and 
AP-1 cascades (Kanoh and Rubin 2010). Moreover, unpublished data from Dr. 
Feola’s lab shows that AZM reduces NF-kB activation through decrease of the 
transcription factor translocation to the nucleus, which could indicate that AZM 
inhibits NF-kB activity via ROS suppression. We found that AZM significantly 
upregulates IL-10 expression after infarction. This evidence implies that in addition 
to its immunomodulatory effects, AZM could exhibit novel antioxidant properties 
contributing to its cardioprotective effects. As such, these effects can be assessed 
in an I/R injury model where ROSs play a central role in the pathophysiology of MI. 
Using AZM alone or in combination with ROS scavengers is an important approach 
for future myocardial preservation studies. 
 
4.8 AZM and age impact on ischemic heart disease 
A linear elevation in M1 macrophages and reduction in M2 macrophages in 
the heart is reported with age (Ma, Chiao et al. 2015). It seems that there are 
multiple factors mediating this transition, since stimulating bone marrow derived 
macrophages with different stimuli in vitro produces both phenotypes, suggesting 
no defect in macrophage polarization with age (Mahbub, Deburghgraeve et al. 
2012). Proposed theories as to why the M1 macrophage phenotype dominates 
with age include over-recruitment of monocytes to the heart and alterations in 
cardiac resident macrophage behavior (Ma, Mouton et al. 2018). We observe that 
M2 macrophages dominate the heart after infarction with AZM treatment, as 
justified by the significant reduction of M1/M2 macrophage ratio. Therefore, AZM 
may be more effective in aged mice due to the decrement of M2 and the 
abundance of M1 macrophages. This expected benefit is especially important 
clinically since most MI patients are elderly and they experience exaggerated 
cardiac damage with MI. Thus, future experiments should test the 
 
 
 
157 
 
immunomodulatory efficacy of AZM in aged animals with MI injury to increase the 
clinical relevance of this work. 
 
4.9 AZM and regeneration post-MI 
There is a well-recognized regenerative capability in the heart during the 
neonatal life stage, which ends 7 days after birth (Inamura, Ohta et al. 2000, Wan, 
Yeap et al. 2013). This regenerative capacity is completely disturbed in the 
absence of macrophages (Aurora, Porrello et al. 2014). Important questions that 
must be addressed are as follows: (a) Are macrophages solely responsible cell 
effectors or are other immune cells involved? (b) What is the optimal activation 
state of macrophages to induce regeneration? (c) What is the best way to modulate 
macrophage activation to enhance regeneration considering the plasticity of 
macrophages? AZM administration could address these questions through design 
of in vivo and in vitro experiments.  Examining changes in the progenitor cells with 
AZM administration in multiple organs such as BM, blood, and heart may be the 
first step in determining whether AZM influences the cardiac regenerative capacity 
post-MI. Markers such as c-kit and Ki-67 can be used to identify stem cells or 
regeneration, respectively. In vivo experiments with AZM in neonatal mice may be 
useful in examining the mechanisms involved in heart renewal. Additionally, in vitro 
experiments such as treating cardiomyocytes with AZM, then challenging them 
may highlight whether AZM has a direct effect in enhancing cardiomyocyte 
survival. In this regard, treating cardiomyocytes with conditional media from 
macrophages incubated with AZM, or co-culturing them with these macrophages 
may also be elucidating experiments. 
 
4.10 Advanced research techniques 
State-of-the-art technology can provide answers to important questions 
related to the immunopathology post-MI and to the role of AZM in MI. These are 
some of these technologies:  
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a) Histo-cytometry: This technique unites immunohistochemistry with 
cytometry software to determine spatially different cell populations in tissues 
(Deniset and Kubes 2016). Although we used Celigo in our experiments to 
determine the co-localization of immune cells with liposomes, it is likely that this 
technique could provide more insights about this interaction such as whether these 
liposomes are located inside or outside the cells, or whether they remain separate. 
 
b) Next-generation sequencing: This technique depends on high-
throughput sequencing platforms able to generate information about cell-specific 
transcriptome and gene regulation profiles (Deniset and Kubes 2016). Relative 
contribution of various immune cells in heart-injury-triggered inflammation requires 
further exploration. We can isolate inflammatory cells (macrophages, monocytes, 
and neutrophils) from the heart post-MI and determine the gene profile for each 
cell type and the effect of AZM on the cell activation state. These approaches will 
address novel roles for these cells in the pathogenesis of adverse cardiac 
remodeling and heart failure, possible cardioprotective mechanisms, and potential 
therapeutic targets for myocardial preservation after MI. 
 
c) Mass cytometry: In this technique, cells are labeled with heavy metal 
conjugated antibodies and then run through a mass spectrometer. There is no 
need for compensation and it can deal with larger panel sizes of antibodies 
compared to conventional flow cytometry techniques (Deniset and Kubes 2016). 
This technique could be beneficial in determining the multiple activation states of 
immune cells (macrophages, monocytes, and neutrophils) with and without AZM 
therapy by adding more markers. It is also possible to track whether AZM 
influences the activity of progenitor cells, which could explain changes in the 
infiltration of immune cells to the heart post-MI. 
 
d)  Fate-mapping and cell-specific loss-of-function approaches: These 
studies could be useful in examining whether AZM-induces repolarization of 
macrophages from one state to another or whether its actions are due to 
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downregulation of one activation state (M1) and/or upregulation of other activation 
states (M2). 
 
4.11 Repurposing AZM 
The National Center for Advancing Translational Sciences defines the 
repurposing process for drugs equates to discovering new clinical benefits of drugs 
that are already approved to treat other diseases or conditions with proven safety 
record in humans. It is estimated that 30% of new drugs and vaccines approved 
by the US FDA in recent years are attributed to the process of drug repurposing, 
repositioning, and rescuing (Agranat, Caner et al. 2002). This process offers many 
advantages including cost and time saving from circumventing the extensive 
testing typically required for newly developed drugs. Since these drugs are 
approved for human use, the well-characterized properties (pharmacology, 
toxicology, and formulation) of these candidates allow for a quick therapeutic 
switch to novel clinical use. The estimated cost associated with the development 
of a new drug is over $2 billion, and the timeline typically involves more than 12 - 
16 years. In contrast, a repurposed drug can be approved in a shorter time frame, 
3- 12 years, with an average cost of $300 million (DiMasi and Grabowski 2007). 
Due to extensive financial and time commitments required for new drug 
development, repurposing an old drug to a new market with a relatively low cost is 
very attractive.  In addition, approval rates for new drugs are extremely low, 
typically close to 10% while the approval of therapeutically repurposed drugs is 
typically triple that figure. Finally, the process of repurposing drugs represents 
substantial assistance for low-income patients. This increases the significance of 
our work since AZM has a proven safety record in humans and could be beneficial 
in the management of millions of patients with acute myocardial infarction 
worldwide. 
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4.12 Limitations in preclinical animal studies 
In preclinical studies, enthusiasm for the role of inflammation in various 
pathological conditions, and the large body of positive evidence of animal studies 
could be misguided (Frangogiannis 2014). Negative experiments are often 
unpublished, creating selection bias, which results in unrealistic expectations from 
new therapies. Targeting the inflammatory pathways using animals with certain 
genetic modifications or specific inhibitors has examined the role of inflammation 
in the progression of myocyte death. However, there is still controversy since 
positive studies are contradicted by others that fail to demonstrate reduction in 
infarct expansion and disappointing clinical trials. These opposite observations 
could be attributed to an overstated role for the inflammatory response in MI, or 
methodological variability in study design and data analysis/interpretation. For 
instance, MI in young mice is often associated with a profound inflammatory 
response that is not particularly observed in older mice (Frangogiannis 2014). 
Furthermore, variability in collateral blood flow and post-MI metabolic rate 
significantly impacts scar size (Ito, Tate et al. 1987). It is also important to note that 
the inconsistency observed in these studies is related to the different MI 
experimental designs (permanent ligation vs. I/R). It is assumed that I/R provokes 
a stronger inflammatory response (Moro, Jouan et al. 2007). Using large animals 
like pigs or dogs could reduce this variability in experimental MI models compared 
to rodents but one must consider the cost and logistic demands as well (Verdouw, 
van den Doel et al. 1998). 
Patients with MI are a heterogeneous population, adding another layer of 
complexity for direct clinical translation of successful strategies in animal studies 
(Frangogiannis 2014). Most MI patients suffer comorbidities (diabetes, 
hypertension, and hyperlipidemia), are typically older and exhibit a wide range of 
pre-existing pharmacological treatments. All these factors could markedly change 
the inflammatory and reparative stages post-MI. These variable factors make the 
clinical relevancy of animal models challenging and problematic (Frangogiannis 
2014).  
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However, experimental MI models in mice remain tremendously useful to 
study cellular and molecular mechanisms controlling the pathophysiology of MI 
(Frangogiannis 2014), and to explore new therapeutic interventions. This model 
provides a way to assess both acute and long-term benefits of novel therapeutic 
approaches after MI. Recent advancements in genetic and surgical interventions 
of murine models of cardiovascular disease have significantly reduced variability 
and provide a more complete understanding of cardiovascular response to 
ischemic injury, making it a beneficial tool in predicting the influence of various 
factors in human heart function. Furthermore, principal similarities of the immune 
response initiated by MI between mice and humans (Tahto, Jadric et al. 2017) 
make animal studies extremely helpful in appropriately determining the role of 
inflammation in acute injury and its subsequent complications.  
In this work, we used AZM in a murine MI model as a means to modulate 
intense inflammation and improve cardiac recovery after infarction. The finding that 
free/targeted liposomal AZM therapy is effective in moderating cardiac 
immunopathology of ischemic cardiac injury may be very important to clinical 
practice. Our work with AZM in mice allowed us to test multiple protocols, doses, 
controls, and dosage forms to identify immunomodulatory and cardioprotective 
effects of the drug in MI. To enhance clinical translation of our work, it would be 
quite interesting to explore the cardioprotective effect of AZM in ApoE-/- mice that 
show a prolonged inflammatory phase and a trend towards hyperlipidemia similar 
to that of humans (Panizzi, Swirski et al. 2010). Additionally, we can treat these 
mice with high fat diet, to represent the pathogenesis of human atherosclerotic 
patients, and then subject them to MI injury. In another but rather complementary 
direction, these initial results in small animals can be confirmed in a large animal 
model that more closely resembles the human heart function, anatomy, and 
genetic conservativeness (Heidt, Courties et al. 2014).  Nevertheless, it is also 
important to consider the economic, ethical and logistic limitations with large 
animals as they are more expensive to buy and maintain compared to smaller 
rodents (Chen and Frangogiannis 2017). 
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4.13 Concluding remarks 
 
The work of this dissertation reveals novel findings, which are summarized in the 
following points: 
a) We found that AZM (free and liposomal formulations) reduces cardiac 
inflammation and improves adverse cardiac remodeling after infarction via shifting 
immune cell response towards the reparative state. 
b) This work is early evidence of a novel and clinically relevant immunotherapy 
using AZM for ischemic heart disease, which could be applicable for other sterile 
inflammatory diseases.  
c) This is the first study to demonstrate the immune modulatory properties of 
liposomal AZM, which are previously unexamined and have potential wide 
therapeutic applications beyond the cardiovascular field. 
d) This the first study to clearly demonstrate that the liposomal dosage form of 
AZM is indeed protective against the drug adverse effects such as hemodynamic 
modifications, which is a truly important consideration in clinical practices of high 
risk patients. 
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Figure 4.1 Illustration of the immunotherapeutic effects of AZM in MI. 
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